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MERKEL CELL POLYOMAVIRUS POSITIVE MERKEL CELL CARCINOMA                                                 
- FROM DIAGNOSIS TO THERAPY 
Reety Arora 
 University of Pittsburgh, 2012  
 
Merkel cell polyomavirus (MCV) is one of the newer members of the polyomavirus family, 
recently discovered as clonally integrated into the genomes of a subset of Merkel cell 
carcinoma (MCC). MCV is the first polyomavirus that is widely accepted to cause a human 
cancer and its identification has resulted in a paradigm shift in the understanding of MCC 
biology. In the vast majority of the population, MCV is a harmless member of the normal 
human microbial flora, but can initiate an aggressive cancer if it integrates into the host 
genome and acquires a precise set of viral mutations that result in replication incompetence (in 
a susceptible host). 
This dissertation describes how the identification of a new viral cause of MCC was 
harnessed to develop new diagnostic assays and therapeutic options for MCC. To assess MCV 
infection and its association with MCC as well as other human diseases, a monoclonal antibody 
that specifically recognizes both endogenous and transfected MCV large T antigen was 
developed. Using this antibody, specific nuclear localization of MCV T antigen in MCC tumor 
cells was demonstrated. A quantitative PCR assay revealed that MCV is present in MCC at > 1 
copy per tumor cell. These assays were used to survey non-MCC tissues including 
hematolymphoid malignancies, neuroendocrine tumors, and various dermatologic cancers. 
None showed association with MCV infection. Restricted expression of the MCV LT oncoprotein 
to MCC tumor cells provides the mechanistic underpinning supporting the notion that MCV 
causes a subset of MCC. 
To investigate treatment options for MCC two methods were used. An in vitro drug 
screen of 1360 chemotherapeutic and pharmacologically active compounds resulted in the 
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identification of a proteasome inhibitor, bortezomib, as a potent but nonselective candidate. To 
rationally and specifically target MCV positive MCC, deep-sequence profiles of MCV positive 
MCC tumors were compared to MCV negative MCC tumors. Among 64 cell death related genes, 
a seven fold differential expression of survivin was observed in MCV positive MCC. MCV T 
antigen knock down in MCV positive cell lines decreased survivin mRNA and protein expression. 
Also, exogenously expressed MCV T antigen increased survivin protein in non-MCC primary cells 
in an RB protein binding dependent manner. A survivin inhibitor, YM155 initiated selective non-
apoptotic MCV positive MCC cell death. YM155 was nontoxic and halted MCV positive MCC 
xenograft tumor growth in mice while bortezomib was inactive and caused significant toxicity in 
vivo.  
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1.0  INTRODUCTION 
The work described in this dissertation was initiated in 2008, when Merkel cell polyomavirus (MCV) 
had just been discovered as a new human polyomavirus clonally integrated into the Merkel cell 
carcinoma (MCC) genome. Studies over the past four years, including the ones described here, 
reveal various aspects of virus-mediated tumorigenesis of MCC. More than half a century of work 
studying simian virus 40 (SV40), a model polyomavirus, has produced important molecular and 
cellular tools to investigate MCV biology. Although polyomaviruses have been linked to human 
disease, BK virus to nephropathy and JC virus to progressive multifocal leukoencephalopathy as 
examples, MCV is the first polyomavirus convincingly linked to human cancer. MCV discovery has 
changed the perception of an intractable cancer MCC, leading to new opportunities for its early 
diagnosis and targeted treatment. MCV has become a new model for human cancer, in which a 
common, harmless member of the human viral flora can initiate cancer if it acquires a set of 
mutations in a susceptible host (immunosuppressed or elderly). Also, with the discovery of four 
additional human polyomaviruses since 2008, studies of polyomavirus basic science have become 
increasingly relevant, and future investigations of these viruses may give new insights into their 
connection with human disease. 
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1.1 VIRUSES AND CANCER 
1.1.1 Discovery of link between viruses and cancer 
Infections, mostly viruses, cause approximately 20% of cancer cases worldwide [1, 2]. It has 
been over 100 years since Francis Peyton Rous discovered the first tumor virus, and 
considerable research has been devoted to the understanding of this group of viruses [3]. Virus-
associated cancers have identifiable viral targets amenable for diagnosis and therapy. 
Vaccination programs for the prevention of two common tumor virus infections, hepatitis B 
virus (HBV) and human papillomavirus (HPV) have begun to make a difference in tumor burden 
and the general health of the global population [4, 5].  
In a groundbreaking discovery in 1911, Francis Peyton Rous showed that viruses could 
induce cancer. He successfully transplanted sarcoma from a 15-month old hen into other 
chickens through cell-free tumor extracts [3, 6]. The isolated etiologic agent, Rous sarcoma 
virus (RSV), was the first tumor virus identified. After an initial period of inattention, interest in 
the field re-emerged following Ludwik Gross’s discovery of an acute transforming murine 
retrovirus and a polyomavirus that caused murine tumors [7]. The impact of these 
achievements was enormous. Soon after Rous received the Nobel Prize for his discovery, study 
of the RNA tumor virus-RSV lead to the discoveries of reverse transcription and the cellular 
origin of viral oncogenes (beginning with v-src of RSV) [8-11]. Subsequently, the study of tumor 
viruses has accelerated.  
1.1.2 Human tumor viruses 
Anthony Epstein, Bert Achong and Yvonne Barr discovered the first human tumor virus in 1964. 
They identified herpesvirus-like particles in cell lines from equatorial African patients with an 
unusual, geographically confined childhood cancer called Burkitt’s lymphoma [12]. The virus 
was named Epstein-Barr virus [13]. Despite studies that demonstrated EBV infection as 
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persistent, asymptomatic and ubiquitous in adults worldwide, EBV-associated cancers were 
uncommon. This dissociation between prevalence of infection and occurence of cancer initially 
confused scientists’ understanding of how viruses cause tumors [14, 15]. Additionally, sporadic 
Burkitt’s lymphomas were observed in developed countries that frequently lacked EBV but 
retained a signature mutation of Burkitt’s lymphoma c-myc IgG gene chromosomal 
translocations [16]. Although the proposed role of EBV in Burkitt’s lymphoma was viewed with 
skepticism at first, its strong association with lymphomas and nasopharyngeal carcinomas, and 
follow-up studies of the tumorigenic potential of its viral proteins added more credence to the 
idea. The understanding of the “multistep” process of cancer development and the recognition 
that chronic viral infection functions together with various other non-viral host factors 
contribute to cancer (such as insect-borne parasitic infections like malaria, young age, status of 
immune system, nutrition, etc), finally led to the acceptance of EBV as a human tumor virus. 
The International Agency for Research on Cancer (IARC) declared EBV as a group 1 (carcinogenic 
to humans) human carcinogen in 1997 [14, 17]. 
Scientists have made numerous attempts to search for human tumor viruses using a 
similar electron microscopy approach. These efforts however, were disappointingly negative. It 
was later understood that cancer viruses generally do not replicate as virions in tumors, but 
exist as latent episomes or integrate into the host genome [18, 19]. Six other human cancer 
viruses have been identified since EBV and surprisingly all of them come from different classes 
of viruses (Table 1). Interestingly, almost all of these human tumor viruses have close relatives 
that do not cause human cancer.  
 The identification of the Australia (Au) antigen (antigen from the blood of an Australian 
aborigine found to cross react to an American hemophilia patient serum) by Baruch Blumberg 
in 1965 eventually led to the identification of the Hepatitis B virus. Persistent infection and 
asymptomatic carriage of the virus in healthy populations [20] obscured the association 
between HBV and disease, and several years elapsed before a link between the virus and 
hepatocellular carcinoma (HCC) was made in 1975 [21]. HCC is among the most
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Table 1 Human tumor viruses  (Modified from Moore and Chang, Nat Rev Cancer 2010) 
 
Virus Year identified 
Method of 
identification Genome Cancer associations Reference 
Epstein–Barr virus (EBV) 1964 Electron microscopy Double-stranded DNA herpesvirus 
Most Burkitt's lymphoma and 
nasopharyngeal carcinoma, most 
lymphoproliferative disorders, 
some Hodgkin's disease, some 
non-Hodgkin's lymphoma and 
some gastrointestinal lymphoma 
Epstein et al., 
Lancet, 1964 
Hepatitis B virus (HBV) 1965 Serologic screening 
Single-stranded and 
double-stranded DNA 
hepadenovirus 
Some hepatocellular carcinoma 
Blumberg et 
al., JAMA, 
1965 
Human T-lymphotropic virus-I 
(HTLV-I) 1980 Tissue culture 
Positive-strand, single-
stranded RNA 
retrovirus 
Adult T cell leukaemia Poiesz et al., PNAS, 1980 
High-risk human 
papillomaviruses (HPV) 16 and 
HPV 18  
1983–1984 DNA cloning Double-stranded DNA papillomavirus 
Most cervical cancer and penile 
cancers and some other 
anogenital and head and neck 
cancers 
Durst et al., 
PNAS, 1983  
Boshart et al., 
EMBO J, 1983 
Hepatitis C virus (HCV) 1989 cDNA cloning Positive-strand, single-stranded RNA flavivirus 
Some hepatocellular carcinoma 
and some lymphomas 
Choo et al., 
Science, 1989 
Kaposi's sarcoma herpesvirus 
(KSHV) 1994 
Representational 
difference analysis  
Double-stranded DNA 
herpesvirus 
Kaposi's sarcoma, primary 
effusion lymphoma and some 
multicentric Castleman's disease 
Chang et al., 
Science, 1994 
Merkel cell polyomavirus (MCV) 2008 Digital transcriptome subtraction  
Double-stranded DNA 
polyomavirus Most Merkel cell carcinoma 
Feng et al., 
Science, 2008 
      EBV is also known as Human Herpesvirus 4 (HHV4) and KSHV is also known as Human Herpesvirus 8 (HHV8) 
 Besides HPV 16 and HPV 18, some other α-HPV types are also carcinogens 
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common malignancies in the world and is fatal. In adults, primary HBV infection either results in 
acute hepatitis or can be asymptomatic, if the immune system clears the virus. However in 
about 5% of infected neonates and adults where primary infection fails to resolve, long-term 
chronic infection with active viral replication in liver cells and viremia is seen. Persistent chronic 
infection as well as risk factors such as aflatoxin and hepatitis C virus or parasitic infections, 
increase the risk of HCC development [22-24].              
HBV-induced liver cancer is responsible for >300,000 deaths per year worldwide and is a 
major public health concern. An important milestone in prevention of these cancers came with 
Merck’s HBV vaccine in the late 1900s. The vaccine, still in use today, is a recombinant HBV 
surface antigen subunit vaccine produced in yeast cells, and protects against not only acute and 
chronic hepatitis but also the development of HCC [25, 26].  
With the discovery of HBV and advancements in molecular biology, it became possible 
to screen for and identify virtually every patient infected with HBV. These assays unexpectedly 
distinguished a transfusion-associated serum hepatitis, not infected with HBV or hepatitis A 
virus (another close relative causing hepatitis in people). Non-A, non-B hepatitis is an acute 
disease that is relatively mild but ultimately results in chronic infections that lead to serious 
chronic liver disease and cirrhosis. Exploiting the observation that the disease could be 
transmitted to chimpanzees, Choo et al. generated a lambda phage cDNA expression library 
from nucleic acid extracted from the plasma of a chronically infected chimpanzee [27]. Using 
serum from a chronic non-A, non-B hepatitis patient to screen this library in 1989, Houghton 
and colleagues found an antigen encoded by an unknown RNA flavivirus. This virus was named 
Hepatitis C virus or HCV and is now recognized as another etiologic agent of chronic hepatitis, 
liver cirrhosis and HCC worldwide. Chronic HCV infection affects more than 170 million 
individuals, 20% of whom have or later develop cirrhosis and an increased risk of developing 
HCC (highest risk in Japanese individuals) [28-31]. 
 In 1980, Bernard Poiesz, Robert Gallo and colleagues discovered the first and only known 
human retrovirus directly linked to a specific human cancer. HTLV-1 or Human T-lymphotropic 
virus-1 was discovered by searching for reverse transcriptase activity in a survey of adult T cell 
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leukemia/lymphoma (ATL) cell lines [32, 33]. Yorio Hinuma, Isao Miyoshi and colleagues 
visualized retroviral particles in ATL derived leukemia cell line and confirmed these findings the 
next year [34]. Over the following few years, the causal role of HTLV-1 in ATL was established. 
HTLV-1 infections correlated geographically with ATL cases distributed in Japan, central African 
coastal regions, Taiwan, the Caribbean, and Papua New Guinea. Cancer cells cultured from 
patients with ATL had proviral DNA and infection of normal, healthy human T cells with HTLV-1 
induced cellular immortalization. Virtually every ATL patient demonstrated HTLV-1 infection 
and carried antibodies specifically recognizing HTLV-1 antigens. Other retroviruses closely 
related to HTLV-1, such as bovine leukemia virus and simian T-cell leukemia virus 1, caused 
leukemia in their respective animal hosts. In total, these epidemiologic and molecular studies 
implicated HTLV-1 as the etiologic agent of ATL [33, 35-37]. Intriguingly, by contrast to 
mechanisms typical of animal retroviruses, HTLV-1 does not cause tumors by insertional 
mutagenesis or by capturing and activating cellular proto-oncogenes. Instead, reminiscent of 
DNA tumor viruses, HTLV-1 produces an oncogenic protein called Tax that is essential for viral 
replication and perturbs various host cell growth regulatory pathways. Also, similar to other 
known human tumor viruses, HTLV-1 infects healthy individuals, but is kept in check by the 
immune system and remains latent/dormant for long periods. It is detected early in life and less 
than 5% of infected individuals develop ATL after 20-30 years. 
 Sexual activity was a known risk factor for the development of cervical cancer, the third 
most common cancer in women worldwide [38]. Based on the emerging evidence at the time, 
linking human papillomaviruses (HPV) to gential warts, Harald zur Hausen reasoned that HPV 
was the etiologic agent for cervical cancer, despite the general belief that herpes simplex virus 
2 (a sexually transmitted virus) was the likely cause. In his landmark studies in 1983 and 1984, 
his group cross-hybridized known papillomavirus DNA to cervical cancer DNA and discovered 
two novel HPV genotypes (HPV16 and HPV18) [39, 40]. These genotypes, classified as high-risk 
HPVs, and are now confirmed as etiologic agents for 70% of cervical cancers worldwide. 
Subsequently, various other high-risk HPV genotypes were found to be associated with 
anogential cancers as well as head and neck cancers. HPVs are associated with more human 
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cancers than any other virus [41-44].  
 The success of the HBV vaccine in decreasing liver cancer prompted HPV biologists to 
develop a safe preventative HPV vaccine. Such an endeavor was successful when a quadrivalent 
virus like particle (VLP)-based vaccine (using the recombinant capsid protein L1 from HPV types 
6, 11, 16 and 18) cleared clinical trials in 2006 conferring immunized women with type-specific 
protection against HPV infection, as well as associated cervical, vulvar and vaginal disease [45-
50]. VLPs are non-infectious virions resulting from the self-assembly of viral capsid proteins, and 
are used in making conformational viral epitope-based vaccines [51]. The vaccines, marketed as 
Gardasil by Merck and Cervarix by GlaxsoSmithKline, are widely used and recommended for 
young individuals (both girls and boys, ages 9 through 26). Based on current estimates, these 
vaccines can lead to the prevention of greater than 300,000 cervical cancer cases per year 
globally. 
 Targetted searches for viruses as etiologic agents of human malignancies led to the 
discoveries of the two newest human tumor viruses, KSHV and MCV. Kaposi sarcoma herpes 
virus (KSHV) or Human Herpes virus 8(HHV-8) was discovered by Yuan Chang and Patrick Moore 
in 1994 using a molecular technique called representational difference analysis (RDA) [52]. 
Briefly, DNA sequences present in diseased tissue (Kaposi’s sarcoma tumor tissue in this case), 
but absent in healthy tissue of the same patient, were specifically enriched and isolated 
following rounds of PCR amplification and subtractive hybridization. DNA fragments isolated by 
RDA were found to have homology to herpesvirus saimiri (HVS) and led to the identification and 
sequencing of KSHV. Although initially described in 1872 as an endemic tumor in the 
Mediterranean basin and Africa by Moritz Kaposi [53], Kaposi’s sarcoma (KS) is now also 
recognized as an AIDS defining disease. A viral etiology of KS explains the increased prevalence 
of KS seen among men who have sex with men (MSM) with AIDS-associated 
immunosuppression following the HIV pandemic [54, 55]. Both AIDS related and unrelated 
forms of Kaposi’s sarcoma invariably contain KSHV DNA and KSHV infection, measured by 
serology assays. Accumulated epidemiologic evidence demonstrated that KSHV is also sexually 
transmitted among homosexual men in the United States. Collective data from numerous 
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studies indicate a causal role of KSHV in conjunction with host factors (such as 
immunosuppression), in the development of Kaposi’s sarcoma [56, 57]. 
Merkel cell carcinoma is an uncommon but aggressive primary cutaneous neoplasm 
frequently having a poor prognosis [58, 59]. The risk of developing MCC is 13-fold higher in AIDS 
patients and 10-fold higher after solid organ transplantation [60]. MCC is also more common in 
patients receiving immunosuppressive therapy, elderly individuals and patients with other 
cancers such as chronic lymphocytic leukemia, basal cell carcinoma and squamous cell 
carcinoma [61-67] (none of these cancers have been linked to MCV infection [68-73]). Based on 
a strong association with immunosuppression and its epidemiology, Merkel cell carcinoma was 
selected and subjected to a direct sequencing-based method called Digital Transcriptome 
Subtraction (DTS) [74, 75]. Complementary DNA (cDNA) libraries were created from mRNA of 
four MCC tumor tissues and exhaustively sequenced to generate a stringent high fidelity 
transcriptome database of MCC tumors. An in silico subtraction of known human sequences 
against curated and highly verified human genomic sequence databases (made available 
through the Human Genome Project) identified candidate nonhuman sequences for further 
examination. A transcript with homology to other polyomaviruses was identified and led the 
way to the discovery of a novel virus associated with MCC (GenBank accession numbers 
EU375803 and EU375804) [74]. For detailed description please see section 1.5.1 (Discovery of 
Merkel cell polyomavirs).  
1.1.3 Human immunodeficiency virus: an indirect carcinogen  
Discovery of human immunodeficiency virus (HIV), another human retrovirus discovered in the 
late 1900s [76-78], substantially increased our understanding of these viruses and their link to 
immunosuppression, specifically Acquired Immune Deficiency Syndrome (AIDS). The discovery 
resulted in a Nobel Prize award to Françoise Barré-Sinoussi and Luc Montagnier, in 2008 [79]. 
HIV is not a direct agent of carcinogenesis, but is responsible for a number of cancers by 
indirectly “setting the stage” through immunosuppression. AIDS patients usually have an 
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elevated risk for developing cancer, specifically virus-induced cancers, as compared to the HIV 
uninfected human population [80-82]. Due to these reasons, IARC designated HIV-1 as a group 
1 carcinogen in 1996 [79]. 
1.2 POLYOMAVIRUSES 
1.2.1 Introduction and phylogeny 
Polyomaviruses are small, non-enveloped viruses which have icosahedral capsids and carry a 
double stranded, covalently closed, superhelical genome approximately 5200 bp in length. 
Distantly related to papillomaviruses, they were previously (now obsolete) taxonomically 
grouped together as papovaviruses. Polyomaviruses usually have restricted host ranges and 
have been identified in various species including humans, monkeys, rodents, rabbits, and birds. 
Recently the International Committee on the Taxonomy of Viruses (ICTV) has divided 
polyomaviruses into three groups: Orthopolyomavirus group, Wukipolyomavirus group (both of 
which contain mammalian species) and the Avipolyomavirus group (contains avian species) 
(Figure 1) [83]. They all encode a variably spliced hallmark oncoprotein called the tumor (T) 
antigen. These T antigens usually retain the 5’exon at the amino terminal region, but differ in 
the carboxy terminal region [84, 85]. The expression of these T antigens not only causes tumors 
in animal models, but often leads to malignant transformation of primary cells in culture [86].  
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Figure 1 Phylogenetic relationships and taxonomical classification of polyomaviruses based on whole genomic 
sequences.  
ClustalW alignment of the 26 known polyomavirus species was performed using Mac Vector software. The tree 
was created using neighbor joining method and FigTree software. Assignment of the viruses to the genera is 
indicated by the different colors used (red for Avipolyomavirus (Avian), blue for Wukipolyomaviurs and black for 
Orthopolyomavirus (Mammalian)). Boxes highlight human polyomaviruses. MCV is highlighted in a grey box. 
Information on the polyomaviruses, including their full names, abbreviations and Genbank accession numbers of 
the genome sequences is presented in Table 21 in Appendix A. 
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1.2.2 History and association with human cancer 
The first known polyomavirus, called murine polyomavirus (MPyV), was discovered by Gross in 
1953 as a filterable agent recovered from mouse leukemic extracts, that caused salivary gland 
carcinomas in inbred C3H mice [7]. The name “polyoma” virus (Greek terms: poly, meaning 
many; and oma, meaning tumors) was subsequently proposed due to its ability to cause 
multiple tumors in newborn mice, hamsters, and rats [87]. Since then the cell transformation 
and tumor formation abilities of polyomaviruses have been extensively studied and they have 
been proposed to play a causal role in human cancers. 
Between 1959 and 1960, a scientist as the National Institute of Health (NIH), Bernice 
Eddy examined rhesus monkey kidney cells under the microscope and found that they would 
die without any obvious cause. She injected suspensions of these cells into hamsters, and 
observed that these hamsters developed tumors [88]. Shortly thereafter, in 1960 B.H. Sweet 
and M.R. Hilleman, scientists at the pharmaceutical company Merck & Co., discovered simian 
vaculoating virus (SV40), which was later determined to be the same virus identified by Eddy 
(89). SV40 was soon found as a major contaminant of lots of poliovirus vaccine [88-90]. It is 
estimated that 10-30 million of the 98 million individuals who received injected polio vaccine, 
during the period (1955-1963), actually received a vaccine that contained SV40. Approximately 
10,000 volunteers, who received an experimental oral polio vaccine between 1959-1961, may 
also have been exposed to SV40 [90]. In addition, SV40 was found in adenovirus vaccines given 
to more than 100,000 young men in army camps and as a contaminant of respiratory syncytial 
virus vaccine given to a few volunteers in a live virus infection experimental study during that 
period [86, 90, 91].  
Although, it does not cause tumors in its natural Rhesus macaque host, SV40 causes 
tumors when injected into mice. Concerns regarding exposure of the human population to 
SV40 led to an extensive search for SV40 in brain cancers, osteosarcomas, non-Hodgkin 
lymphomas and mesotheliomas. Using PCR based analysis; SV40 T antigen sequences, but not 
viral genomes, were reported in these cancers. However, PCR contamination with laboratory 
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plasmids and cell lines (293 T cells) resulted in a lot of false positives in many tests, which have 
neither been reproducible nor consistent [86, 90, 92]. Antibodies to SV40 were detected in 
cancer patients, however subsequent case-control studies found equal prevalence in control 
cases. These antibodies were later found to cross-react to BKV and JCV viruses (infections are 
asymptomatic and common in the human population) [93, 94]. In 1998, the National Cancer 
Institute reported findings from an extensive study spanning decades of cancer incidence and 
mortality data (using SEER database and Connecticut Tumor Registry) and showed that, after 30 
years, there was no increased incidence of cancer in persons who may have received SV40-
containing vaccines [95]. Carbone et al. also specifically compared incidence of rare cancers in 
persons exposed as infants with non-exposed control populations and found no significant 
increase [96]. Various groups in United States and Europe have looked for, but have not found 
an elevated risk for cancer related to SV40 exposure [97, 98]. Although, there is strong 
corroboration from cell-culture studies and animal cancer bioassays that SV40 is oncogenic, 
numerous well-conducted studies show no convincing evidence that human cancers are caused 
by SV40 [86, 98]. Nonetheless, SV40 has become the prototype species and model virus for the 
Polyomavirus family. It is considered a workhorse for molecular biology and is extensively used 
for the study of DNA replication, transcription, oncogenic transformation and signal 
transduction pathways active in cancer [99-103]. 
 Primate lymphotropic polyomavirus (LPyV) or African green monkey polyomavirus, 
known to infect only B-lymphoblast cells of African green monkeys, is another member of the 
mammalian polyomavirus family. Interestingly, zur Hausen et al. reported that 15-30 % of 
humans harbor specific antibodies to LPyV. This suggested the presence of a still unidentified 
polyomavirus in humans [104, 105]. A recently discovered polyomavirus (in 2011), Human 
polyomavirus 9 (discussed belowin section 1.2.5), shows a high level of sequence similarity to 
LPyV and may explain seropositivity against LPyV detected by zur Hausen et al. 
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1.2.3 Genome	  organization	  
Polyomavirus	   genomes	   (range	   =	   4.6	   kb	   -­‐	   5.4kb)	   consist	   of	   covalently	   closed,	   circular,	   double	  
stranded	  DNA.	   Their	   genomes	   are	  often	   referred	   to	   as	  minichromosomes,	   since	   their	  DNA	   is	  
closely	   associated	  with	   histones	   and	   resembles	   cellular	   chromatin.	   They	   are	   enclosed	  within	  
nonenveloped,	   icosahedron	  capsids	  ~40-­‐45	  nm	   in	  size.	  Viral	  genomes	  are	  usually	  divided	   into	  
three	  parts:	  the	  early	  region,	  the	  late	  region	  and	  the	  noncoding	  regulatory	  region	  (NCRR).	  The	  
early	  and	  late	  nomenclature	  is	  based	  on	  the	  expression	  of	  transcripts	  before	  and	  after	  the	  onset	  
of	  viral	  replication.	  The	  NCRR	  divides	  the	  early	  and	  late	  region	  almost	  equally	  and	  contains	  the	  
origin	  of	   replication	  as	  well	  as	   the	   transcriptional	   control	  elements/	  early	  and	   late	  promoters	  
[106].	  Representative	  genomes	  of	  SV40	  and	  MPyV	  are	  shown	  in	  Figure	  2.	  
The	  early	  message	   is	  differentially	  spliced	  to	  encode	  2	  to	  5	  proteins	  depending	  on	  the	  
particular	   polyomavirus.	   These	   proteins	   are	   known	  as	   tumor	   (T)	   antigens,	   originally	   detected	  
using	  antibodies	  from	  tumor	  bearing	  animals.	  Large	  T	  and	  small	  T	  are	  expressed	  in	  all	  known	  
Figure	  2	  Overview	  of	  SV40	  and	  MPyV	  genome	  organization.	  	  
The	   genomes	   of	   SV40	   (5,243	   bp)-­‐	  NC_001669	   and	  MPyV	   (5,297	   bp)-­‐	  NC_001515	   are	   outlined.	   The	   early	   region	  
encodes	   the	   T	   antigens	   and	   the	   late	   region	   encodes	   the	   capsid	   proteins	   VP1-­‐3	   (VP4	   is	   unique	   to	   SV40).	   The	  
noncoding	   regulatory	   region	   (NCRR)	   separates	   the	   early	   and	   late	   regions.	   Different	   open	   reading	   frames	   are	  
generated	  through	  alternate	  splicing.	  A	  miRNA	  known	  to	  target	  the	  early	  message	  is	  also	  included.	  The	  numbering	  
direction	   of	   nucleotide	   nomenclature	   is	   opposite	   for	   the	   polyomaviruses,	   and	   is	   studied	   as	   shown.	   Some	   key	  
differences	   to	   note	   are	   the	   agnoprotein	   and	   VP4	   in	   SV40	   late	   region,	   and	   the	  middle	   T	   antigen	   and	   the	   tiny	   T	  
antigen	  unique	  to	  MPyV.	  The	  complete	  genome	  sequences	  were	  obtained	  from	  NCBI	  database	  (NC_001669—SV40	  
and	  NC_001515–	  MPyV)	  and	  analyzed	  using	  Macvector	  and	  XPlasMap	  softwares	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polyomaviruses, including all the nine human polyomaviruses (confirmed by protein expression 
or predicted via open reading frame analysis).  Splicing results in additional T antigen isoforms 
including 17kT from SV40 [107], middle T [108] and tiny T from MPyV [109], T’165, T’136 and 
T135 from JCV [110], truncT from BKV [111] and  57kT from MCV [112] (Figure 3). These T 
antigens usually share the N terminal exon 1 regions and diverge in their alternately spliced C 
terminus regions (Figure 3). Except for MPyV MT’s role in transformation [108, 113, 114] and 
JCV T antigens’ roles in promoting efficient viral replication [115], the functions of these axillary 
T antigens remain largely unknown.  
Through differential splicing and internal translation, the late region produces distinct 
capsid proteins (VP1, VP2 and VP3). The capsid is comprised of 72 pentamers of VP1 that 
contact VP2/3 proteins. VP1 is the major capsid protein and can spontaneously assemble into 
virus-like particles (VLPs) when expressed alone in cell culture. These VLPs are useful tools for 
serologic assays, which detect antibodies to polyomaviruses allowing estimates on exposure 
prevalence in human populations [116]. The VP4 capsid protein has so far been detected only in 
SV40, where it promotes egress of the virus after cell lysis [117]. In the cases of BKV and JC 
viruses the leader part of the late region also produces another protein called the agnoprotein, 
implicated in virion maturation. Although VP1 has been clearly defined as only a capsid protein, 
some studies have shown interactions of VP1 to c-myc, c-fos, poly (ADP-Ribose) polymerase 1 
(PARP-1), caspases and Akt-1 proteins, indicating unexplored alternate functions [118, 119].  
In 2005, Sullivan et al. discovered SV40 miRNAs using in silico screening followed by 
northern blot analysis and ribonuclease protection assays (shown in Figure 2) [120]. These 
miRNAs are perfectly complementary to the early viral mRNAs, targeting them for RISC-
mediated cleavage. SV40 miRNAs accumulate late during infection and reduce the expression of 
viral T antigens. SV40 mutants lacking miRNAs have higher levels of intact early mRNAs, but 
similar total infectious virus yields as compared to wild-type virus. The functional significance of 
these miRNAs came from the observation that SV40-miRNA-lacking mutant infected cells had a 
higher susceptibility to cytotoxic T cell (CTL) mediated cell lysis and triggered more interferon-γ 
production [120]. The existence of these autoregulatory miRNAs indicates that viruses have 
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evolved to use the host RNAi machinery, to generate small RNAs that help evade the host 
immune system and increase the probability of a successful infection. JCV and BKV viruses also 
produce microRNAs homologous to SV40 miRNAs with a few nucleotide differences in their 
seed regions. They also direct the cleavage of early viral transcripts and downregulate large T 
antigen expression. JCV miRNAs were detected in brain tissues of PML patients, suggesting a 
functional role in vivo [120, 121]. MPyV also encodes a microRNA that similarly cleaves early 
viral mRNAs but it is not essential for infection of cultured cells or experimentally inoculated 
mice [122]. MCV encoded miRNA is discussed Section 1.5.2.  
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Figure 3 Splicing patterns of various polyomavirus T antigens.  
The splicing patterns for JCV, BKV, SV40 and MPyV are compared to MCV T antigens. Different colors represent 
different reading frames and the dotted lines represent introns. The nucleotide positions and amino acid (aa) 
residue lengths of the different proteins are also shown. The N-terminus of each T antigen is shared (exon 1, range 
= 78-82 aa), but the C-terminus is most often unique (except 57kT and T‘165). The asterisks on MCV LT reveal the 
premature stop codons found in truncated LTs (350 and 339 prototypes in that order respectively). (Modified from 
Gjoerup and Chang, 2010)  
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1.2.4 Viral life cycle and general properties 
The polyomavirus life cycle begins with the interaction of the VP1 capsid protein with sialic acid 
or specific ganglioside receptors. Gangliosides GM1 are known receptors for SV40, GD1a and 
GT1b for MPyV, GD1b and GT1b are for BKV, GT1b and serotonin receptor 5HT2AR for JCV and 
co-receptors - GT1b and heparin sulfate (a glycosaminoglycan) - for MCV [123-126]. 
Gangliosides are components of the plasma membrane that comprise glycosphingolipids with 
one or more sialic acids. Once the virus binds to the receptor, the early stage of the life cycle 
proceeds via the virus being internalized through caveole for most polyomaviruses, or clathrin-
dependent endocytosis pathways for JCV [127]. Cellular factors compromise the lipid bilayer 
and allow release of the viral genome into the cytoplasm. Viral DNA traffics to the nucleus 
where transcription factors are recruited to allow early gene expression. Translated Large T and 
small T antigens drive infected cells into S phase where LT promotes cellular expression of DNA 
replication factors and initiates DNA replication of the viral genome from the origin region in 
the NCRR [102]. Commencement of viral replication leads to transition into the late phase of 
the viral life cycle. Viral DNA replication proceeds bidirectionally on the circular DNA genome, 
involving leading and lagging strands. Replication terminates when the two-replication forks 
meet [128]. It is thought that LT transcriptionally activates the late gene promoter and 
represses the early promoter. This leads to the expression of the capsid proteins, which then 
assemble into capsids and encapsulate the viral genome. The virus then lyses cells and exits. An 
SV40 infection cycle takes 3-4 days in permissive cells (such as CV1 or BSC40 African green 
monkey cells) in vitro, eventually resulting in cell death and the production of 300 infectious 
progeny virions per infected cell [129] (Figure 4). 
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Both	   species	   and	   cell-­‐type	   dictate	   the	   outcome	   of	   polyomavirus	   infection	   [130].	  
Polyomaviruses	   are	   able	   to	   productively	   infect	   their	   natural	   host,	   lyse	   cells	   and	   cause	   virion	  
release.	   They	   usually	   establish	   a	   persistent	   infection	   that	   is	   lifelong	   and	   asymptomatic	   or	  
subclinical.	   These	   viruses	   are	   usually	   kept	   in	   check	   by	   the	   immune	   system.	   Rarely	   are	   these	  
infections	   associated	   with	   tumors	   or	   other	   diseases,	   except	   in	   immunocompromised	   or	  
newborn	  animals.	  For	  example	  SV40	  is	  found	  to	  cause	  polyomaviral	  disease	  in	  its	  natural	  host	  
rhesus	  macaques	  only	  when	  they	  are	  immunosuppressed	  by	  simian	  immunodeficiency	  virus	  co-­‐
infection	  [131].	  	  
	  
	  
Figure	  4	  Representation	  of	  the	  polyomavirus	  life	  cycle	  in	  a	  permissive	  host	  cell.	  	  
1-­‐	   Virus	   attachment,	   entry	   and	   intracellular	   trafficking	   to	   the	   nucleus.	   2-­‐	   T	   antigens	   expression	   from	   the	   early	  
message	  (E-­‐mRNA)	  and	  function,	  3-­‐	  T-­‐antigens	  directed	  reprogramming	  of	  cells.	  4-­‐	  Viral	  DNA	  replication	  followed	  by	  
capsid	   protein	   expression	   from	   the	   late	   message	   (L-­‐mRNA).	   5-­‐	   Virion	   assembly	   and	   release.	   (Reproduced	   from	  
Fanning	  et	  al.,	  Chapter	  1,	  DNA	  Tumor	  Viruses,	  2009)	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Three outcomes of SV40 infection have been observed (Figure 5). 
1. SV40 infection of “permissive” cells, such as CV-1 or BSC40 lines of African green 
monkey kidney cells, results in cell death and production of infectious virions [132, 
133]. 
2. SV40 infection of some rodent cells does not result in cell lysis and virion production. 
Although the early events of the virus infection occur normally and the cells are 
driven into the S phase, the virus fails to initiate DNA replication and activate 
transcription from the late promoter. For example, when mouse embryonic cells 
(MEFs) are infected with a high multiplicity of infection of SV40 all the cells become 
infected. However, due to lack of viral replication T antigen expression is often lost by 
cell division related dilution or degradation of viral DNA. Many cell types, in culture, 
support infectious entry of polyomaviruses but do not appear to support the late 
phase of the viral life cycle [99, 133].  
3. An abortive infection, defined by normal viral entry and early gene expression but no 
viral replication and no late gene expression, is seen in some so-called 
“nonpermissive” cells. Initially, whole cell populations can become infected, but after 
subsequent cell divisions only rare transformants carrying an integrated viral genome 
grow out. Since this is a dead-end event that prevents the multiplication and spread 
of virions, it is often viewed as a “biological accident”. This accident is the mechanism 
believed to result in most tumors caused by polyomaviruses [19, 43, 99, 133]. The 
cells continue to express SV40 T antigens but are incapable of replicating the virus. A 
study by Gluzman and collaegues, in 1982, recognized this requirement for 
transformation of cells. They found that SV40 with mutations that disrupt viral 
replication and helicase activity show enhanced transforming activity [134]. 
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1.2.5 Human	  polyomaviruses.	  	  
Nine	  human	  polyomaviruses	  have	  been	  identified	  to	  date	  (in	  2012)	  (Table	  2).	  JC	  virus	  (JCV)	  and	  
BK	   virus	   (BKV),	   named	   after	   their	   source	   patient’s	   initials,	   were	   the	   first	   of	   the	   human	  
polyomaviruses	   to	   be	   discovered.	   They	   were	   culture	   isolated	   from	   diseased	   tissue	   of	  
immunosuppressed	   individuals,	   JCV	   from	   brain	   tissue	   of	   a	   patient	   suffering	   progressive	  
multifocal	   leukoencephalopathy	  and	  BKV	   from	  urine	  of	  a	  posttransplant	  nephropathy	  patient	  
with	  poor	   renal	   function	   [135,	  136].	   JCV	  has	  a	   limited	   tissue	   tropism	  and	   infects	  only	  kidney,	  
bone	   marrow,	   oligodendrocytes	   and	   astrocytes	   [137].	   In	   animal	   models,	   JCV	   causes	   tumor	  
formation	  in	  rodents	  as	  well	  as	  in	  non-­‐human	  primates	  [138-­‐143].	  Similar	  to	  JCV,	  expression	  of	  
BKV	  early	  region	  also	  transforms	  mouse	  and	  hamster	  cells	  and	  immortalizes	  human	  cells	  [144-­‐
Figure	  5	  Fate	  of	  SV40	  in	  different	  cellular	  environments.	  	  
(A)	  Infection	  of	  permissive	  cells	  results	  in	  cell	  lysis	  and	  virion	  production.	  (B)	  SV40	  infection	  of	  some	  rodent	  cells	  
induces	  S-­‐phase,	  but	  no	  cell	  death	  or	  virus	  production	  is	  observed	  (C)	  Integration	  of	  viral	  DNA	  in	  very	  few	  
nonpermissive	  cells	  and	  lack	  of	  replication	  lead	  to	  stably	  transformed	  cells	  	  (abortive	  infection,	  a	  biological	  
accident)	  (Modified	  from	  Ahuja	  et	  al.,	  Oncogene	  2005)	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147]. Additionally, BKV inoculation of newborn mice, rats and hamsters causes various tumors 
including ependymoma, neuroblastoma, fibrosarcoma and osteosarcoma [148, 149]. Based on 
these results, although JCV and BKV are linked to and investigated in various brain cancers, 
colorectal cancers and gastric cancers, a consistent and robust association between the viruses 
and diseases has not been made [137, 148, 150-159]. Both the viruses however, are common in 
the general population and maintain lifelong disease-free infection in immunocompetent 
individuals [160]. Studies by Knowles et al., Egli et al. and Kean et al. show an overall 
seroprevalence rate of 81-82% for BKV and 35-58% among healthy blood donors from UK, 
Switzerland and the United States [160-162]. Seroconversion occurs early in childhood and 
dampens in elderly individuals for BKV but increases steadily upto ~50% in 60-69 aged 
individuals for JCV [161]. 
Two more closely related human polyomaviruses were found in 2007: Karolinska 
Institute (KIV) and Washington University (WIV) polyomavirus. Both were isolated from samples 
from children with acute respiratory tract infections by enriching for viral particles using DNase 
treatment, constructing deep sequenced cloned cDNA libraries and blasting against NCBI 
databases for non-human sequences [163, 164]. Current experimental evidence does not 
support causation of any respiratory illnesses and no other link to disease of symptomatic 
infection exists [165-168]. Both viruses show a wide geographic distribution and seropositivity 
estimates range widely from 1-65% among the general healthy population [160, 169-174]. 
Merkel cell polyomavirus was the fifth human polyomavirus identified. It is the 
underlying focus of this thesis and is discussed in detail in the subsequent sections (section 1.5). 
Using a method called rolling circle amplification (RCA), three more polyomaviruses 
were discovered recently. RCA is a random primer extension technique that uses a DNA-
dependent polymerase (such as phi29) that preferentially amplifies circular DNA and can 
displace an annealed DNA strand [175]. In 2010, during a search for MCV on skin surfaces using 
RCA, Schowalter et al. serendepitiously discovered Human polyomavirus 6 and 7 (HPyV6 and 
HPyV7) from skin swabs of healthy human foreheads. Follow up studies failed to reveal any
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Table 2 Human Polyomaviruses (Modified from Chang and Moore, Annual Reviews Pathology 2011) 
 
Virus Year identified Method of identification 
Prevalence in 
human 
population 
Disease associations 
Genome 
size 
(prototype) 
GenBank Reference 
BK virus (BKV) 1971 Culture isolation from urine of renal transplant recipient >90% of adults 
Cystitis, polyomavirus-
associated 
nephropathies, 
ureteral stenosis 
5153 bp NC_001538 Gardner et al., Lancet, 1971 
JC virus (JCV) 1971 
Culture isolation from brain 
tissue with progressive 
multifocal leukoencephalopathy 
>70% of adults Progressive multifocal leukoencephalopathy 5130 bp NC_001699 
Padgett et al., 
Lancet, 1971 
Karolinska Institute 
polyomaviurs (KIV) 2007 
Deep sequencing of DNAase-
treated respiratory fluids 
55–70% of 
adults Not defined 5040 bp NC_009238 
Allander et al., 
JVI, 2007 
Washington 
University 
polyomavirus (WUV) 
2007 
Deep sequencing of DNAase-
treated respiratory fluids from 
children with upper respiratory 
infections 
69–80% of 
adults Not defined 5229 bp NC_009539 
Gaynor et al., 
PLoS 
Pathogens, 
2007 
Merkel cell 
polyomavirus (MCV) 2008 
Digital transcriptome 
subtraction of Merkel cell 
carcinoma tissue 
42–70% of 
adults Merkel cell carcinoma 5387 bp NC_010277 
Feng et al., 
Science, 2008 
Human Polyomavirus 
6 (HPyV6) 2010 
Rolling-circle amplification of 
skin and hair samples Not defined Not defined 4926bp NC_014406 
Schowalter et 
al., Cell host 
&microbe, 2010 
Human Polyomavirus 
7 (HPyV7) 2010 
Rolling-circle amplification of 
skin and hair samples Not defined Not defined 4952 bp NC_014407 
Schowalter et 
al., Cell host 
&microbe, 2010 
Trichodysplasia 
spinulosum 
polyomavirus (TSV) 
2010 
Rolling-circle amplification of 
trichodysplasia spinulosum 
lesion in transplant recipient 
Not defined 
Transplant-associated 
trichodysplasia 
spinulosum 
5232 bp NC_014361 
Van der 
Meijden et al., 
PLoS 
Pathogens, 
2010 
Human Polyomavirus 
9 (HPyV9) 2011 
Consensus PCR and deep 
sequencing Not defined Not defined 5026 bp NC_015150 
Scuda et al., JVI, 
2011 
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link between HPyV6 and HPyV7 and basal cell carcinomas, MCV negative MCCs, melanomas, 
and cutaneous B and T cell lymphomas [176].  These two viruses are most similar to WUV and 
KIV and are classified into the Wukipolyomaviruses group in the new ICTV taxonomical 
classification [83]. 
In 2010, an eighth human polyomavirus was isolated from virus-associated 
trichodysplasia spinulosum (VATS), a rare type of dysplasia seen only in transplant and 
immunosuppressed individuals that manifests as hyperkeratotic spinous papules. Based on 
previous ultrastructural detection of polyomavirus like particles in VATS [177] and its close 
association with immunosuppression, van der Meijden et al. applied RCA to VATS tissue and 
found trichodysplasia spinulosum polyomavirus (TSaPyV) [178]. TSaPyV was detected at high 
viral DNA load showing abundant protein expression only in the affected hair follicles, 
suggesting a causative role in trichodysplasia spinulosa pathogenesis [179, 180]. 
Most recently (2011), Human Polyomavirus 9 (HPyV9) was identified from serum of an 
immunosuppressed kidney transplant patient by using consensus PCR [181]. The extraordinary 
homology between HPyV9 and LPV may explain the previously detected, but unexplained high 
human seropositivity to LPV [182, 183] 
The majority of these newly discovered human polyomaviruses appear to be previously 
unrecognized, widespread infections. With improvement of detection techniques and assays 
the subfamily of human polyomaviruses is likely to expand revealing more viruses, either linked 
to disease or as a part of normal human microbial flora. 
1.3 SV40 T ANTIGENS- CLASSIC MODELS FOR STUDYING CANCER 
Polyomaviruses, specifically SV40, have been used as classic model systems for understanding 
basic cellular biology relating to cellular immortalization and oncogenic transformation. Over 
the last 50 years, since they were discovered, studies of polyomaviruses and their target 
pathways have lead to fundamental insights into key biological processes. Because of their 
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small	   genomes,	   these	  viruses	   rely	  heavily	  on	   their	  multifunctional	  T	  antigen	  proteins	  and	   the	  
cellular	   machinery	   to	   perform	   various	   functions	   in	   their	   life	   cycle	   [85,	   129].	   They	   begin	   by	  
reprogramming	   the	   host	   cell	   cycle	   to	   induce	   progression	   into	   S-­‐phase,	   thereby	   creating	   an	  
appropriate	  environment	  for	  viral	  replication.	  This	  is	  particularly	  important	  for	  SV40	  infection	  of	  
its	  natural	  host	  rhesus	  macaque,	  because	  SV40	  is	  believed	  to	  infect	  non-­‐cycling,	  often	  growth-­‐
arrested,	  epithelial	  cells	  of	  the	  kidney	  [99].	  	  
A	  tumor	  cell	  can	  be	  distinguished	  from	  its	  normal	  counterpart	  by	  a	  variety	  of	  indicators	  
such	  as	  changes	  in	  cellular	  morphology,	  the	  ability	  to	  grow	  in	  the	  absence	  of	  anchorage,	  loss	  of	  
density-­‐dependent	  growth	  inhibition,	  decreased	  dependence	  on	  serum	  growth	  factors,	  and	  the	  
capability	   to	   form	   tumors	   in	   animal	   hosts	   [184,	   185].	  Multiple	   assays	   have	   been	   established	  
over	   the	   years	   to	   study	   transformation	   phenotype,	   in	   vivo	   and	   in	   vitro,	  elicited	   by	   SV40	   and	  
other	   polyomaviruses.	   In	   each	   of	   these	   assays,	   cells	   are	   placed	   under	   conditions	   of	   selective	  
growth	  pressure	  so	  that	  only	  the	  transformed	  cells	  are	  able	  to	  survive	  and	  proliferate	  whereas	  
the	   normal	   cells	   die	   or	   enter	   senescence.	   These	   form	   the	   basis	   by	   which	   SV40	   and	   other	  
polyomavirus’	  ability	  to	  transform	  cells	  have	  been	  assessed	  [184].	  
1.3.1 Large	  T	  antigen	  (LT)	  
The	  ability	   to	   transform	  cells	   is	   linked	   to	  SV40	  T	  antigen’s	  ability	   to	   target	  and	  alter	  different	  
cellular	  pathways	  that	  are	  also	  important	  in	  preparing	  the	  cellular	  environment	  for	  replication.	  
Figure	  6	  Schematic	  of	  binding	  domains	  and	  interacting	  partners	  of	  SV40	  Large	  T	  antigen.	  
(Modified	  from	  Gjoerup	  and	  Chang,	  Adv	  Cancer	  Res	  2010)	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SV40 LT is multifunctional, nuclear phosphoprotein that is modular in structure. It has discrete 
regions corresponding to binding domains of its various interaction partners. Some of these 
interaction partners include pRB, p53, p107, p130 Hsc70, Cul7, Bub1, IRS1, p300/CBP, and 
FBW7 (Figure 6) [103, 186-197]. Two of the well-known tumor suppressor genes, p53 and the 
Retinoblastoma protein, were either discovered (p53) or functionally dissected (pRB) as a result 
of their interaction with SV40 [84, 85, 198]. The following sections will review and discuss the 
biochemical properties of SV40 LT and sT. 
1.3.1.1 Interaction with pRB family of proteins 
 
 We now know that a majority of tumor viruses target pRB or components of the pRB 
pathway, for inactivation. Polyomavirus T antigens share a highly conserved LXCXE motif, which 
binds to RB family proteins [195, 199-203]. Most cancers (viral and nonviral) contain 
aberrations in the regulation of the pRB pathway [204]. This reveals a common mechanism 
shared between viruses in targeting specific cellular proteins and demonstrates the importance 
of this protein family in tumorigenesis. 
 Knudson et al. first identified the retinoblastoma susceptibility gene in 1971. They 
statistically analyzed a genetic study, which suggested that childhood retinoblastoma had a 
hereditary component, and concluded that two independent mutation events were responsible 
for development of the disease. In hereditary retinoblastoma, the child inherited a mutated 
gene and acquired a second mutation in a somatic cell. In contrast, two independent mutations 
in the same somatic cell (later found to be two alleles of the same gene [205, 206] led to the 
development of sporadic retinoblastoma [17]. The gene was subsequently found and cloned 
from chromosome 13q14. The gene expresses a 110-kDa nuclear phosphoprotein [207].  
 A significant insight into pRb function was that it underwent phosphorylation in a cell 
cycle dependent manner. In the G0 state of quiescent or differentiated non-cycling cells and in 
the G1 phase of cycling cells, Rb protein is hypo- or under-phosphorylated. In this state pRb 
binds E2F transcription factors and represses transcriptional activity of genes having E2F-
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dependent regulatory elements. As cells enter the S phase of the cell cycle, Rb is hyper-
phosphorylated by sequential cyclin dependent kinases and dissociates from the E2Fs, 
permitting them to stimulate transcription of their target genes. The products of these genes 
then usher the cell from late G1 phase into S phase. The point of entry into early S phase of the 
cell cycle is often known as the “R point”/ “the restriction point” or the point of no return, as 
the hypophosphorylated form of pRb keeps the cells from entering into the cell cycle.    
 The Rb protein has been shown to bind over a hundred protein partners and mediates 
transcriptional regulation of numerous target genes [208]. These molecules mediate the various 
cellular functions of pRb, including temporary and permanent cell cycle arrest, differentiation, 
genomic stability and apoptosis. E2Fs are one of the most well studied and validated targets of 
pRb. E2F factors normally heterodimerize with DP family of proteins to facilitate DNA binding. 
The Rb protein binds this complex and effects its transcriptional repression by recruiting 
chromatin-remodeling elements, such as histone deacetylases [209]. 
 The first demonstration of a viral oncogene targeting a known tumor suppressor came 
from the recognition of pRB as a critical transformation target of adenovirus E1A protein [203].  
Following this, Decaprio et al. showed that SV40 T antigen binds pRB and more intriguingly T 
antigen LXCXE mutants, incapable of binding pRB, failed to transform cells (in a variety of cell 
types and assay systems) [195, 199]. The viral onocproteins bind and sequester 
hypophosphorylated form of pRb and free E2F transcription factors to activate cell cycle 
regulated genes, thereby steering the cell into the S phase and increasing cellular proliferation 
(see Figure 7 for a simplistic model) [195, 199]. 
 The Retinoblastoma protein is structurally composed of two domains, A and B, forming a 
pocket conformation critical for tumor suppression and is thus often referred to as a pocket 
protein [204]. This region constitutes the binding site for the LXCXE motif and mutations in 
human malignancies usually map to this region. Although, the binding sites for both viral T 
antigens and E2F1 map to the pocket domain, they are distinct and pRB can bind both 
simultaneously.  
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Figure	  7	  Simplistic	  Model	   for	   SV40	   LT	  mediated	   sequesteration	  of	  Rb	  and	   subsequent	  S	  phase	   related	  gene	  
expression.	  	  
Hypo-­‐phosphorylated	  pRb	  (green)	  binds	  to	  the	  E2F	  transcription	  factor	  (which	  is	  usually	  bound	  to	  a	  DP1	  protein	  
(blue	   and	   yellow))	   and	   discourages	   transcription	   of	   several	   S	   phase	   related	   genes	   by	   attracting	   histone	  
deacetylase	  (HDAC,	  gray)	  enzymes	  to	  repress	  them.	  In	  normal	  cycling	  cells,	  when	  the	  cell	  enters	  the	  S	  phase,	  pRb	  
becomes	   hyper-­‐phosphorylated	   and	   is	   released	   from	   the	   complex,	   freeing	   E2F	   to	   transactivate	   and	   regulate	  
gene	  expression	  (top).	  SV40	  LT	  binds	  and	  sequesters	  pRb	  and	   is	  able	  to	  free	  E2F	   independent	  of	  the	  cell	  cycle	  
phase.	  This	  helps	  activate	  cell	  cycle	  S	  phase	  related	  genes	  and	  progression	  (bottom).	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 Two other pocket proteins p107 and p130 were identified as additional cellular proteins 
in the RB family that bound to the transforming LXCXE domain of adenoviral E1A and SV40 LT 
[210-213]. Although partially redundant with pRB, a number of features distinguish the three 
proteins. A central spacer domain is present between the A and B pockets, in both p107 and 
p130. This region binds to cyclin A and E, when in complexes with CDK2 (cyclin dependent 
kinase 2). Also, different pRB family members bind different E2Fs. The pRB protein 
preferentially binds E2F1-3 (the “activating” E2Fs), in contrast the p107/p130 preferentially 
bind E2F4/5 (the “repressing” E2Fs) [199]. 
 Studies of SV40 have revealed the importance of LT antigen HPDKGG/J domain in the 
inactivation of pRb. The model proposed is that large T antigen binds to the hypo-
phosphorylated form of pRb and then recruits Hsc70 via its J domain. Once bound, the Rb-E2F 
complex first interacts with the substrate-binding domain of Hsc70 and then with its ATPase 
domain. Here, ATP hydrolysis and conformational changes lead to the dissociation of the 
complex [214, 215]. In addition to the LXCXE motif, the DnaJ domain is also essential for the 
inactivation of p107 and p130 [192, 216, 217]. 
 Pocket proteins negatively regulate cell cycle and cell growth. With an enhanced 
understanding of RB and several of its cellular functions, the basic model proposed above 
seems an oversimplication. It is now known that different complexes of pRB and E2F form in 
different stages of the cell cycle and their absolute levels are also cell cycle dependent. Notably, 
p130-E2F4 complexes are found in G0 phase, E2F-pRB and E2F4-p107 complexes are found in 
G1 phase, whereas S phase has free E2F1, -2 and -3. [199]. Quiescence is maintained, in part, by 
the presence of a repressive complex called DREAM (DP1, p130 (p107 in p130’s absence), E2F4 
and MuvB like proteins: LIN9, LIN37, LIN52, LIN54, and RBBP4) [218], which is anchored on the 
promoters of E2F-responsive genes by E2F4. It is believed that SV40 LT binds to this complex 
and with the aid of Hsc70-mediated ATP hydrolysis, dislodges E2F from p130 and sends p130 to 
the proteasome for degradation [129, 191]. This eventually leads to de-repression of the target 
genes where activating E2Fs then bind and activate gene expression transitioning the cell into S 
phase. 
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1.3.1.2 Interaction with p53 
 
 The p53 tumor suppressor protein was discovered (in 1979) as a cellular protein - binding 
partner of SV40 LT, both in SV40 transformed cells and infected cells [196, 197]. It is now 
recognized as a tumor suppressor found frequently mutated or deleted in approximately 50% 
of human cancers [219]. Also known as the “guardian of the genome”, p53 is a DNA damage 
and cellular stress responsive transcription factor which affects DNA synthesis and repair, 
imposes cell cycle arrest or leads to apoptosis or senescence [220]. Most viruses inactivate p53. 
Two well-known examples are adenovirus E1B 55k which binds and transcriptionally represses 
p53; together with E4orf6 that targets p53 for degradation, and human papillomavirus E6 
protein which targets p53 for proteasomal degradation [221, 222]. 
 The p53 binding sites within SV40 LT is bipartite at residues 351-450 and 533-626 [223]. 
Reported in 2006, the co-crystal structure of LT ATPase domain bound to p53 revealed a region 
within the core DNA binding domain of p53 as the interaction site of LT [224]. By blocking p53 
from binding to DNA promoter regions, the interaction between T antigen and p53 thus blocks 
p53- dependent gene expression [224, 225]. T antigen’s ability to bind p53, though necessary is 
not sufficient in many cases for transformation [223, 226]. Interestingly, some studies found 
that the interaction of T antigen and p53 also blocked T antigen’s replicative functions. 
Although one of the results of the interaction between LT and p53 is prevention of a DNA 
damage response, the consequences of this interaction are now known to be more complex. 
With the recent knowledge of the diverse downstream targets of p53, it is becoming clear that 
the effects of the LT and p53 interaction are not completely understood [227, 228]. Studies of 
LT transformation efficiencies and growth phenotypes in the presence or absence of p53 and 
p53 mutants led to the idea that LT stabilizes p53 and probably induces it to gain an unknown 
function [229-231]. The observation that presence of wild-type p53 enhances tumor formation 
in LT transgenic mice is consistent with this gain of function phenotype [232]. A popular 
hypothesis explaining this observation is that LT stabilizes p53 to gain access to p300/CBP, 
which then acts on promoters, or other LT bound proteins [233]. Several naturally occurring 
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p53 mutants seen in cancers exhibit a similar gain of function mutation [234, 235]. Hence, 
further studies of this effect are likely to reveal common mechanisms of tumorigenesis in 
nonviral malignancies as well. 
1.3.1.3 Other interactions 
 
DnaJ Domain 
The common region between LT and sT, implicated in transformation, includes a canonical 
HPDKGG motif [236]. This N terminus region of the two T antigens exhibits significant sequence 
homology and folds into a DnaJ domain like structure [236]. DnaJ proteins are co-chaperone 
proteins that recruit heat shock family proteins (DnaK family) for protein folding and protein 
transport. LT DnaJ domain binds to the constitutively expressed Hsc70 chaperone and 
stimulates its ATPase activity [103, 190, 236]. Classic D44N and H42Q mutants disrupt this 
binding and have been used to demonstrate the importance of the DnaJ domain in viral 
replication and in oncogenic transformation (via functional inactivation of pRB family members, 
as discussed in the previous section) [103, 190, 191, 217, 236, 237]. The DnaJ domain’s 
contribution to LT mediated cellular transformation is limited to a subset of assays. The D44N 
mutant immortalizes mouse embryo fibroblasts normally and in anchorage- independent 
growth measuring assays it shows no defect [191]. However, LT requires the DnaJ domain in cis 
with the pRB family binding site to disrupt p107/p130 and E2F4 complexes and promote growth 
in low serum and growth to high saturation density [191, 216, 217]. 
 Based on sequence homology, all polyomavirus T antigens appear to have a functional 
DnaJ domain. However, other viral oncoproteins such as human papillomavirus E6/E7 and 
adenovirus E1A/E1B do not have such a domain. Given the convergence of viral oncoproteins 
on other targets such as p53, pRB family and p300/CBP, this is surprising observation.  
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CR1 region 
 An adenovirus E1A conserved region 1 (CR1) like sequence is found in the N terminal region of 
SV40 LT. In E1A, this region is required for pRB and p300 binding, however there is no evidence 
that the CR1-like region in LT functions in a similar fashion [238]. In contrast, based on LT 
structural studies, it is likely that the CR1 domain is buried within a hydrophobic core. Further 
studies are required to determine the function of this region in SV40 and other polyomavirus T 
antigens [103]. 
 
p300/CBP and p400 
Cyclic-AMP response element binding (CREB)- protein (CBP) and p300 are large scaffold 
proteins involved in transcriptional regulation. They act as co-activators, in part via their 
intrinsic histone acetylase (HAT) activity and mediate a number of biological processes, 
including cell growth and transformation and are thus considered tumor suppressors [239]. 
Adenovirus E1A was first shown to bind p300/CBP and this binding was linked to adenovirus 
transformation and cellular DNA synthesis [240, 241]. Subsequent studies by Yaciuk et al. 
showed that pRB binding-deficient SV40 LT, but not DnaJ domain mutants, complemented 
p300/CBP binding- defective mutants of E1A to restore transformation in primary baby rat 
kidney cells [242]. This suggests analogous targeting of p300/CBP by E1A and LT. Although 
initial studies suggested LT’s CR1-like sequence as a binding site for p300/CBP, it was later 
demonstrated that LT C terminal residues 251- 708 are responsible for the interaction, although 
with decreased efficiency compared to wild-type LT [194, 243].  The binding is mainly indirect 
and is bridged by p53. LT-CBP interaction results in a K697 acetylation of LT in a p53-dependent 
manner [233, 244]. The significance of this remains unclear. Recent work by Ahuja et al., based 
on structure-guided mutational analysis of LT, indicates a direct binding of LT and p300/CBP 
proteins that is essential for oncogenic transformation [186].  
Like E1A, SV40 LT also binds to the p400 protein, through its C terminal 251-708 
fragment, but the significance of this interaction in LT-mediated transformation has not been 
elucidated [194, 245]. The p400 protein is a SW12/SNF2 family of chromatin remodeling factor, 
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interacts with a c-myc binding protein called TRRAP and is likely to be involved in the p53-p21 
cellular senescence pathway and p53-dependent apoptosis [246-248].  
 
Cul7 
Cul7 is a 185 kDa cellular protein that is a member of the SCF (skp1, cullin, F-box) type E3 
ubiquitin ligase complex. It assembles into complexes with Skp1, Fbxw8 and Rbx1 ring finger 
proteins and targets cellular proteins for proteasomal degradation [249]. The Cul7 protein was 
identified from a large-scale immunoprecipitation experiments coupled with mass 
spectrometry of LT1-135 overexpressed in mouse NIH3T3 cells [187]. Subsequent genetic 
analysis identified the Cul7 binding site to residues 69-83 in LT [250]. Although a mutant 
defective in binding Cul7 exhibits normal binding to Bub1, pRB and p53, it is defective in soft 
agar and high-density growth assays [250]. LT transformation relevant substrates for Cul-7 
mediated degradation have not been identified, but IRS1, involved in the insulin signaling 
pathway, and Mre11-Rad50-Nbs1 complex are reported candidates [251, 252].  
 
Bub 1 
Using LT1-135 as bait, a yeast two-hybrid screen revealed Bub 1, as an interactor for LT [188]. 
Bub1 is a mitotic checkpoint kinase that participates in the spindle checkpoint, at the 
metaphase to anaphase transition; ensuring correct attachment of kinetochores to spindle 
microtubules [253]. Coimmunoprecipitation experiments confirmed this interaction both in 
vitro (human cells) and in vivo (in mouse). Subsequent genetic mapping experiments identified 
residues 89-97 on LT as the Bub1 binding site. These sites contain a critical WEXWW motif, 
which is conserved in SV40, JCV, BKV and bovine polyomavirus T antigens. LT’s interaction with 
Bub1 leads to a compromise of the spindle checkpoint and is also important for forming foci in 
Rat-1 cells (measure of independence from contact inhibition) [188]. Interestingly, reduced 
Bub1 expression in mice causes impaired chromosome segregation and aneuploidy that leads 
to tumorigenesis, and sporadic Bub1 mutations has been detected in human colorectal cancers 
[254, 255]. 
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IRS1 
Insulin receptor substrate 1 (IRS-1) is a downstream target of insulin growth factor I (IGF-I) and 
plays an essential role in the signal transduction pathway in transmitting signals from insulin 
and insulin-like growth factor I receptors (IGF-IR) [256]. LT binds IRS-1 and LT is unable to 
transform IGF-IR deficient cells in the absence of IRS-1 [189, 257]. The IRS-1 binding site is 
located in the first 250 amino acids of LT. This interaction implicates LT in IGF-I/insulin signaling 
and both SV40 and JCV LTs were shown to translocate IRS-1 from the cytoplasm to the nucleus 
[258, 259]. Although a specific IRS-1 binding mutant has not been identified, recently a pRB 
binding mutation was shown to disrupt LT interaction with IRS-1 and a consequent defect in 
PI3K/Akt activation [260].  
 
Nbs1 
Nbs1, the Nijmegen breakage syndrome protein is a component of the MRN (Mre11, Rad50, 
Nbs1) complex and functions in double strand break DNA repair, possibly as a sensor of the 
double strand breaks. Nbs1 is mutated in the Nijmegen breakage syndrome, which is associated 
with chromosomal instability and increased cancer susceptibility. SV40 LT binds to Nbs1 and 
allows unrestrained firing of the viral origin [261, 262]. This binding requires the LT origin-
binding domain and a deletion mutant of residues 147-259 is defective in binding to Nbs1 [262]. 
Since the MRN complex is degraded by LT during infection, via its interaction with Cul7 [251], 
the significance of LT-Nbs1 interaction in genomic instability and oncogenic transformation is 
not completely understood.  
 
Fbw7 
The extreme C-terminus of SV40 LT binds to the F-box FBW7 protein via a phosphodegron, 
similar to the consensus found in FBW7 substrates. FBW7 is a component of the SCF complexes 
that recognizes the substrates and targets these cellular proteins for proteasomal degradation. 
LT was shown to mislocalize FBW7 from the nucleoli to the nucleoplasm, but this region is not 
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required for the full-length LT mediated transformation [263]. The extreme end of the C-
terminus of SV40, BKV and JCV also has a host-range function, which allows SV40 to grow in cell 
lines such as CV-1, but is not required for growth in other cells such as BSC40 [264]. The host 
range function may be mediated by binding to an unknown cellular protein [265].  
TEF-1 
T antigen binds to the transcription factor TEF-1 through its origin-binding region [266]. This 
interaction plays a role in the early to late switch in viral transcription and appears to modulate 
transcription of cellular genes as well. Although, a TEF-1 binding deficient mutant (S189N) is 
less efficient than wild-type T antigen in focus formation assays, this has not been fully 
characterized. Further studies are required to assess the importance of T antigen TEF-1 
interaction in the context of cellular transformation and viral replication [99, 267]. 
1.3.2 Small T antigen (ST) 
SV40 viruses that fail to produce ST are viable, but grow slowly and produce fewer replicated 
virions [268, 269]. While LT expression is sufficient for focus formation in many rodent 
transformation assays, ST is required for anchorage-independent growth [269-271]. Hahn et al. 
first accomplished human cell transformation in 1999 [272]. Using a combination of LT, ST, 
oncogenic H-ras and hTERT (human telomerase reverse transcriptase) they transformed normal 
human embroyonic kidney cells (HEK) and primary foreskin fibroblast cells (BJ). Cells expressing 
all three genetic elements were anchorage independent and formed tumors in 
immunodeficient nude mice. This study demonstrated that both LT and ST are important for 
transformation but also established that hTERT is essential for this phenotype in human cells 
[272]. 
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SV40	  ST	  is	  a	  174	  amino	  acid	  long	  protein	  that	  shares	  its	  first	  82	  aa	  with	  LT,	   including	  a	  
functional	  DnaJ	  domain.	  Unlike	  the	  LT	  DnaJ	  domain,	  the	  function	  or	  target	  of	  ST’s	  DnaJ	  domain	  
have	  not	  been	  elucidated	  nor	  implicated	  in	  ST-­‐mediated	  transformation	  [190].	  Although	  LT	  is	  a	  
nuclear	  protein,	  ST	  is	  found	  both	  in	  the	  nucleus	  and	  cytoplasm.	  The	  C-­‐terminus	  of	  ST	  has	  two	  
CXCXXC	  clusters	  that	  bind	  Zinc	  and	  confer	  conformational	  stability	  (Figure	  8)	  [273].	  
	  
PP2A	  
Protein	   Phosphatase	   2	   A	   (PP2A)	   is	   a	   heterotrimeric	   serine-­‐theronine	   phosphatase	   enzyme	  
composed	  of	  an	  A	  scaffold	  subunit,	  a	  B	  regulatory	  subunit	  and	  a	  C	  catalytic	  subunit.	  There	  are	  
two	  different	  A	  subunits,	  two	  different	  C	  subunits	  and	  17	  known	  B	  subunits	  that	  can	  assemble	  
together,	   in	  various	  combinations,	   into	  more	   than	  100	  different	  holoenzyme	  complexes	   [274,	  
275].	  The	  different	  isoforms	  of	  PP2A	  regulates	  a	  variety	  of	  proliferative	  and	  apoptotic	  pathways	  
inside	  a	  cell.	  	  
SV40	   ST	   C-­‐terminal	   region	   binds	   to	   the	   PP2A	   family	   of	   proteins	   and	   a	  majority	   of	   its	  
activities	  can	  be	  attributed	  to	  this	  association.	  ST	  residues	  97-­‐103	  are	  crucial	  for	  this	  interaction	  
with	  PP2A	  [276].	  Human	  cell	   transformation	  requires	  ST	  and	  depends	  on	   its	  binding	   to	  PP2A.	  
Mutants	  in	  ST	  that	  disrupt	  its	  PP2A	  interaction	  are	  defective	  in	  transformation.	  In	  addition,	  an	  
ST	  truncation	  mutant	  containing	  only	  the	  PP2A	  binding	  domain	  (aa	  88-­‐174)	  retains	  the	  ability	  to	  
promote	  transformation	  [270,	  272,	  277].	  Effects	  of	  ST	  in	  anchorage-­‐independent	  growth	  were	  
mimicked	  by	  knockdown	  of	  the	  PP2A	  B56Y	  subunit	  in	  human	  embryonic	  kidney	  epithelial	  cells,	  
indicating	  PP2A	  as	  a	  key	  target	  [278].	  Mutations	   in	  PP2A	  subunits	  have	  been	  found	   in	  human	  
cancers,	  suggesting	  a	  tumor	  suppressor	  function	  [274].	  One	  of	  the	  many	  diverse	  targets	  of	  PP2A	  
potentially	   involved	   in	   ST-­‐involved	   tumorigenesis	   is	   Akt,	   a	   component	   of	   the	  
Figure	  8	  Schematic	  of	  binding	  domains	  and	  interacting	  partners	  of	  SV40	  Small	  T	  antigen.	  
(Modified	  from	  Gjoerup	  and	  Chang,	  Adv	  Cancer	  Res	  2010)	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phosphatidylinositol 3-kinase (PI3K) pathway. ST inhibition of PP2A leads to the 
phosphorylation and activation of Akt, which further activates the mTOR complex resulting in 
increased cap-dependent translation. It was shown that in human mammary epithelial cell 
transformation assays constitutively active forms of PI3K or Akt and a small GTP binding protein 
named Rac could replace ST [279]. More than 30 kinases are regulated by PP2A [280]and the 
effect of ST-PP2A interaction on the PI3K pathway is likely to be a small part of its impact on ST-
mediated transformation.  
1.3.3 Insights into malignant progression from SV40 transgenic mouse models 
T antigen has been expressed in a variety of different cell and /or tissue types including 
mammary glands, pancreas, liver, prostate, salivary glands, intestine, brain, lung, kidney, eye, 
smooth muscle, cartilage, and bone, both in vitro and in vivo [99, 281, 282]. The cell type plays 
an important role in the development of tumors. This is underscored by the observation that in 
different cell systems either LT alone or in conjunction with ST can induce hyperplasia, 
dysplasia, carcinoma, and metastasis or in contrast, no stimulation of proliferation at all. 
Targeted expression of only LT in the epithelium of choroid plexus, a structure in the brain that 
produces and filters the cerebrospinal fluid, is one of the most thoroughly studied SV40 mouse 
model systems [283-285]. The mice rapidly develop aggressive tumors and die within 1-2 
months. Interestingly, use of a N-terminal fragment of the first 121 amino acids (T121) of LT, 
that lacks the p53 interacting function, produces identical, but slower growing tumors. 
However, in a p53 deficient background this T121 mutant causes rapid tumor growth with 
minimal apoptosis. A mutant T121 with a defective LXCXE pRB-binding motif is unable to induce 
tumors. Disruption of the Rb pathway causes abnormal entry of quiescent epithelial cells into 
the S-phase by upregulation of E2F1. The E2F1 transcription factor then triggers a p53-
dependent checkpoint poised to eliminate tumor cells via apoptosis. However, T antigen 
prevents cell death by binding and inactivating p53 [284, 286, 287]. These experiments 
elegantly demonstrate the necessity of inactivating both the pRB and p53 pathways to induce 
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proliferation. Cell-type specific expression of T121 in the mammary gland also shows that p53-
dependent apoptosis limits tumor development [288].  
The requirement of p53 inactivation for tumor formation and development is cell 
context dependent. LT causes tumors in a variety of cell types and tissues, independently of its 
effect on p53. For example, targeted expression of T121 in astrocytes led to aberrant 
proliferation along with extensive apoptosis that was dependent on functional PTEN. A 
combination of pRB inactivation by T121 and PTEN loss accelerated astrocytomas in this model 
system [289]. In addition, expression of T121 in the liver causes hepatocellular carcinomas and 
requires an intact pRB and DnaJ domain [290].  
Several studies indicate that p53 does not play a role in the tumorigenesis induced by LT 
in intestinal enterocytes. Expression of amino-terminus truncation mutants of LT in these cells 
leads to hyperplasia, that progresses to dysplasia with age [291-293]. LT fails to stabilize p53, 
which is undetectable in normal or T antigen expressing mice villi, and genetic removal of p53 
also does not change or affect the frequency of this hyperplasia formation [228, 293, 294]. 
Microarray analysis by Rathi et al. indicate that LT and LT1-136 regulate a highly overlapping set 
of genes via their intact DnaJ and pRB binding motifs [228]. A majority of these are targets of 
the pRB/E2F pathway, underscoring its importance in hyperplasia formation in enterocytes.    
Expression of both LT and ST has been successfully used in the prostate and in acinar 
cells of the pancreas to produce cancers. When expressed in the prostate epithelium under a 
probasin promoter, hyperplasia, adenocarcinoma and metastases are observed [295, 296]. 
PTEN, rather than p53, is the activator of apoptosis and inhibitor of tumor progression in this 
system. Truncated N terminal versions of T antigen are sufficient to induce pancreatic acinar 
carcinomas, again indicating that a disruption of p53 is not required to generate neoplasia 
[297]. 
Transgenic mouse models are valuable systems because they allow a direct assessment 
of the individual contribution of different genes to tumorigenesis in distinct cell and tissue 
types. In addition, they often provide a representation of human cancer useful for therapeutic 
compound testing. Although not entirely clear, the varied responses elicited by LT across 
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different systems may reflect the general heterogeneity of cancer. In their recent review, 
Robles and Pipas suggest two models to explain this observation. One model suggests that in 
addition to pRB and p53, LT could interact with other unique binding proteins within each cell 
type that contributes uniquely to specific aspects of tumorigenesis. A second model proposes 
that although LT interacts with the same set of proteins in each cell type, the responses differ 
because the cellular proteins and pathways are differentially regulated based on the cell system 
[281]. A combination of the two scenarios is also possibile. In mouse models of cancer, pRB 
inactivation appears to be more important than p53 inhibition, but the contribution of 
additional binding proteins (within the amino-terminus of LT, Bub1, Cul7, IRS1) remains unclear. 
1.4 MERKEL CELL CARCINOMA 
1.4.1 Origin and pathology 
Merkel cell carcinoma (MCC) is an uncommon but aggressive, primary cutaneous neoplasm 
frequently having a poor prognosis [58, 59]. Initially named trabecular carcinoma of the skin, it 
was first described by Toker in 1972 [298]. MCC derives from mechanoreceptor Merkel cells 
(named after Friedrich Sigmund Merkel who first described them in 1875) located at the basal 
layer of the epidermis. These Merkel cells originate from epidermal progenitors during 
embryonic development and play a role in the sensory system of the skin [299-304]. Although 
MCC has variable manifestations, they most commonly appear as solitary purple to red nodules 
or plaques (in the early benign stages, Figure 9 A). MCC cells have round to oval nuclei with 
scant cytoplasm (Figure 9 B). Most common primary sites of MCC occurence are sun-exposed 
sites such as the head and neck, followed by the lower and upper extremities and the trunk 
region. Tumor cells are usually arranged in sheets, solid nests, or anastomosing trabeculae [62, 
305]. Most tumor cells contain dense, membrane bound core structures in the cytoplasm 
similar to neurosecretory-type granules (80-120 nm). Sibley et al. and Tang et al. first identified 
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these through electron microscopy [305, 306]. Due to this expression of chromogranin, 
synaptophysin and other such neuropeptides in Merkel cell neoplasia, MCC is also referred to 
as a neuroendocrine carcinoma. Gene expression profiling and clinical analysis suggest that 
MCC comprises two clinically similar diseases with different causes [307]. 
Diagnosis of MCC has been challenging due to its similarity with other cancers, 
especially basal cell carcinoma [308, 309], metastatic small cell lung carcinoma [310, 311], and 
small cell sweat gland carcinoma [312]. MCC expresses a variety of neuroendocrine and 
epithelial markers. Positivity for Cytokeratin 20 (CK20) in a perinuclear dot-like pattern upon 
immunohistochemical staining (Figure 9 C), combined with negativity for thyroid transcription 
factor 1 (TTF-1), leukocyte common antigen (LCA) is the most distinguishing feature of MCC 
[313-315]. MCC shows variable positive staining with other epithelial markers - AE1/AE3, 
Cam5.2, neuroendocrine markers - neuron specific enolase and chromogranin, and neural 
marker CD56 and negative staining for synaptophysin and neurofilament. These markers are 
also clinically used to help confirm diagnosis [316-322].  
 
B C A 
Figure 9 Clinical appearance and pathology of Merkel cell carcinoma  
(A) Raised, red, nodular MCC lesion on arm of a patient. (Adapted from Chang and Moore, Annual. Rev. Pathol, 
2012) Merkel cell carcinoma tissue staining with (B) Hematoxylin-eosin (H&E) and (C) Cytokeratin-20 (CK20). 
(Reproduced from Feng et al., Science, 2008) 
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1.4.2 Risk factors and clinical features 
AIDS patients have a 13-fold higher age and sex-adjusted risk for developing MCC, compared 
with the general population [60]. MCC incidence rises sharply in elderly populations (median 
age =65 years) [62] and immunosuppression following transplantation and immune-related 
cancers is another recognized major risk factors for MCC [58]. Similar to melanoma, MCC also 
shows a strong correlation to UVB exposure [323]. The majority of the patients with MCC are 
fair skinned men [58, 59, 324]. Heath et al. have summarized the most significant features of 
MCC in an acronym: AEIOU (asymptomatic/lack of tenderness, expanding rapidly, immune 
suppression, older than 50 years, and ultraviolet-exposed site on a person with fair skin) [62]. 
1.4.3 Staging 
MCC is divided into four clinical stages depending on the severity of disease. The stage 
determined at diagnosis informs prognostication, chance of spread (metastasis), and treatment 
options. According to American Joint Committee on Cancer’s (AJCC) 2009 staging manual, MCC 
is defined as Stages I and II if the tumor is localized to the skin at the primary site. Stage I is for 
primary lesions less than or equal to 2 cm in diameter, whereas stage II is when primary lesions 
exceed 2 cm. Stage III is defined as disease that involves nearby/regional lymph nodes and 
stage IV, the most severe form, is found beyond the lymph nodes [325]. The 5-year disease 
specific survival rate for MCC ranges from 60% for stage I to only 18% for stage IV disease [325, 
326].  
1.4.4 Incidence 
MCC age-adjusted incidence rates range between 0.18 to 0.4 per 100 000 persons [327]. 
Although rare, MCC’s overall SEER (Surveillance, Epidemiology, and End Results Program of the 
National Cancer Institute (NCI), United States) study of 3870 cases collected from 1973-2006 
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[327], revealed tripling of incidence rates from 1986-2001. The incidence reached about 1,500 
cases per year in the United States in 2006 [59]. A few other population-based studies in 
Scandinavian Europe [66, 328-330] also reveal similar patterns as in the USA.  
1.4.5 Molecular studies  
Although molecular studies of MCC have revealed amplification of L-Myc gene (~30% tumors) 
loss of pRB1 genetic region (~25%tumors), UV-B specific mutations in p53 and H-ras genes, 
activating c-kit mutations, VEGF alterations, and CD117 positivity, none of these distinct 
pathways have convincingly been linked to MCC tumorigenesis [331-336]. Cytogenetic deletions 
in chromosomes 3p, 4, 5q, 7, 10q, 13q and 17q and extra copies of regions on chromosomes 1q, 
3q, 5p, 6 and 8q have also been observed [311, 332]. BRAF and MAPK signaling cascade 
alterations, although present, do not seem to play an important role in the biology of MCC 
[337-339].  
1.4.6 Treatment 
Treatment and optimal care for Merkel cell carcinoma patients is based on various issues that 
are highly variable: immune suppression, overall health of the patient, node status, tumor size 
and location, stage of the disease, age, lymphovascular invasion of primary lesion, etc. There 
are several treatment options for this disease. These include, surgical excision of the primary 
lesion, followed by (if needed) lymph node resection, radiation therapy and chemotherapy. 
Wide surgical excision (with greater than or equal to 2 cm margin) and sentinel node biopsy is 
usually the mainstay of treatment for patients with MCC. Due to the high radiosensitivity of 
MCC, radiation therapy is also used for unresectable or recurrent tumors. On the other hand, 
chemotherapy is uncommon and not usually effective. It is usually given for palliative therapy 
to patients with stage IV disease. Adjuvant chemotherapy is sometimes used to destroy any 
cancer cells that remain after surgery and/or radiation therapy. Although there is no well-
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established combination chemotherapy for MCC, due to its similarities with other 
neuroendocrine carcinomas (such as small cell lung cancer), regimens that show good results in 
these diseases are used [340, 341].        
 A number of groups have tested and analyzed the chemosensitivity of commonly used 
chemotherapeutic cytotoxic drugs on MCC [342-344]. In 1999, Voog et al. [343] summarized 
101 cases of locally advanced and metastatic MCC treated with a multiagent regimen. 
Cyclophosphamide, doxorubicin, and vincristine were the most frequently used regimen 
producing a response rate of 67%. The small-cell lung cancer regimen of cisplatin/etoposide 
produced a 47% response rate in MCC patients. The duration of these responses however was 
limited to 8 months overall and only 3 months for those with partial response. Full responders 
had a median survival of approximately 20 months and treatment toxicities were significant 
with a total of 9 treatment-related deaths (increasing age being a major risk factor).    
 The expression of the KIT receptor in MCC implicated the use of imatinib mesylate 
(Gleevec) in MCC [345, 346].  However, phase II trial of imatinib mesylate performed by Sondak 
et al. however did not show treatment effects in advanced MCC patients as anticipated [347].  
 Pascucci’s group successfully showed an unusual compound selection to work. They 
treated 4 cases of stage-1 MCC with surgery followed by intralesional Bleomycin, and saw no 
evidence of recurrence or metastasis for 5 years [348]. This was a considerable improvement 
from a usual ~30% recurrence rate seen stage I-III MCC patients at a median follow up of 3.6 
years [349]. Bleomycin is a glycopeptide antibiotic that induces DNA strand breaks and has 
antiviral properties against drug-resistant HIV strains [350]. Although the study has implications 
in viral associated diseases such as MCC, the sample size used by Pascucci et al. was limited and 
more data is needed to make any conclusion.       
 Due to the rarity of MCC cases clinical trials are difficult to perform. There are three 
recent ones that have generated interest among MCC clinicians and hold promise for future 
patients. One uses Oblimersen (also known as Augmerosen or Genasense), a bcl-2 antisense 
oligodeoxyribonucleotide developed by Genta Incorportaed [351] (Clinical Trail Identifier on 
clinicaltrials.gov: NCT00079131). In the second trial, patients are given interleukin-12 gene 
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therapy (NCT01440816) and the third clinical trial involves treating patients with the drug BB-
10901/IMGN901 or Lorvotuzumab Mertansine (NCT00346385). IMGN901 is a CD56 antibody 
conjugated to a cytotoxic microtubule inhibitor (Mertansine of DM1). Since MCC is one of the 
few cancers that express CD56 on its surface, it was considered a good candidate for studying 
IMGN901 efficacy. This drug carries orphan drug status for MCC treatment and was developed 
by Immunogen Inc. While two out of the three trials are still recruiting patients, the Oblimersen 
trial was recently completed. In a study of 12 patients probable antitumor activity was 
documented in 1 patient, but no objective responses as per RECIST (Response Evaluation 
Criteria in Solid Tumors) criteria were observed [351]. A recent study by Willmes et al. shows 
inhibition of MCC cell line growth and regression of MCC mouse xenograft tumors by using 
interferon [352].          
 In Chapter 3 of this dissertation, the use of a recently developed survivin inhibitor 
YM155 in treating MCC cells both in vitro and in mouse xenograft models is described. The drug 
is in early stages of clinical development and a phase II clinical trial for MCC using YM155 is 
anticipated to begin patient recruitment in the fourth quarter of 2012 (ECOG # E1611). 
1.5 MERKEL CELL POLYOMAVIRUS 
Similar to other polyomaviruses (especially LPV [104] and SV40 [353]),  MCV is also a non-
enveloped, icosahedron shaped, small, double stranded DNA virus that is phylogenetically 
classified into the mammalian Orthopolyomavirus genera [83]. Polyomaviruses’ ability to induce 
neoplastic transformation in cell culture and neoplasias in vivo have been well documented 
([354]) however none have been consistently and convincingly linked with human cancer thus 
far. MCV discovery, as an integrated part of MCC represents the first widely accepted 
association of a specific human cancer with the consistent presence of a polyomavirus genome.  
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1.5.1 Discovery	  of	  MCV	  
MCV	  was	  discovered	  in	  2008	  by	  Feng	  et	  al.	  [74],	  using	  a	  technique	  called	  Digital	  Transcriptome	  
Subtraction	   (DTS)	   [75].	   As	   a	   result	   of	   the	   generation	   of	   curated	   and	   highly	   verified	   human	  
genomic	   sequence	   databases	   (made	   available	   through	   the	   Human	   Genome	   Project)	   and	   the	  
development	  of	   low-­‐cost,	  high-­‐throughput	  sequencing,	  DTS	  became	  a	  practical	  computational	  
approach	   to	   detect	   new	   virus	   agents	   associated	   with	   human	   cancers.	   Complementary	   DNA	  
(cDNA)	  was	  made	  from	  mRNA	  of	  four	  MCC	  tumor	  tissues	  through	  reverse	  transcription.	  These	  
libraries	  were	  then	  exhaustively	  sequenced	  to	  generate	  a	  stringent	  high	  fidelity	  transcriptome	  
database	   of	   MCC	   tumors.	   An	   in	   silico	   subtraction	   of	   known	   human	   sequences	   from	   human	  
RefSeq	  RNA,	  mitochondrial,	  assembled	  chromosomes,	  and	  immunoglobulin	  sequences	  in	  NCBI	  
databases	   identified	   candidate	   nonhuman	   (suspected	   pathogen)	   sequences	   for	   further	  
examination.	   These	   candidates	  were	   then	  explored	  using	   lower-­‐stringency	  alignment	   to	   virus	  
databases.	  Of	  395,734	  MCC	  transcripts	  sequenced,	  382,747	  sequences	  formed	  the	  high-­‐fidelity	  
data	  set	   (HiFi)	  and	  after	  screening,	  2395	  were	   identified	  as	  non-­‐human	  DTS	  candiadates.	  One	  
transcript	  had	  59%	  homology	  to	  the	  African	  green	  monkey	   lymphotropic	  polyomavirus	   (LPyV)	  
tumor	   T	   antigen	   [104,	   355]	   and	   human	   BK	   polyomavirus	   [135]	   T	   antigen	   sequences.	   Further	  
experimental	   extension	   (RACE	   and	   genome	   walking)	   using	   this	   transcript	   completed	   the	  
sequence	  of	  the	  entire	  genome	  of	  MCV	  (GenBank	  accession	  numbers	  EU375804)	  [74].	  
Figure	  10	  Pictoral	  Representation	  of	  DTS	  Analysis	  of	  Merkel	  cell	  carcinoma	  
(Modified	  from	  Feng	  et	  al,	  Science	  2008,	  and	  Feng	  AACR	  Meeting	  presentation)	  
	  	  
	   45	  
1.5.2 Genomic	  organization	  of	  MCV	  
MCV	  has	  a	  ~5.4	  kb	  (range	  5.2	  –	  5.4	  kb)	  genome	  that	  is	  divided	  into	  early	  and	  late	  coding	  regions	  
by	   a	   noncoding	   regulatory	   region	   (NCRR).	   The	   early	   region	   encodes	   a	   large	   T	   antigen	   (LT),	   a	  
small	  T	  antigen	  (sT)	  and	  a	  57kT	  antigen	  (analogous	  to	  the	  SV40	  17-­‐kT	  antigen	  [107]),	  all	  of	  which	  
share	   a	   78	   amino	   acid	   stretch	   in	   the	  N	   terminus.	   These	   three	  proteins	   are	   expressed	   from	  a	  
multiply	  spliced	  mRNA	  (with	  frame	  changes)	  as	  shown	  in	  Figure	  11.	  	  
MCV	  late	  region	  encodes	  3	  capsid	  proteins	  (VP1,	  VP2	  and	  VP3)	  that	  are	  expressed	  after	  
the	   onset	   of	   viral	   DNA	   replication.	   These	   structural	   proteins	   self-­‐assemble	   into	   a	   ~55-­‐nm	  
diameter	   icosahedron	  viral	  particles,	  that	   look	  similar	  to	  other	  polyomaviruses	  under	  electron	  
microscopy	   [116,	   356].	   Unlike	   other	   polyomaviruses	   however,	   MCV	   does	   not	   encode	   an	  
agnoprotein	  [357,	  358]	  or	  VP4	  [359].	  Formally,	  little	  is	  known	  about	  the	  kinetics	  and	  regulation	  
of	  MCV	  late	  gene	  expression	  because	  virus	  replication	  studies	  have	  been	  limited.	  Comparison	  of	  
Figure	  11	  Genome	  organization	  of	  Merkel	  cell	  polyomavirus.	  
Merkel	  cell	  polyomavirus	   (wild-­‐type)	  has	  a	  circular,	  5387	  bp	  genome	  divided	   into	  two	  halves	  by	  the	  noncoding	  
regulatory	  region	  (NCCR).	  This	  NCCR	  contains	  the	  origin	  of	  replication	  of	  the	  virus	  as	  well	  as	  the	  promoters	  and	  
regulatory	   elements	   to	   bidirectionally	   encode	   early	   and	   late	   viral	   proteins.	   The	   early	   region	   encoded	   proteins	  
comprise	  the	  Large	  T,	  small	  T	  and	  the	  57kT	  antigens.	  Viral	  protein	  1,	  2	  and	  3	  (VP1,	  VP2	  and	  VP3)	  constitute	  the	  
gene	  products	  of	  the	  late	  region.	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late gene expression for the MCV-HF molecular clone to a replication defective mutant clone 
having a point mutation in the viral origin suggests that MCV late gene expression depends on 
active DNA replication of the viral genome [360]. 
The NCRR region of MCV contains a 71-bp viral replication origin. This core sequence 
comprises of an AT-rich tract that helps in DNA melting and 8 GAGGC pentanucleotide 
sequences that bind MCV LT. Although the origin region maintains efficient full length (wild 
type) T antigen-directed DNA replication, tumor-derived LT is replication incompetent [361]. 
Interestingly, a naturally occurring point mutation in the core origin region that ablates 
replication was found in tumor derived viral genome (MCV350) [362]. The NCRR also contains 
bidirectional transcriptional promoters and regulatory elements for early and late viral gene 
expression. 
Recent studies have identified an MCV encoded miRNA- MCV-mir-M1 [363]. It is 
encoded from the late strand (similar to MPyV) and is antisense to early transcripts (regions 
1201-1245). Similar to the SV40 miRNA, it is predicted to cleave early viral RNAs during MCV 
infection and was shown to negatively regulate expression of chimeric luciferase reporters 
containing a portion of the early transcript in vitro [120]. Although MCV-mir-M1 was found 
using an in silico and in vitro approach, it was recently detected in 2/3 and 19/38 MCV positive 
MCC tumors by direct sequencing and real-time PCR methods respectively. A 2-nucleotide 
difference (shift) from the in silico predicted mature miRNA was found [364]. This microRNA 
shares no sequence identity with any other previously known miRNAs of viral and host origin. 
Further studies in MCV encoded miRNAs and their potential target viral and cellular genes in 
MCC tumors are needed to understand their function.  
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1.5.3 Tumor specific signature truncation mutations   
MCV large T antigen retains conserved domains that are present across different virus families 
(including polyomaviruses), such as CR1, DnaJ and LXCXE Rb binding motifs [85, 99]. These are 
described in Figure 12. Besides tumor suppressor targeting domains, LT also encodes origin 
binding and helicase/ATPase regions needed for viral replication [112]. Recently Liu et al. found 
a novel interaction of MCV LT with human Vamp6 protein (hVam6p), a protein involved in 
lysosomal processing. The binding site was mapped to a unique region immediately adjacent to 
the Rb binding motif [365]. LT binds and sequesters the cytoplasmic Vam6p protein to the 
nucleus, causing a disruption in lysosomal clustering. Other consequences of this re-location are 
unknown, preliminary work indicates that Vam6p may regulate MCV replication [360].  
 MCC tumor-derived MCVs have premature stop codon mutations (substitutions, 
frameshift, missense, insertions and deletions) that truncate the LT protein, eliminating its C 
terminal domain [366, 367]. Although these truncation mutations ablate the replication 
functions of MCV T antigen in the tumors, they occur after the LXCXE retinoblastoma-binding 
(and other pocket protein binding) motif and do not interfere with other N-terminal LT domains 
[368]. However, a putative p53-binding domain is also disrupted by these mutations [223, 224]. 
These two independent mutation events – virus integration and T antigen truncation that leads 
to replication incompetence appear to play a mechanistic role in the development of MCC. 
Since both events are rare mutational events, but present in all MCV positive MCCs they may 
also explain MCC rarity.         
 MCV T antigen also has a nuclear localization signal mapping to aa 277-280 (Arg-Lys-Arg-
Lys) [369]. This NLS is different from the KKKR (or K) KVEDP sequence that constitutes the SV40, 
JCV and BKV polyomavirus’ NLS [370]. Although highly conserved and functional in MCC clinical 
samples there are exceptions where the NLS is lost in the truncated tumor Ts [74, 112, 369].  
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Figure	  12	  T	  antigen	  locus	  genome,	  transcript	  and	  protein	  features.	  	  
MCV	  T	  antigen	  contains	  conserved	  protein	  motifs,	  similar	  to	  other	  polyomaviruses.	  These	  include	  CR1	  (conserved	  
region	  1),	  DnaJ,	  Rb	  (retinoblastoma)	  binding,hVam6p	  binding	  and	  a	  nuclear	  localization	  signal	  (NLS)	  in	  the	  N-­‐terminal	  
part	  of	  the	  proteins.	  The	  C	  terminal	  motifs	  (required	  for	  replication)	  :Origin	  Binding	  domain	  (OBD),	  Zinc	  finger,	  
leucine	  zipper	  and	  helicase	  domain	  are	  lost	  in	  tumor	  Tags	  due	  to	  stop	  codon	  truncation	  mutations	  (red	  arrows	  mark	  
the	  mutation	  sites	  for	  the	  two	  prototypes	  MCV350	  and	  MCV339).	  The	  Rb	  binding	  site	  however	  is	  always	  retained.	  
The	  small	  T	  antigen	  expresses	  a	  conserved	  PP2A	  (protein	  phosphatase)	  binding	  motif	  common	  with	  SV40	  and	  MPyV	  
small	  T	  antigens.	  The	  genomic	  T	  antigen	  locus	  encodes	  for	  4	  transcripts	  and	  three	  alternatively	  spliced	  proteins	  (LT,	  
sT	  and	  57kT).	  MCV	  expresses	  a	  unique	  set	  of	  amino	  acids	  in	  exon2	  of	  its	  large	  T	  antigen	  that	  are	  distinct	  from	  other	  
polyomaviruses.	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1.5.4 T antigen dependency 
An important affirmation of MCC tumorigenesis is the requirement of MCV protein expression 
to maintain the tumor phenotype. To assess the importance of MCV T antigens in MCC tumor 
cells both MCV LT and sT (panT) were knocked down in five different MCC cell lines. Three 
different exon 1 target sequences, and two independent selection methods were used. Knock 
down of both LT and sT caused cellular death, as measured by wst-1 cell proliferation and 
lactate dehydrogenase (LDH) release cell death assays. No late apoptotic markers, cleaved 
caspase3 or cleaved PARP expression, were observed and the mechanism of cell death is 
unknown [371]. Knockdown of sT alone, through the intron 1 sequence, does not fully 
recapitulate pan-T knockdown, but causes cell cycle arrest (not cell death) [372]. Figure 13 
shows the effect of panT and sT knockdown on MKL-1, an MCV positive MCC cell line. 
Due to the overlap of 3’ coterminal transcripts and the sequence pattern of LT it is 
difficult to knockdown LT alone. However, by targeting the splice site between exon1 and 
exon2, Houben et al. succeeded in knocking down LT alone and observed a reduced growth 
phenotype. By expressing LT insensitive to the shRNAs used, they partially rescued the 
observed growth inhibition. This rescue was dependent on LT’s ability to bind RB1, suggesting 
the importance of this interaction in MCC tumors [373].  
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Figure 13 T antigen is necessary for MCV positive MCC survival.  
(A) Location of two shRNAs targeting MCV T antigens for knockdown is shown. sh-panT targets the exon 1 region 
and thus both Large T and small T antigen. sh-sT targets the intron 1 region and thus only small T antigen. CM8E6 
antibody epitope is part of exon 1 and is used to detect both sT and LT. (B) Infection with sh-panT lentivirus 
decreases both LT and sT expression in MKL-1 cells. However infection with sh-sT decreases only sT expression 
specifically. (C) Knockdown of T antigens cause a decrease in cell proliferation in MCV positive MCC cells (MKL-1), 
but not in MCV negative MCC cells (UISO) (D) Knockdown of both LT and sT causes cell death (measured via release 
of LDH), whereas knockdown of small T antigen alone does not kill cells but perhaps causes cell cycle arrest. 
(Modified from Shuda et al., JVI 2010, Shuda et al., JCI 2011 and Feng AACR Presentation 2011) 
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1.5.5 Transformation activity    
Polyomavirus T antigens are extensively described in the literature as having the ability to 
overcome contact inhibition and anchorage dependence upon expression in rodent cell lines 
and display serum independence of human cell lines. These assays are well-established 
methods of measuring oncogenicity of candidate proteins [185]. Unlike SV40 and MPyV, MCV 
small T alone but not other T antigens, possesses this transforming activity [354, 374-376]. 
Recent studies by Shuda et al., describe both foci formation and soft agar growth caused by 
MCV sT expression in rodent fibroblast cells [372]. Although MCV sT transformation was 
independent of sT-PP2A (Protein Phosphatase 2A) interaction which is important in other 
polyomavirus mediated transformations, a constitutively active 4E-BP1 that could not be 
phosphorylated antagonized this phenotype. These results indicate the contribution of 
deregulation of cap-dependent translation through 4E-BP1 hyperphosphorylation to Merkel cell 
carcinogenesis [372].   
  
1.5.6 MCV seroprevalence              
MCV serology, largely based on antibodies reactive to the late structural capsid protein VP1, 
has revealed MCV to be a common human infection among both children and adults. Similar to 
other polyomaviruses primary infection may be asymptomatic. Initially Kean et al. [160] and 
Carter et al. [377] studied reactivity to GST-VP1 fusion proteins and found between 25-59% 
MCV prevalence in healthy donors. However, more sensitive and specific assays that use MCV 
VP1 conformational epitopes (present in assembled virus like particles (VLP)) as antigens found 
antibodies against MCV in 60-80% of healthy adults [116, 378, 379]. The rate of seroprevalence 
observed increased with age, from 9% in children younger than 4 years of age, 35% by 4-13 
years of age, 49% in children and young adults between 15 to 26 years of age, to finally 80% in 
elderly individuals >50 years of age [378, 380, 381]. Unlike other polyomaviruses, antibody 
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responses to MCV VLPs are not diminished by cross-competition with other polyomaviurs 
antigens, indicating their specificity to MCV infection [182, 380, 381].  
1.5.5 Role of MCV immune reactivity in MCC          
Viral capsid protein 1 antibody titers, seen in healthy individuals, seem to correlate to the 
presence of MCV on the skin of healthy individuals [382, 383]. Despite the widespread VLP 
seropositivity seen among the healthy population, antibody titers are unusually high in MCV 
positive MCC patients than in non-MCC patients. However, in MCV positive MCC patients no 
correlation between tumor viral load and serum antibody titer has been observed [384]. 
Notably, Touze et al. did associate higher antibody titers with a better prognosis among MCC 
patients, implying a strong immune response to viral infection as a surrogate marker for 
prognosis [384]. However, a direct effect of the VP1 antibody response is unlikely because 
tumors do not express detectable amounts of MCV VP1 proteins [385]. In addition, in a recent 
longitudinal study of healthy adult gay and bisexual men, 18 years of age and older, 79% had 
antibodies to MCV at entry and subsequently 5.5% of the others seroconverted to MCV 
positivity. On analysis, no measurable signs or symptoms or common diagnostic test results 
were significantly associated with primary MCV infection (time of seroconversion) [386]. High 
serum IgG antibodies against MCV T antigen proteins (epiptopes match to the common/shared 
region between LT and sT) are also seen in MCV positive MCC patients, with a good correlation 
to viral load [116, 387]. These antibodies are rarely detectable in the general population and 
correspond to tumor burden and disease status.  Although antibodies to the viral capsid 
indicate prior MCV infection and titers are higher in MCC patients, MCV T antigen antibody 
titers are likely to be more useful clinical indicators.      
 Additional indications of immune surveillance come from MCC gene expression profiling 
studies that show increased intratumoral CD8+ lymphocyte invasion in MCV positive MCC 
patients [388]. These studies also correlate signs of stronger immune function to better 
prognosis for MCC patients [388, 389]. Furthermore, researchers have also shown that MCV 
increases T-helper cell proliferation and related IFN-gamma responses in MCV seropositive 
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individuals [390].          
 Impaired immune function is an epidemiologically recognized risk factor for MCC. 
However, different degrees of immunologic impairment are observed among MCC patients. 
Among MCV positive MCC patients, it is likely that immunologic surveillance mechanisms 
actively inhibit MCV mediated carcinogenesis [19, 43]. Immune function may potentially be 
influencing both the induction of MCC by virus reactivation following immunosuppression and 
also MCC clinical outcome.  
 
1.5.7 Transmission 
Transmission routes have been proposed for different polyomaviruses, but none have been 
definitely established. BKV and JCV are likely to be transmitted by fecal-oral and oral routes, 
whereas even though KIV, WUV and MCV are found in urban sewage samples as well, they 
seem to have a respiratory route of transmission [167, 170, 391-395]. Interestingly, DNA from 
most human polyomaviruses can be detected in tonsillar tissue, a possible entry point. JCV is 
believed to begin its life cycle in humans by infecting tonisillar tissue, but it is probably 
disseminated by B-lymphocytes, which help it cross the blood-brain barrier into the central 
nervous system. BKV is found to persist in the kidneys and the urinary tract, and causes viruria 
in transplant patients [271, 396-399]. Transmission of MCV is likely through casual contact but 
the precise mode is not known.   
 MCV has been difficult to cultivate in the laboratory as a natural infection. Several 
independent attempts have been made to produce infectious MCV molecular clones [360, 400, 
401]. In each case, primary low-level virion production can be achieved, however, secondary 
transmission to uninfected cells has not been successful. Early electron microscopy studies 
suggested that MCV virions might be seen in some MCC tumors [402] but the weight of 
evidence demonstrate that the structural proteins required for encapsidation are not expressed 
in MCC [385, 403].  
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1.6 MCC CELL LINES 
Due to the uncommon occurrence of MCC, patient samples are limited. Hence, MCC cell lines 
are critical in studying MCV dependent and independent MCC tumorigenesis. Several Merkel 
cell carcinoma cell lines were established years ago and have recently been tested for MCV 
positivity, integration sites, viral sequence and truncation patterns [311, 404-406]. Recently, 
new MCC cell lines have also been created from Merkel tumor biopsies [371, 406]. These newer 
cell lines have the advantage of being in early passage, as compared to previously derived cell 
lines, which may have been adapted to changes after extended culturing. The following table 
summarizes the cell lines used in this study. 
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Table	  3	  MCC	  Cell	  Lines	  used	  in	  this	  study	  (Modified	  from	  Houben	  et	  al.,	  JVI	  2010)	  
Table 1:  MCC cell lines used in this study.  
!!!!!!!!!!! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !!!!!!!!!!!!!!!!!!!!!!!!!!
Expression! of! cytokeratin! 20! (CK620),! pan6cyto! keratin! (pan6CK),! neuron6specific! enolase! (NSE),! and! Ki667! was! measured! by! immunohistochemistry.! Synaptophysin! and!
chromogranin!A!expression!was!analyzed!by!quantitative!real!time!PCR.!ND6!not!determined!or!unknown,!NA6not!applicable.!References!:!Ronan!et!al.,1993,Van!Gele!et!al.,!2002,!
Rosen!et!al.,!1987!and!Shuda!et!al.,!2009.!
!
!
!
! Source! ! ! Detection!of!MCV!by!6! ! LT! ! Expression!of!
Cell!
line!
Age!of!
patient!
Sex!of!
patient! Location! Morphology!
Doubling!
time!
(days)!
PCR! Southern!blotting! !
Stop!
codon!
mutation!
Predicted!!
molecular!
mass!
(kDa)!
! CK620! pan6CK! NSE! Chromogranin!A! Synaptophysin!
MKL61! 26! M! Nodal!metastasis! spheroidal! 3! +! +! !
Deletion!
16127
1657!
36!kDa! ! +! +! ++! +! +!
MKL62! 72! M! ND! spheroidal! 5! +! +! ! C1453A! 30!kDa! ! ND! ND! ND! +! +!
MS61! 59! F! Adrenal!metastasis! spheroidal! 4! +! +! !
Deletion!
19127
1951!
47!kDa! ! +! +! +! +! +!
WaGa! 67! M! Ascites! single!cell!suspension! 4! +! ND! ! C1461T! 30!kDa! ! +! +! +! +! +!
UISO! 46! F! Thigh! adherent! 1.5! 7! 7! ! NA! NA! ! 7! ND! ++! 7! 7!
MCC13! 80! F! Nodal!metastasis! adherent! 1! 7! 7! ! NA! NA! ! 7! 7! +! +! 7!
  
 56 
2.0  MERKEL CELL POLYOMAVIRUS T ANTIGEN EXPRESSION IN MCC AND OTHER CANCERS  
Work described in this section was published in the International Journal of Cancer, American 
Journal of Surgical Pathology and Blood 
 
Int J Cancer. 2009; 125(6): 1243-9.  
with authors Shuda M, Arora R, Kwun HJ, Feng H, Sarid R, Fernández-Figueras MT, Tolstov Y, 
Gjoerup O, Mansukhani MM, Swerdlow SH, Chaudhary PM, Kirkwood JM, Nalesnik MA, Kant JA, 
Weiss LM, Moore PS and Chang Y. 
 
R. Arora, M. Shuda and H.J. Kwun contributed equally to this work. 
R. Arora, M. Shuda and H.J. Kwun performed the qPCR studies and analysis. R Arora and M. 
Shuda performed the immunoblotting and immunofluorescence experiments. Dr Mary Ann 
Accavitti produced CM2B4 antibody. Ms. Mary Acquafondata and Ms. Yuan-Yuan Chen 
perfomed immunohistochemistry. R. Arora, M. Shuda, H.J. Kwun, Y. Chang and P. S.Moore 
conceived the project, analyzed the results and wrote the manuscript. 
 
 Am J Surg Pathol. 2009; 33(9): 1378-1385    
 
with authors Busam KJ, Jungbluth AA, Rekthman N, Coit D, Pulitzer M, Bini J, Arora R, Hanson 
NC, Tassello JA, Frosina D, Moore PS and Chang Y. 
 
R. Arora performed qPCR and data analysis for samples provided by Klaus Busam group. 
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and 
 
 Blood. 2010; 115(23): 4973-4  
with authors Tolstov YL, Arora R, Busam KJ, Chaudhary PM, Chang Y and Moore PS  
 
R. Arora, Y. L. Tolstov and S. Scudiere performed the PCR, ELISA and Immunohistochemistry 
respectively. R. Arora, Y.L. Tolstov, S. Scudiere, K.J. Busam, PM. Chaudhary, Y. Chang and PS. 
Moore analyzed and interpreted the data. Y.L. Tolstov, R. Arora, Y. Chang and P.S. Moore wrote 
the manuscript. 
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MCV was discovered as monoclonally integrated in the MCC tumor genome. To further assess T 
antigen expression in tumors and its association with human diseases, it became important to 
develop assays and tools of detection. To this effect we screened 33 antibodies to other 
polyomaviruses for cross reactivity to MCC. When none of them specifically detected MCV T 
antigen, we then developed a monoclonal antibody (CM2B4) using a peptide from a ~200 
amino acid MCV unique region (absent in other viruses) in exon 2 of MCV large T antigen. We 
found that CM2B4 specifically recognizes both endogenous and transfected MCV large T (LT) 
antigens. We also found that MCV LT protein localizes to the nucleus of tumor cells from MCC. 
Of 62 CK20 positive MCC tissues tested for CM2B4 staining, 46 (74.2%) were positive. 
 We developed a qPCR assay for detection of MCV genome copy numbers in both MCC 
and other disease tissue. MCV genome is present at an average of 5.2 (range 0.8–14.3) T 
antigen DNA copies per cell, supporting a direct carcinogenic mechanism.   
 Since MCV is closely related to lymphotropic polyomavirus (LPV) and MCC occurs in 
association with many other malignancies, we used both qPCR based detection and CM2B4 
staining to survey hematolymphoid malignancies (especially chronic lymphocytic leukemia), 
neuroendocrine tumors, and collision tumors tissues. Although 2.2% of 325 hematolymphoid 
malignancies surveyed showed evidence for MCV infection by DNA PCR, none were positive at 
high viral copy numbers. None of 173 lymphoid malignancies examined on tissue microarrays 
expressed MCV LT protein in tumor cells. None of the 26 pulmonary neuroendocrine tumors or 
7 collision tumors showed signs of MCV T antigen protein expression either.   
 Expression of this viral oncoprotein in tumor cells indicates the mechanism supporting 
the notion that MCV causes a subset of MCC. As with some of the other human 
polyomaviruses, lymphocytes may serve as a tissue reservoir for MCV infection, but 
hematolymphoid malignancies associated with MCC are unlikely to be caused by MCV. MCV is 
thus specific to MCC. 
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2.1 MATERIALS AND METHODS 
2.1.1 Human tissue samples 
For University of Pittsburgh study 
For Merkel cell carcinoma, fresh frozen tumor samples were obtained from the Cooperative 
Human Tissue Network [407]. An MCC tissue core microarray consisting of 36 MCC specimens 
was generated from archival paraffin-embedded tissues from the pathology departments at 
Hospital Universitari del Mar and the Hospital Universitari Germans Trias i Pujol, Barcelona, 
Spain as previously described [408]. Tissue microarrays for lymphoid malignancies and normal 
controls were purchased commercially (US Biomax, Inc.). Genomic DNA samples from 
consecutive hematolymphoid tumor tissues were collected and archived by the late Dr. Anne 
Matsushima, Columbia University, from excess tissue submitted for diagnostic pathology. This 
was supplemented with additional hematolymphoid tissues obtained from tissue banks at the 
Department of Pathology, University of Pittsburgh. For reasons of confidentiality, minimum 
patient identification and demographic data are available for most of these specimens. PBMC 
specimens were obtained from two sources: 1- excess samples submitted to the Division of 
Molecular Diagnostics, University of Pittsburgh Medical Center for genetic screening and 2- 
PBMC collected from HIV-positive persons participating in Kaposi's sarcoma epidemiologic 
studies [409]. None of these study subjects were diagnosed with Merkel cell carcinoma. All 
specimens were tested under University of Pittsburgh Institutional Review Board-approved 
guidelines. 
For Memorial Sloan- Kettering Study 
Patients 
The study was approved by the Institutional Review Board. All patients were seen at or sought 
consultations from physicians at Memorial Sloan-Kettering Cancer Center (MSKCC). Consent 
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was obtained for use of tumor tissue for research. Clinical information and follow-up was 
abstracted from the medical records or by contacting the patient’s clinician directly. 
Tumor Tissue 
Slides and tissues of primary and metastatic tumors were retrieved from the archives 
and the tissue bank of the institution’s department of pathology. The material included 17 
snap-frozen tumor samples of MCC, which had been stored at −70°C (MSKCC tumor bank) and 
formalin-fixed and paraffin-embedded (FFPE) archival tissue, which was used for 
immunohistochemical studies. 
For a tumor to be accepted as MCC and selected for this study, the following criteria had 
to be present. The tumor had to be predominantly composed of nuclei with pale salt and 
pepper chromatin pattern, scant cytoplasm, and mitotic figures. Immunohistochemically, the 
tumor had to be positive for CK20, or, for the rare tumors, which lacked labeling for CK20, 
positive for the CAM 5.2 in a paranuclear dot-like pattern and/or positive for chromogranin 
and/or negative for thyroid transcription factor-1 (TTF-1). Furthermore, there had to be clinical 
evidence in support of a primary skin tumor or, for metastatic lesions, evidence in support of a 
derivation from a primary skin tumor or at least clear documentation that there was no 
extracutaneous primary in the rare cases of metastatic MCC with unknown primary. Cases of 
patients who carried a prior or concurrent diagnosis of an extracutaneous neuroendocrine 
carcinoma were excluded from this analysis. 
In this study, immunohistochemical stains were performed on 3 sets of FFPE Merkel cell 
tumors: 
1. Fifteen tumor samples corresponding to the same tumors, which were analyzed by 
quantitative PCR (qPCR; a total of 17 frozen tumor samples were tested by qPCR, but 
suitable archival material for a parallel analysis by IHC was available in 15 of 17 cases). 
2. Thirty-six tumor samples spotted on a tissue microarray. Each case was represented in 
triplicate 1 mm punch biopsy samples from the donor tumor block. 
3. A set of 7 combined primary skin tumors, which showed mixed features of squamous 
cell and CK-20-positive neuroendocrine carcinoma. 
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To test for the potential presence of MCV in neuroendocrine tumors noncutaneous 
origin, IHC with mAb CM2B4 was also performed on a series of 26 lung tumors, consisting of 16 
primary small cell carcinomas and 10 large cell neuroendocrine carcinomas. 
2.1.2 Real time quantitative PCR 
For University of Pittsburgh study, quantitative PCR was performed using primers amplifying 
the MCV T antigen, TAg (1051–1131 nt; forward: 5′-cctctgggtatggg tccttctca-3′, reverse: 5′-
atggtgttcgggaggtatatc-3′) and VP2 (4563–4472 nt, forward: 5′-agtaccagaggaagaagccaatc-3′, 
reverse: 5′-ggc cttttatcaggagaggctatattaatt-3′) loci with internal TaqMan probes (TAg: 5′-
cccaggcttcagactc-3′, VP2: 5′-gcagagttcctc-3′) labeled with FAM and MGB quencher (Applied 
Biosystems). For the additional 10 peripheral blood samples with CLL, and Memorial sloan 
kettering MCC samples primers designed against MCV T antigen promoter region (98–184 nt 
forward: 5′-cccaagggcgggaaactg-3′, reverse: 5′-gcagaaggagtttgca gaaacag-3′) and internal probe 
(5′-ccactccttagtgaggtagctcatttgc-3′) labeled with FAM and BHQ quencher (Biosearch 
Technologies) was also used. Copy numbers were established from standard curves of Ct values 
from serial dilutions of known concentrations of MCV DNA originally amplified by PCR using 
contig 3 and contig 12 primer sets for TAg and VP2 detections, respectively [74]. Water was 
used as control to detect template contamination. No evidence of PCR template contamination 
was observed in the PCR reactions with water control. RNaseP (Applied Biosystems) or β-actin 
primer-probe mixtures (forward: 5′-cactggctcgtgtgacaagg-3′, reverse: 5′-
cagacctactgtgcgcctacttaa-3′, probe: 5′-tggtgtaaagcggccttggagtgtgt-3′) (Biosearch Technologies) 
were used to determine cell genome copy number. qPCR reactions were performed using 
PRISM 7700 Detection System, PRISM 7900HT Fast Real-Time PCR System (Applied Biosystems) 
and/or Smart Cycler 5RX4Z01 (Cepheid) with TaqMan reagents (UNG (+) TaqMan Universal PCR 
Master Mix). Amplification reactions of all target genes were performed with the following 
condition: 50°C for 2 min, denaturing at 95°C for 10 min, 40 cycles of 95°C for 15 sec and 60°C 
for 1 min. Results were expressed as numbers of viral copies per cell calculated from Ct values 
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of viral and cellular gene standards. Cellular viral DNA copy number below 1.0 × 10−3 per cell 
was considered negative. 
2.1.3 Cell lines and transfection conditions 
Human embryonic kidney 293 cells (ATCC) were grown in DMEM medium supplemented with 
10% fetal calf serum. Cells were transfected with expression constructs using Lipofectamine 
2000 (Invitrogen) following manufacturer's instructions on 90% confluent cells. Cells were 
harvested 48 hr after transfection for analysis. 
2.1.4 Plasmids 
To clone 57 kT wt, the genomic T antigen expression plasmid constructed from appendix 206 
[74] was transfected into 293 cells with Fugene 6 (Roche). After 48 hr, total RNA was extracted 
with Trizol (Invitrogen). First strand cDNA was synthesized with oligo-d(T) primer using 
Superscript III First-Strand Synthesis System (Invitrogen). Multiply spliced products were 
amplified by PCR with primers: MCV.EcoRV(S) (5′-ccgatatcatggatttagtcctaaaagg-3′) and 
MCV.XhoI(AS) (5′-gggctcgagtattgagaaaaagtaccagaa tattggg-3′). A PCR fragment corresponding 
to 57 kT antigen was cloned into pcDNA6 expression vector with EcoRV and XhoI sites. To 
generate the pMCV TAg-EGFP expression constructs, pcDNA6 gLT206 encoding wild type full-
length genomic T antigen7 was digested with NheI and SacII and cloned into pEGFP-N1 
(Clonetech) in-frame to C terminus GFP using same restriction sites. LT expression constructs 
for JCV and BKV were kindly provided by Dr. James DeCaprio[410]. SV40 T antigen cDNA cloned 
in pCMV vector is described elsewhere[411]. 
 
  
 63 
2.1.5 Generation of CM2B4 mAb 
Monoclonal antibody CM2B4 (IgG2b isotype) was generated by standard methods of 
immunizing mice with KLH-derivatized SRSRKPSSNASRGA peptide from the MCV T antigen exon 
2 with a C-terminal cysteine (Epitope Recognition Immunoreagent Core Facility, University of 
Alabama). 
2.1.6 Immunofluorescence and immunohistochemistry 
For immunofluorescence staining, cells were spotted on glass slides by Cytospin3 (Shandon), 
fixed with 10% buffered formalin for 20 min and permeabilized with phosphate-buffered saline 
(PBS) with 0.1% Triton X-100. After blocking, cells were reacted with CM2B4 (1:100 dilution) at 
4°C overnight followed by secondary antibody (Alexa Fluor 488-conjugated anti-mouse, 1:1,000 
Invitrogen) for one hour at room temperature. Stained cells were mounted in aqueous medium 
containing DAPI (Vector Laboratories, CA). For immunohistochemical staining of paraffin 
embedded tissues, epitope retrieval was performed using EDTA antigen retrieval buffer (Dako, 
Glostrup, Denmark) at 126°C for 3 min after deparaffinization and hydrogen peroxide 
treatment. After blocking with Protein Block (Dako), samples were reacted to primary antibody 
for 30 min at room temperature with dilutions described below. After washing, samples were 
incubated with Mouse Envision Polymer (Dako) for 30 min at room temperature for subsequent 
deaminobenzidine (DAB) reaction. mAbs used for immunohistochemistry were: CM2B4 (1:10–
1:50 hybridoma supernatant), CK20 (Dako; 1:50), Chromogranin A (Dako, 1:600), Synaptophysin 
(Biogenex, San Ramón, CA; 1:100), and CD56 (Novocastra, Newcastle upon Tyne, United 
Kingdom; 1:50).  
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2.1.7 Immunoblotting 
Transfected cells were lysed in buffer (10 mM Tris–HCl pH8.0, 0.6% SDS) containing proteinase 
inhibitor cocktail (Roche). Lysate was electrophoresed in 10% SDS-PAGE, transferred to 
nitrocellulose membrane (Amersham) and reacted with Pab416 (1:10) or CM2B4 mAb (1:10) 
overnight at 4°C, followed by anti-mouse IgG-HRP conjugates (Amersham, 1:5,000) for 1 hr at 
room temperature. Detection of peroxidase activity was performed by Western Lightning plus-
ECL reagent (Perkin Elmer). 
2.2 RESULTS 
2.2.1 MCV T antigen expression in Merkel cell carcinoma tumors 
To show that MCC tumor cells are infected with MCV and express MCV T antigen protein, we 
developed a monoclonal antibody (CM2B4) to a peptide epitope (SRSRKPSSNASRGA) in exon 2 
of the MCV T antigen (Figure 14 A and Figure 37 in Appendix A). This epitope is located N-
terminal to an LFCDE motif previously found to bind retinoblastoma protein and is likely to be 
conserved in viruses from both tumor and nontumor tissues[112]. CM2B4 is predicted to target 
the MCV LT protein and a T antigen isoform translated from a multiply spliced mRNA, but not 
the small T antigen (Figure 14 B). CM2B4 immunoblotting of lysates from 293 cells transfected 
with a wild-type genomic T antigen expression construct shows MCV LT protein migrating at 
∼120 kDa and an additional ∼57kDa T antigen isoform translated from an alternatively spliced, 
SV40 17kT antigen-like mRNA (Figure 14 C). The identity of the 57 kDa protein was confirmed 
by transfection of a 57kT cDNA clone. T antigen loci cloned from tumor derived MCV sequences 
express faster migrating LT proteins with sizes corresponding to the presence of truncating 
mutations. The MCV infected MKL-1 cell line also expresses a truncated LT consistent with a 
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premature	   stop	   codon	  mutation,	   whereas	  MCV	   negative	   UISO,	  MCC13,	   and	  MCC26	   cell	   line	  
lysates	  showed	  no	  specific	  reactivity	  (Figure	  14	  C).	  
	  
By	  immunofluoresence	  microscopy,	  precise	  nuclear	  colocalization	  of	  CM2B4	  occurs	  with	  
green	  fluorescence	  when	  an	  MCV	  LT-­‐GFP	  fusion	  construct	   is	  expressed	   in	  293	  cells	   (Figure	  15	  
A).	   CM2B4	   is	   highly	   specific	   for	  MCV	   and	   does	   not	   react	   to	   T	   antigens	   from	   JCV	   or	   BKV	   by	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Figure	  14	  CM2B4	  –	  a	  monoclonal	  antibody	  detecting	  MCV	  T	  antigen	  	  
(A)	  Amino	  acid	  alignment	  of	  MCV	  with	  known	  human	  polyomaviruses,	  SV40,	  and	  LPV.	  Region	  containing	  epitope	  site	  of	  
CM2B4	   is	   not	   conserved	  with	   these	  other	   polyomaviruses.	   (see	   Figure	   37	   in	  Appendix	  A	   for	   an	   alignment	  with	   all	   9	  
human	  polyomaviruses)	   (B)	  Transcript	  diagram	  from	  various	  wild-­‐type	  and	  tumor-­‐derived	  MCV	  T	  antigen	   loci.	  Yellow	  
box	  represents	  epitope	  site	  and	  does	  not	  overlap	  with	  putative	  small	  T	  antigen	  (gray).	  (C)	  CM2B4	  western	  blotting	  of	  
constructs	  diagrammed	   in	   (B)	   shows	  detection	  of	   full	   length	  or	   truncated	   tumor	  LT	  antigens	   (open	  arrowheads)	  and	  
57kT	  antigen	  (solid	  arrowhead).	  Only	  the	  truncated	  LT	  antigen	  is	  seen	  in	  the	  MCV	  infected	  MKL-­‐1	  cell	  line,	  whereas	  no	  
specific	  protein	  is	  detected	  from	  lysates	  of	  MCV	  negative	  UISO,	  MCC13	  and	  MCC26	  cell	  lines.	  Asterisk	  (*)	  denotes	  non-­‐
specific	  reactivity.	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immunofluorescence	  (Figure	  15	  B)	  or	  to	  T	  antigens	  from	  JCV,	  BKV	  or	  SV40	  by	  immunoblotting	  
(Figure	   15	  A).	   In	   contrast,	   an	   anti-­‐SV40	   T	   antigen	  mAb,	   PAb416,	   cross-­‐reacts	  with	   T	   antigens	  
from	  other	  SV40-­‐group	  viruses	  including	  JCV	  and	  BKV,	  but	  not	  with	  MCV	  T	  antigen	  (Figure	  15	  B	  
and	  16	  A).	  We	  examined	  33	  other	  anti-­‐SV40	  and	  anti-­‐other	  polyomavirus	  T	  antigen	  mAbs	  [412],	  
none	   show	   reactivity	   to	   MCV	   T	   antigen	   on	   immunoblotting	   (Table	   4).	   Tissue	  
immunohistochemistry	   with	   CM2B4	   of	   an	  MCV	   DNA	   positive	  MCC	   biopsy	   also	   shows	   strong	  
reactivity	  among	  tumor	  cells,	  but	  not	  surrounding	  tissues	  (Figure	  15	  C).	  CK20,	  a	  low	  molecular	  
weight	   cytokeratin	   marker	   for	   MCC[316,	   413-­‐415]	   has	   a	   characteristic	   perinuclear	   dot-­‐like	  
pattern	  in	  CM2B4	  positive	  cells	  (Figure	  16	  C).	  Similarly,	  examination	  of	  the	  MCV	  positive,	  MCC-­‐
derived	  MKL-­‐1	  cell	   line	  shows	  expression	  of	  LT	  protein	  in	  a	  diffuse	  nuclear	  distribution	  (Figure	  
16	   B).	   CM2B4	   does	   not	   react	   to	   JCV	   T	   antigen	   in	   a	   brain	   section	  with	   progressive	  multifocal	  
leukoencephalopathy	  (Figure	  16	  C).	  
Table	  4	  Polyomavirus	  antibodies	  tested	  against	  MCV	  T	  antigen	  
	  
Polyomavirus'-T-antigen--
Antibodies References
Gurney,(E.G.(et(al.(,(J(Virol,((1986.
Tack,(L.C.(et(al.,(J(Virol,((1989.(
Mole,(S.E.(et(al.(,Philos(Trans(R(Soc(Lond(B(Biol(Sci,(1987.
Gannon,(J.V.(et(al.,New(Biol,((1990.
PAb(
405,409,407,416,419,423,430,
431,433,441,442
Harlow,(E.(et(al.,(N.M.(,(J(Virol,(1981.
PAb(602,603,605,606 Mole,(S.E.et(al.(,(Philos(Trans(R(Soc(Lond(B(Biol(Sci,(1987.
Karjalainen,(H.E.(et(al.,(J(Virol(,1985.
Thompson,(D.L.(et(al.,Virology,((1990.
Fu,(T.M.(et(al.,(Virology,((1996.
Hamster(Anti(T(antigen((HAT),(
Goat(Anti(T(antigen((GAT) Soule,(H.R.(and(Butel,(J.S.,(J.(Virol,(1979(,(Pipas,(J.(unpublished
18W8W8 Schaffhausen,(B.(et(al.,(JBC,(1982
F2A,(F3(A/B,(F4(A/B,(F5(A/B(and(
F8(A Pallas,(D.C.(et.al.,(J.(Virol,(1986.
Pab(762 Dilworth,(S.M.(et(al.(,(Nature(1994.
Anti(LPV(Hamster(serum Pawlita,(M.(et.(al.,(Virol.(1985.
PAb101,(108
PAb(204,210,(211,(216
PAb(901,902
Gifts(of(Dr.(Gjoerup,(Dr.(Pipas,(Dr.(Pallas,(Dr(Pawlita(and(Dr(Dilworth
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Figure 15 CM2B4  immunofluorescence  
(A) MCV T antigen-EGFP fusion protein (green) colocalizes with CM2B4 staining (red) in 293 cells transfected with 
pMCV TAg-EGFP or pEGFP, an empty EGFP vector. (B) Immunofluorescence staining of 293 cells over-expressing T 
antigen constructs from JC, BK and MCV shows that CM2B4 specifically detects MCV T antigen. PAb416 shows 
reactivity with JC and BK T antigens, but not with MCV T antigen. (C) Sequential sections from an MCC skin excision 
shows small, round blue sheets of tumors cells (H&E) which express MCV LT (CM2B4) and CK20 proteins. 
Expression of MCV LT protein shows a diffuse nuclear pattern in MCC tumor cells but not in surrounding tissues 
including the epidermis, adnexal epithelium (arrow), endothelial cells or dermal fibroblasts. 
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Figure 16 CM2B4 does not crossreact with other polyomaviruses  
(A) Constructs encoding LT genes for JCV, BKV, SV40 and MCV were expressed in 293 cells and cell lysates were 
immunoblotted with CM2B4 or PAb416 antibodies. PAb416 cross-reacts with JCV and BKV LT proteins but not with 
MCV LT. (B) CM2B4 detects robust T antigen expression in a diffuse nuclear pattern in each cell from the MCV 
positive MKL-1 cell line. These cells retain perinuclear CK20 expression seen in Merkel cell carcinomas. (C) Brain 
tissue with progressive multifocal leukoenchephalopathy shows JCV infection of oligodendroglial cells by JCV 
specific in situ hybridization (left panel), and CM2B4 shows no reactivity to JCV antigens (right panel). 
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 These results were extended by examining two tissue microarrays with CM2B4. Tissue 
microarray 1 (from Barcelona, Spain) contained 30 CK20-positive MCC, 6 CK20-negative but 
clinically suspect MCC, and 4 CK20-negative neuroendocrine control tumors. Of the 30 CK20 
positive MCC, 21 (70%) were positive for LT protein expression. This suggests that the majority 
of MCC is caused by MCV infection whereas a subset of CK20+ MCC may have a different 
etiology. Of the 6 CK20-negative tumors diagnosed as MCC, none were positive for MCV LT 
protein expression but variably expressed neuroendocrine markers CD56, synaptophysin, or 
chromogranin (Table 5). A second tissue array (from Memorial Sloan-Kettering) with 36 cases of 
MCC was analyzed by IHC for CK20 and CM2B4. Thirty-two of the 36 tumors (89%) were 
positive for CK20 (Table 5). Positive staining was seen in 13 of 14 (93%) primary and 19 of 22 
(86%) metastatic tumors. The staining was predominantly paranuclear dot-like, but 
membraneous staining was also focally seen.       
 Twenty-seven of the 36 tumors (75%) were immunoreactive for CM2B4. In the majority 
of tumors, the staining of tumor cell nuclei for CM2B4 was strong and homogeneous, labeling 
more than 75%, and up to 100% of the tumor cell population (Figure 15). Of the 14 primary 
tumors, 2 were immunonegative for CM2B4. One of them was a primary cutaneous 
neuroendocrine carcinoma, which had an associated in situ and invasive squamous cell 
carcinoma component (combined squamous cell and neuroendocrine carcinoma). Of the 22 
metastatic tumors, 15 (68%) were immunopositive for CM2B4. One of the negative metastatic 
tumors was derived from a primary combined squamous cell and neuroendocrine carcinoma 
(the metastatic component had a pure neuroendocrine appearance).   
 Any combination of staining results for CK20 and CM2B4 was seen (Figure 17). Most (25 
of 36) tumors expressed CK20 and stained with CM2B4. All but 2 tumors, which were positive 
for CM2B4, coexpressed CK20. Six CK20-positive tumors failed to react with CM2B4. Two 
tumors were negative for both CK20 and CM2B4 (Table 6).     
 The results of the immunohistochemical staining were compared with the patients' 
clinical information regarding potentially compromised immune status, and sun-exposure to 
the site of the primary tumor. Seven of the 12 CM2B4-immunopositive primary tumors were 
  
 70 
from sites of chronic sun-damage (face and extremities with histologic evidence of marked solar 
elastosis in the adjacent non-neoplastic dermis). Five were from sun-protected sites (buttocks, 
with no significant solar elastosis). Of the group of patients with immunopositive tumors, one 
person was known to be clinically immunosuppressed (had chronic lymphocytic leukemia). 
There was also one patient with known immunosuppression (status post-organ transplant) in 
the group of patients with CM2B4-negative tumors (Table 6).    
 In combination, 46 out of 62 CK20 positive MCCs tested in the two tissue microarrays 
showed positive immunostaining for MCV LT by CM2B4. This 74.2% positivity is in sync with the 
initial finding that about 80% of MCC are positive for MCV  (Table 7) [74]. 
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Table 5 Summary Of Merkel Cell Carcinoma Tissue Microarray I Staining 
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Figure	  17.	  Tissue	  microarray	  2	  staining	  (patterns	  of	  colabeling	  for	  CK20	  and	  monoclonal	  antibody	  CM2B4).	  	  
A	  and	  B,	  A	  tumor	  is	  positive	  for	  both	  CK20	  (A)	  and	  CM2B4	  (B)[most	  commonly	  seen].	  C	  and	  D,	  A	  tumor	  negative	  
for	   CK20(C),	   but	   immunoreactive	   for	   CM2B4	   (D).	   E	   and	   F,	   A	   tumor	   expresses	   CK20	   (G)	   and	   CM2B4(H).	   CK20	  
indicates	  cytokeratin	  20.	  
	  
Tissue&Microarray CK20+ CM2B4+ Both&CK20+&
and&CM2B4+
TMA$1$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
(from$Hospital$Universitari$del$Mar$
and$Hospital$Universitari$Germans$
Trias$I$Pujol,Barcelona,$Spain)
30 21 21$(70%)
TMA2$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
(Memorial$Sloan$Kettering$Hospital,$
New$York,$USA)
32 27 25$(78.1%)
Total 62 48 46&(74.2%)
Table	  7	  	  Summary	  of	  two	  tissue	  microarrays	  tested	  
	  
	  
Table	  6	  	  Immunohistochemical	  detection	  of	  MCV	  with	  CM2B4	  on	  tissue	  microarray-­‐2	  and	  comparison	  with	  CK20	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University	  of	  Pittsburgh	  study	  
To	  correlate	  MCV	  LT	  protein	  expression	  with	  the	  level	  of	  MCV	  infection,	  we	  next	  developed	  a	  
quantitative	  real-­‐time	  PCR	  (qPCR)	  assay.	  DNA	  from	  ten	  tumors	  previously	  examined	  [74]	  were	  
tested	   with	   primers	   designed	   to	   amplify	   regions	   of	   the	   T	   antigen	   and	   VP2.	   Seven	   of	   these	  
Southern	  blot	  positive	  tumors	  had	  an	  average	  of	  5.2	  (range	  0.8–14)	  T	  antigen	  DNA	  copies	  per	  
cell	  consistent	  with	  clonal	  integration	  and	  viral	  genome	  concatenation	  (Table	  8).	  Similar	  results	  
were	   found	   using	   VP2	   qPCR	   except	   for	   MCC345	   and	   MCC347.	   These	   tumors	   had	   robust	   T	  
antigen	  qPCR	  positivity	  (5	  copies	  per	  cell)	  but	  minimal	  amplification	  of	  the	  VP2	  gene,	  which	  may	  
reflect	  integration	  and	  loss	  of	  this	  late	  viral	  capsid	  gene	  region	  as	  has	  been	  described	  by	  Kassem	  
et	   al.	   [416]	   CM2B4	   staining	   in	   CK20+	   MCCs	   was	   concordant	   with	   qPCR	   results	   for	   all	   cases	  
except	   MCC344,	   which	   showed	   abundant	   viral	   DNA	   but	   was	   negative	   with	   CM2B4	   staining	  
(Table	  8).	  
	  
Table&2.!qPCR&detection&of&MCV&genome&in&MCC.!
MCC!Tissue!
MCV!genome!copies!per!cell*! Genomic!
Southern†!
Immunostaining!
T!Ag! VP2! CM2B4! CK20§!
MCC337! <!10F3! 0! 8& 8& +&
MCC339! 5.2! 11.1! +& +& +&
MCC343! 0! 0! 8& 8& +&
MCC344! 6.3! 13.7! +& 8& +&
MCC345! 4.9! <!10F3! +& +& +&
MCC346! <!10F3! 0! 8& 8& +&
MCC347! 1.6! 0! +& +& +&
MCC349! 3.3! 8.0! +& +& +&
MCC350! 0.83! 3.0! +& NT‡! NT!
MCC352! 14.3! 47.5! +& +& +&
*!RNaseP! copy! number! was! divided! by! two! to! determine! cellular! equivalent! of! DNA.!†!MCV!
positivity!was!previously!examined!by!Southern!blotting! (Feng!et!al.,!2008).!‡!NT,!No!paraffin!
embedded! MCC! tissues! to! evaluate.! §! CK20! expression! was! previously! examined! by!
immunostaining!(Feng!et!al.,!2008).!
!
!
!
Table	  8	  	  qPCR	  Detection	  of	  MCV	  genome	  in	  MCC	  (University	  of	  Pittsburgh	  study)	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Memorial Sloan-Kettering study 
Frozen tumor tissue samples of MCC from 17 different patients were examined by qPCR for the 
presence of MCV DNA. The samples included 9 primary cutaneous tumors (5 from sun-exposed 
sites, 4 from sun-protected sites), 6 lymph node metastases, and 2 visceral metastases (Table 
9). MCV was identified in 15 of 17 tumors (88%), with a positive PCR result seen in 8 of 9 
Table 9 Comparison of MCV detection by PCR with CM2B4 staining (Memorial Sloan-Kettering Study) 
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primary and 7 of 8 metastatic tumors (Table 9).      
 The one MCV-negative primary tumor was from the right leg of an 85-year-old woman. 
Its histology was re-reviewed: the primary tumor was a combined superficial squamous cell and 
neuroendocrine carcinoma that had metastasized to the regional lymph node. The metastasis 
had a pure neuroendocrine phenotype.       
 The one MCV-negative metastatic tumor was from a neck lymph node of a 76-year-old 
man who presented with metastatic MCC in the absence of a known primary tumor. The lymph 
node metastasis was re-reviewed. The histologic and immunohistochemical features were 
typical of MCC with positive paranuclear dot-like staining for CK20.    
 Conventional tissue sections of FFPE portions from the same tumors that had been 
analyzed by PCR were examined by IHC, using mAb CMB24. An additional section from each 
tumor was also stained for CK20. Sufficient tissue for this analysis was available in 15 of the 17 
cases. Thirteen of them were positive for MCV by PCR.     
 Ten tumors were immunoreactive for CM2B4 (67% of all tumors with tissue available for 
IHC, 77% of all PCR-positive tumors). All tumors, which were immunoreactive for CM2B4, were 
also positive for MCV by PCR. Seven of the CM2B4-positive tumors showed strong nuclear 
labeling in the vast majority (>75%) of the tumor cell population (Table 9). Three tumors 
showed only partial labeling for CM2B4 (3+ staining, that is, positive labeling of >=50% to 75% 
of tumor cells). All but one tumor was positive for CK20.     
 The one tumor, which was immunonegative for both CM2B4 and CK20, but contained 
MCV by PCR, was a lymph node metastasis. The clinical and histologic findings were re-
reviewed. The tumor was judged to be metastatic MCC, because there was a known primary 
cutaneous tumor, which, like the metastasis, showed classic cytologic features of MCC. 
Furthermore, the tumor was immunohistochemically positive for CAM5.2 in a dot-like 
paranuclear staining pattern and also positive for chromogranin. 
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2.2.2 PBMC infection with MCV 
To assess MCV lymphotropism as seen in other human polyomaviruses [417, 418], 83 whole 
PBMC DNA samples collected from persons undergoing genetic testing for Factor V Leiden 
deficiency were tested by qPCR. These samples were collected mainly from adults (average of 
60 years, range 1–78 years) with 73 (88%) samples from persons over 18 years of age. None 
were positive for viral DNA. However, among 21 PBMC collected from adult HIV/AIDS patients 
without MCC, 2 (9.5%) were positive by either T antigen (2.8 × 10−3 copies per cell) or VP2 (8.8 × 
10−3 copies per cell) primers and one (5%) was positive with both primers (T antigen, 7.9 × 10−3 
copies per cell; VP2, 6.0 × 10−3 copies per cell). Although we are unable to verify MCV 
lymphotropism in this study since examining whole PBMC is unlikely to reliably detect MCV due 
to the dilution effect from nonpermissive PBMC, increased rates of detection in HIV positive 
individuals suggest that immunosuppression may lead to reactivation of virus. 
2.2.3 Survey of hematolymphoid malignancies for MCV infection 
qPCR was further performed on tissue DNA from 104 T cell-associated and 161 B cell-associated 
malignancies, 19 myeloid disorders and 41 other tumors including Hodgkin lymphoma and post-
transplant lymphoproliferative disorders (Table 10). Of these 325 tumors, 7 (2.2%) were 
positive for either T antigen or VP2 DNA and two were positive for both. No consistent pattern 
of virus infection was found among these malignancies: 1 (3%) of 33 chronic lymphocytic 
leukemia, 1 (7.1%) of 14 non-Hodgkin lymphoma, not otherwise specified (NOS), 2 (3.1%) of 65 
diffuse large B cell lymphoma, 1 (11%) of 9 marginal zone lymphoma and 1 (3.3%) of 30 
Hodgkin lymphoma (Table 10). Copy numbers for these positive hematolymphoid malignancies 
however, were all 2–4 logs lower than MCV-positive MCC tumors (Table 11). These results were 
confirmed by CM2B4 staining of commercial tissue microarrays of hematolymphoid tumors. Of 
122 B cell lymphomas, 17 T cell lymphomas, one myeloid disorder and 2 Hodgkin lymphomas 
  
 77 
examined, none showed evidence for LT protein expression (Table 12). Thirty-one healthy 
lymphoid control tissues were also negative for MCV T antigen.  
2.2.4 Immunohistochemial analysis of combined primary cutaneous squamous and 
neuroendocrine carcinomas 
Seven combined primary skin tumors, which contained an intimately admixed component of 
both squamous cell and neuroendocrine carcinoma (Figure 18) were analyzed by IHC for CK20 
and CM2B4. Although the neuroendocrine component of all tumors was positive for CK20 
(Table 13), none of the cases was immunoreactive with CM2B4 in either the squamous or 
neuroendocrine component (Figure 18). 
2.2.5 Immunohistochemical analysis of 26 primary pulmonary (small and large cell) 
neuroendocrine carcinomas 
Twenty-six primary pulmonary tumors (16 small cell and 10 large cell neuroendorcrine 
carcinomas) were analyzed for immunoreactivity with CM2B4. All had been previously 
characterized by a panel of immunomarkers for clinical purposes and found to be positive for at 
least one neuroendocrine marker (chromogranin, synaptophysin, CD56). IHC for TTF-1 was 
performed on 21 of the 26 tumors. Sixteen of them (76%) were immunoreactive for TTF-1. All 
26 pulmonary neuroendocrine carcinomas were retested for CK20 expression and confirmed to 
be negative. None of them showed any nuclear staining with CM2B4. 
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Table&3.&qPCR&detection&of&MCV&genome&in&hematolymphoid&malignancies.!
Hematopathological!samples!studied! No.!Tested!
No.!MCV!positive!!(%!
MCV!positivity)!
B&cell=associated&lymphomas& ! !
Chronic!lymphocytic!leukemia!! 33! 1!(3.0)!
NonBHodgkin!lymphoma,!NOS!! 14! 1!(7.1)!
Diffuse!large!B!cell!lymphoma! 65! 2!(3.1)!
Follicular!lymphoma! 14! 0!
Acute!lymphoblastic!leukemia! 11! 0!
Primary!effusion!lymphoma! 2! 0!
MucosaBassociated!lymphoid!tissue!lymphoma! 5! 0!
Mantle!cell!lymphoma! 8! 0!
Marginal!zone!lymphoma! 9! 1!(11)!
! ! !
T&cell=associated&lymphomas! ! !
Acute!lymphoblastic!leukemia!! 10! 0!
Large!granular!lymphocyte!leukemia! 1! 0!
Mycosis!fungoides! 11! 0!
T!cell!lymphoma,!unspecified! 82! 1!(1.2)!
! ! !
Myeloid&disorders& ! !
Chronic!myelogenous!leukemia!! 5! 0!
Acute!myeloid!leukemia!! 11! 0!
Myelodysplastic!syndrome! 3! 0!
! ! !
Others& ! !
Hodgkin!lymphoma!! 30! 1!(3.3)!
Post!transplant!lymphoproliferative!disorder! 11! 0!
Total! 325! 7!(2.2%)!
 
 
!
Table&S2.&MCV&genome&copies&in&MCV5positive&hematolymphoid&malignancies!
!
Hematolymphoid!malignancies!!
positive!for!MCV!
Copies!per!cell!
T!Ag! VP2!
Chronic!lymphocytic!leukemia!(#354*)! 1.2!x!10I2! 8.4!x!10I3!
NonIHodgkin!lymphoma!(#351)! 1.5!x!10I3! <!10I3!
Diffuse!large!B!cell!lymphoma!(#229)! 1.1!x!10I3! 0!
Diffuse!large!B!cell!lymphoma!(#500)! 3.8!x!10I3! 1.1!x!10I3!
Marginal!zone!lymphoma!(#781)! 5.8!x!10I3! 0!
T!cell!lymphoma!(#18)! 3.2!x!10I3! 0!
Hodgkin!lymphoma!(#86)! 1.8!x!10I3! 2.9!x!10I3!
*!Blinded!testing!number.!
!
!
!
!
Table&S3.&MCV&LT&protein&detection&in&hematolymphoid&malignancies&!
!
& Result!!
B&cell&malignancies! 0/122!
T&cell&malignancies! 0/17!
Myeloid&disorders& 0/1!
Hodgkin&lymphoma& 0/2!
Normal&lymphoid&tissues& !
Normal!splenic!tissue! 0/18!
Normal!lymph!node! 0/13!
!
i!
!
!
!
*These!cases!are!derived!from!tissue!microarray!slides!#SP482t,!#LM801t,!#NHL801t!from!
BioMax.!See!http://www.biomax.us!for!subclassification!and!diagnosis.!
!
!
&
&
&
!!
Table	  10	  qPCR	  Detection	  of	  MCV	  genome	  in	  hematolymphoid	  malignancies.	  
	  
Table	  11	  MCV	  genome	  copies	  in	  MCV-­‐positive	  hematolymhoid	  malignancies	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!
Table&S2.&MCV&genome&copies&in&MCV5positive&hematolymphoid&malignancies!
!
Hematolymphoid!malignancies!!
positive!for!MCV!
Copies!per!cell!
T!Ag! VP2!
Chronic!lymphocytic!leukemia!(#354*)! 1.2!x!10I2! 8.4!x!10I3!
NonIHodgkin!lymphoma!(#351)! 1.5!x!10I3! <!10I3!
Diffuse!large!B!cell!lymphoma!(#229)! 1.1!x!10I3! 0!
Diffuse!large!B!cell!lymphoma!(#500)! 3.8!x!10I3! 1.1!x!10I3!
Marginal!zone!lymphoma!(#781)! 5.8!x!10I3! 0!
T!cell!lymphoma!(#18)! 3.2!x!10I3! 0!
Hodgkin!lymphoma!(#86)! 1.8!x!10I3! 2.9!x!10I3!
*!Blinded!testing!number.!
!
!
!
!
Table&S3.&MCV&LT&protein&detection&in&hematolymphoid&malignancies&!
!
& Result!!
B&cell&malignancies! 0/122!
T&cell&malignancies! 0/17!
Myeloid&disorders& 0/1!
Hodgkin&lymphoma& 0/2!
Normal&lymphoid&tissues& !
Normal!splenic!tissue! 0/18!
Normal!lymph!node! 0/13!
!
i!
!
!
!
*These!cases!are!derived!from!tissue!microarray!slides!#SP482t,!#LM801t,!#NHL801t!from!
BioMax.!See!http://www.biomax.us!for!subclassification!and!diagnosis.!
!
!
&
&
&
!!
Table	  12	  MCV	  LT	  protein	  detection	  in	  hematolymphoid	  malignancies	  	  
	  
Figure	  18	  Combined	  cutaneous	  squamous	  and	  neuroendocrine	  carcinoma.	  	  
(A)	   The	   tumor	   shows	   a	   biphenotypic	   appearance	   (hematoxylin	   and	   eosin-­‐stained	   section).	   It	  
contains	   a	   pink	   squamous	   and	   a	   small	   cell	   neuroendocrine	   component.	   (B)	   The	   neuroendocrine	  
component	  is	  immunoreactive	  for	  cytokeratin	  20.	  (C)	  The	  neuroendocrine	  component	  fails	  to	  react	  
with	  CM2B4.	  
	  
Table	  13	  Combined	  squamous	  and	  neuroendocrine	  carcinomas	  of	  the	  skin	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2.2.6 MCV and chronic lymphocytic leukemia 
Koljonen et al described an association between chronic lymphocytic leukemia (CLL) and MCV–
positive Merkel cell carcinoma (MCC) in a recent large population-based survey from Finland 
[419]. CLL has been reported as a tumor significantly associated with MCC, validating the 
general findings of this study [66, 67]. This association suggests the possibility that MCV may 
play a role in CLL as well as in MCC. 
 As discussed above, we previously examined 33 CLL tissues by qPCR and 12 by MCV large-T 
antigen immunostaining. All specimens were negative for MCV genome or protein expression; 
however, none of these cases were associated with a history of MCC.  
Given the epidemiological relationship between MCC and CLL, we examined additional 
CLL cases for evidence of MCV infection. Ten peripheral blood samples with CLL (WBC counts 
ranging from 13.2 × 109 − 84.3 × 109 cells per L) were harvested and tested for the presence of 
MCV DNA. One displayed low MCV positivity VP2 (2.0 × 10−3 copies per cell). Twelve additional 
paraffin-embedded biopsies with CLL were examined by CM2B4 staining only. All CLL cases 
were uniformly negative for MCV T antigen protein expression. 
Although the occurrences of these 2 neoplasms are significantly associated, the uncommon 
nature of MCC has resulted in only rare published cases [420, 421]. We obtained and tested 2 
cases of concurrent CLL and MCV. We specifically sought evidence of MCV T antigen protein 
expression in CLL cells to circumvent the extremely high sensitivity of PCR, which can detect 
incidentally infected cells in tissues. 
Case 1. 
A 74-year-old female with CLL presented with a right thigh mass and enlarged right groin mass. 
Pathologic examination of thigh mass reveals immunohistochemically confirmed MCC. The 
groin resection contained metastatic MCC to lymph nodes with CLL. Examination of a lymph 
node by CM2B4 and CD20 immunohistochemical staining shows MCV T antigen protein 
expression only in the metastatic MCC (Figure 19 A, C) but not in CD20-positive CLL cells (Figure 
19 B). 
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Case 2. 
A 66-year-old male diagnosed with CLL 12 years earlier presented with a left forearm bump 
(diagnosed as MCC). Biopsy and left axillary dissection reveals cytokeratin-20–positive MCC 
metastatic to 9 of 80 lymph nodes, virtually all having effacement of normal architecture by 
CLL. A node containing metastatic MCC illustrates robust nuclear expression of MCV T antigen 
in tumor cells (Figure 19 D), whereas the CLL component is negative (Figure 19 E). 
We also collected 18 CLL and 18 acute lymphoblastic leukemia (ALL) age-matched sera. Ten of 
Figure 19 Lack of evidence for direct involvement of MCV in CLL  
(A) Case 1: lymph node with both CLL (10x/0.30 NA; B) and metastatic MCC (100x/1.40 NA oil objective; C) 
immunohistochemically stained (Dako EnVision+ Kit) with CM2B4, and counterstained with hematoxylin. Case 2: 
MCC metastatic to lymph node showing strong nuclear expression of MCV T antigen expression (40x/0.75 NA; D) 
and CLL (40x/0.75 NA; E) demonstrating effacement of normal nodal architecture with a population of cells 
comprised predominantly of small lymphocytes with scant cytoplasm, round nuclei, and clumped chromatin. Images 
were acquired on an Olympus Provis AX70 using Spot 3.5.9 software for Mac OS (Diagnostic Instruments). All images 
were processed using Adobe Photoshop CS3. (F) Anti-MCV antibody levels (colored dots and triangles), as measured 
with MCV virus-like particle enzyme immunoassay (VLP ELA), are not significantly different in sera from CLL and ALL 
patients. Median MCV optical density values are indicated by horizontal lines, with bars representing interquartile 
values. 
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18 (55.6%) CLL and 12 of 18 (66.7%) ALL patients showed serologic evidence for MCV exposure 
(Figure 19 F). The median MCV IgG titer for the CLL sera (0.645 OD units) was similar to, and not 
statistically different from, ALL patients (0.521 OD units). 
These findings together indicate that MCV is not likely to be directly involved in chronic 
lymphocytic leukemogenesis. We also do not find MCV infection more commonly among CLL 
patients than among a representative control group [116, 160]. Other possible explanations for 
the association between these 2 cancers include CLL-related immunosuppression predisposing 
to MCC or a pathologic immune response to MCV infection in persons predisposed to CLL. 
2.3 DISCUSSION 
 
Several independent groups have confirmed that MCV infection is present in the majority of 
MCC but not in most tissues from control patients [74, 416, 422, 423] (also see Chapter 3). The 
monoclonal pattern of MCV infection [74] and the pattern of tumor-virus derived mutations in 
T antigen genes [112] provide strong evidence that MCV causes a subset of MCC. We now show 
that MCC tumor cells, but not adjacent non-neoplastic cells, are infected with MCV and express 
MCV T antigen protein in most MCV-positive MCC tumors. This provides additional evidence 
that MCV is a human tumor virus.       
 Quantitative PCR shows that MCC biopsies are generally positive for the virus at >1 copy 
per tumor cell. This is consistent with clonal integration being common in MCV-positive MCCs 
and with antibody staining results that revealed nearly all MCV-positive MCC tumor cells harbor 
virus. Expression of the MCV T antigen in tumor cells may provide clues on the molecular 
origins of these tumors since T antigens from other polyomaviruses have been found to be 
oncoproteins. Animal models show that continued expression of polyomaviral T antigen, for 
example, is required to induce and maintain viral transformation [424, 425]. Additional studies 
are needed to determine whether MCV LT protein or other alternatively spliced T antigen 
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isoforms contribute to cell transformation [112]. Our study does not provide this formal proof 
but it does demonstrate that T antigen is a useful marker for MCC tumor cells. 
 Although a substantial fraction of adult humans may be infected with MCV [74], we only 
find evidence for high virus copy number infection in MCC. Approximately 74.2% CK20+ MCCs 
were positive for LT protein expression in our study. This suggests that the majority of MCC is 
caused by MCV infection whereas a subset of CK20+ MCC may have a different etiology. Other 
clinically suspect MCCs lacking CK20 expression, were all negative for LT protein expression. 
Additional clinical validation is needed for CM2B4 staining as a tissue marker for MCV, but this 
preliminary evidence suggests it is useful in identifying subsets of tumors associated with MCV 
infection.           
 There was no apparent association of MCV detection with anatomic site/mode of sun 
exposure and major clinical immune suppression of the patients. This is not a surprise. Less 
than 10% of MCC occur in patients with major immunosuppression, such as HIV, associated 
lymphoma or status postorgan transplantation [62]. As the majority of MCCs had previously 
been found to be positive for MCV [62, 68, 74, 416, 422] it was already evident that MCV-
associated MCC could not be restricted to severely immunosuppressed patients. Similarly, given 
the high frequency of MCV in MCC and the known anatomic distribution of the tumor [426], it 
was also expected that MCV could be found in tumors of both sun-exposed and sun-protected 
sites.            
 With regard to its potential diagnostic use, our findings suggest that mAb CM2B4 will 
likely emerge as a valuable adjunct reagent for the differential diagnosis of MCC from histologic 
mimics, in particular for the distinction of MCC from a cutaneous metastasis of a pulmonary 
neuroendocrine carcinoma, when current panels of immunomarkers do not allow a definitive 
diagnosis [310, 313, 314, 318, 427-429]. None of the 26 neuroendocrine carcinomas of the lung, 
which we examined in this series, labeled with CM2B4. Further investigations, however, are 
needed to examine the sensitivity and specificity of CM2B4 on a larger set of tumors, especially 
neuroendocrine carcinomas from sites other than skin and lung.   
 Although our results support prior observations that the majority of MCCs are 
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associated with MCV, not all of them are. Lack of virus detection may in part be due to technical 
reasons, for example, tissue preservation of the specimen, or virus mutation that does not 
permit PCR-amplification with the primers used, and/or may also lead to lack of 
immunoreactivity for CM2B4. However, it is also possible that there is a subset of MCCs, which 
may not be associated with MCV. Consequently, MCC may be divided into 2 broad categories—
MCV-positive type, representing the majority of case, and MCV-negative type.  
 It is of interest in this regard that none of the 7 combined cutaneous squamous and 
neuroendocrine carcinomas were immunoreactive with CM2B4. Furthermore, the one PCR-
negative primary MCC tumor turned out to be a combined squamous and neuroendocrine 
carcinoma. Such combined tumors are rare and account for only a minor portion of MCCs. 
Population-based data are lacking. In the patient review of 29 cases of MCC, Walsh found 3 
tumors, in which MCC was associated with a superficial squamous cell carcinoma [430]. In the 
institutional data set of Merkel cell tumors from MSKCC, approximately 5% of patients with a 
diagnosis of MCC have a neuroendocrine tumor that is associated with a superficial invasive 
squamous cell carcinoma (KJ Busam, unpublished observations). Although it is difficult to draw 
definitive conclusions from such as small sample size, it is tempting to speculate that 
neuroendocrine carcinomas arising in association with a squamous cell carcinoma may develop 
via a MCV-independent pathway and are different from “classic” MCCs. One may also question 
whether or not such combined MCV-negative tumors should be designated as “MCC.” 
 Historically, pathologists have classified the combined tumors as variants of MCC, 
because phenotypically, they are primary cutaneous carcinomas with a predominant 
neuroendocrine phenotype (ie, after the differentiation pathway of Merkel cells). Except for the 
associated presence of a (usually minor) superficial squamous cell carcinoma component, the 
histologic and immunohistochemical features of the dominant tumor component are 
indistinguishable from de novo “pure” MCC [430-433]. Furthermore, the combined tumors tend 
to behave clinically similar to pure MCCs [430], and their metastases tend to have a pure 
neuroendocrine appearance. It is of interest that among the patients with combined tumors, 
the proportion of those with chronic lymphocytic leukemia was higher than expected [62], but 
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this may be related to referral bias to a large cancer center.    
 We find little support for the possibility that MCV also contributes to CLL, a malignancy 
that can be associated with MCC, or other common hematolymphoid malignancies. Methods in 
sample collection did not allow us to screen specimens simultaneously for both viral DNA and T 
antigen expression, but results from both assays were consistent and no CLL cases were MCV 
positive at levels found among MCCs infected with the virus. In concurrent cases of CLL and 
MCC we showed that although the MCC part stains positive for MCV LT expression, the CLL part 
does not. MCC arising in the setting of CLL may result from CLL-induced immunosuppression 
[65]. These results do not exclude the possibility that less common hematolymphoid or 
nonlymphoid malignancies might be caused by this virus, and surveys of other tumors and 
diseased tissues are warranted.       
 Quantitative PCR detects MCV infection in peripheral blood cells from infected persons 
but at levels that approach the technical limit of our technique (∼10−3 DNA copies per cell). This 
is similar to other lymphotropic viruses, such as Kaposi's sarcoma herpesvirus, in which only a 
fraction of PBMC are positive from persons known to be infected with the virus [409, 434]. 
Examining whole PBMC is unlikely to reliably detect MCV in most infected persons due to the 
dilution effect from nonpermissive peripheral blood cells. For this reason, it is not surprising 
that low rates of positivity are present for whole PBMC samples from persons screened for an 
unrelated genetic marker (Factor V Leiden) or HIV/AIDS patients. Determining true human 
prevalence for MCV infection requires the development of serologic tests that can accurately 
measure exposure to this virus [380]. Tolstov et al. and others achieved this and the prevalence 
of MCV in adults is determined to be between 42 to 70% [160, 380]. 
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3.0  LITERATURE REVIEW OF MCV POSITIVITY IN MCC AND OTHER TISSUES 
 
Various groups confirmed our study and found MCV in about 70-80 % of MCC tissues tested. 
Researchers from around the world also tested MCV status in MCC, other diseases and healthy 
human tissues by PCR, quantitative PCR, immunostaining for MCV T antigen (with CM2B4 and 
other antibodies), and Southern blotting techniques. The following tables summarize a 
literature review describing the results of the different groups.   
 
3.1 MONOCLONAL INTEGRATION OF MCV IN MCC AT >1 COPY PER CELL    
In the initial investigations Feng and colleagues found 7 out of 10 MCC tumors from different 
patients to be positive for MCV by Southern blotting. Subsequently, we showed these had high 
copy numbers in the range of 1.6 to 48 copies per tumor cell [68, 74]. This high rate of MCV 
positivity in MCC has been confirmed by many other laboratories in various countries (including 
USA, Germany, France, Italy, Finland, Switzerland, Spain, Canada, Australia, Japan and Korea) 
with 74.04% (1743/2354) of MCC cases being positive for MCV DNA (Table 14).   
 Clonal integration of MCV in MCC tumor genome was confirmed by Southern blotting 
and 3’-RACE in both primary tumors and their metastasis [74]. This suggests that MCV infection 
occurred prior to initial monoclonal expansion of cells and tumor development. This viral 
integration pattern is analogous to that seen in high-risk human papillomavirus integration in 
cervical cancer cells and supports the belief that virus–associated tumors are biological 
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accidents [19]. Although virus concatemers are found integrated at a single integration site in 
each tumor tested, there is no consistent or preferential site of integration in the cellular 
genome. In the viral genome however, the breakpoints occur mainly in the second exon of the 
LT, after the pRb-binding site [74, 367, 435, 436].      
 Monoclonal integration and replication incompetence refutes the possibility of MCV as a 
coincidental passenger virus in MCC. Although, one study did report MCV viral particles in 2 of 5 
MCCs by electron microscopy [402], antibodies against the VP1 protein has not detected any 
expression in tumors so far [356, 437].  
3.2 MCV IS SPECIFIC FOR MCC   
Numerous surveys on other tumor types have been performed including various 
hematolymphoid malignancies, neuroendocrine carcinomas, various skin disorders, other 
cancers (including breast, prostate, lung, liver and colon), CNS (central nervous system) tumors, 
other virus-related disorders and many other diseases (Table 15). MCV was found in only 8.5% 
of 6470 non-MCC disease samples tested. In cases where MCV was found in non-MCC tumors it 
is generally at low abundance (2-3 logs lower in copy per cell than found in MCC) and the data 
do not point to any association between the two but may suggest incidental infection [68, 70-
73, 382, 394, 435, 438-447].         
 Researchers also tested samples from HIV+ individuals and found that 25.5% cases 
harbored MCV at low copies (Table 16). This is not surprising, as immunosuppression is a major 
risk factor for MCC and AIDS patients have a 13 fold higher risk of developing MCC [60]. The 
increased detection of MCV in HIV positive individuals suggest that the immune system actively 
keeps MCV under check in healthy individuals and this policing is lost in the 
immunosuppressed.            
 Since 2008, various studies on MCV detection show MCV to be a widespread but 
previously unrecognized human infection. Other than MCC, MCV was detected in 9/84 non-
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MCC tissues in the initial study [74] at low levels (at the limits of PCR sensitivity). Since then 
various studies have detected MCV in healthy skin flora [369, 394, 440, 448, 449], respiratory 
tract samples and nasopharyngeal aspirates [391, 450-452], saliva [394], gut [328, 453], 
lymphoid tissue [68, 328], urine [393, 444, 447, 454] and whole blood from healthy donors 
[444, 453, 455-457] (Table 17). Skin showed the highest level of MCV positivity (56.4%) as 
compared to the digestive system, respiratory system, lymphatic system, blood, urinary system 
and other tissues. These studies claim MCV as a part of the healthy skin flora, which otherwise 
harmless, can undergo certain mutational events and cause tumors in susceptible hosts 
(immunosuppressed, older in age).   
 
3.3 PROGNOSTIC VALUE OF MCV DETECTION IN MCC 
MCV status in MCC has become an important clinical determinant and may even have 
prognostic value. Sihto et al., found that MCV positive MCC patients from Finland have a 
significantly reduced disease-specific mortality, as compared to MCV negative MCC patients 
[328]. Laude et al. also analyzed associations between MCV viral load and survival [436]. They 
reported similar results, demonstrating that patients with more than 1 copy per cell spent 
longer periods in complete remission. However, upon analyzing viral presence in peripheral 
blood cells, they concluded that MCC patients with MCV in PBMC samples had shorter overall 
survival times and fared worse than MCC patients without virus shedding. 
Using PCR based assays such as the ones described in this dissertation, researchers have 
detected MCV abundantly in MCC tumors. Various other cancers - including skin cancers, 
hematolymphoid tumors, neuroendocrine tumors, and other cancers - have been surveyed and 
found to be negative for MCV. However, MCV has been detected at various human body parts, 
making it more evident that it is a part of the normal human viral flora [68, 74, 394, 440, 448-
450]. This complicates the association between viral DNA load and MCC prognosis. 
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The use of MCV immunohistochemistry with CM2B4 antibody is a less sensitive but 
more robust technique than PCR. It has the advantage of detecting a functional outcome of 
MCV presence, namely expression as well as nuclear localization of MCV LT oncoprotein. Bhatia 
et al. used CM2B4 based detection of MCV and reported that MCV positive tumors are 
associated with better prognoses [458]. However, Schrama et al. did not find any differences in 
clinical behaviors and prognoses between MCV positive and MCV negative MCCs [459]. Further 
studies with larger sample sizes are still needed to clearly determine any association between 
the two.  
 Recent studies have also found a link between increased serum antibodies to MCV T 
antigen and disease progression in MCV positive MCCs [384, 387]. Accordingly, disease 
progression may be analyzed and marked by a loss of immune surveillance control, leading to 
viremia and increased antibodies against viral T antigens. 
Nonetheless, MCV status has become an important diagnostic tool in the field of MCC 
study. Most importantly, determining whether an MCC tumor is MCV positive or not, gives us a 
clue about its etiology. Although both virus positive and virus negative MCCs are clinically 
comparable, it is only a matter of time before more specific, MCV-positivity-based disease 
management regimes will become useful. 
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Table 14 MCV Presence in MCC Tissues (Review of Literature) 
Country Total  MCV +ve  Method Used Reference 
USA 10 8 (80%) PCR (LT and VP1) 
sequence analysis, 
Southern 
hybridization,and  
CM2B4 Staining 
Feng et al, Science 2008 and                                                                         
Shuda et al.,Int J Cancer 2009 
USA  16 11 (68.7%) qPCR (LT) Garneski et al., J Invest Dermatology 2009 
USA 13 7 (53.8%) PCR (LT and VP1) Ridd et al., J Invest Dermatology, 2009 
USA 41 32 (78%) PCR (LT and VP1) Duncavage et al., Modern Pathology 2009 
USA 53 42 (79.2%) qPCR and CM2B4 
staining 
Busam et al., Am J Surg Pathol 2009 
USA 31 24 (77.4%) qPCR (VP1) Carter et al., J Nat Cancer Institute 2009 
USA 22 13 (59.1%) qPCR (LT) Paulson et al., J Invest Dermatol 2009 
USA 23 17 (73.9%) PCR (Tag) Bhatia et al., Int J Cancer 2010 
USA 7 6 (85.7%) qPCR (LT and VP1) Loyo et al., Int J Cancer 2010 
USA 6 4 (66.7%) PCR (LT) Lewis et al., Oral Surg, Oral Medicine, Oral Pathol, 
Oral Radiolo and Endodon 2010 
USA 20 15 (75%) CM2B4 Staining Reisinger et al., J Am Acad Dermatol 2010 
USA 4 2 (50%) qPCR (LT) Toracchio et al., Emerg Infect Diseases 2010 
USA 80 59 (73.7%) qPCR (LT) Paulson et al., J Clin Oncol 2011 
USA 4 4 (100%) Hybrid capture and 
next-gen sequencing 
Duncavage et al., J Molecular Diagnostics 2011 
USA 51 47 (92.2%) CM5E1 and CM2B4 
Staining 
Shuda et al., JCI 2011 
USA 52 38 (73.1%) qPCR (LT) Lee et al., J Clin Virology 2011 
USA 58 38 (65.5%) PCR (LT) Nardi et al., Clin Cancer Research 2012 
Switzerland 30 20 (66.6%) PCR (LT and VP1) Mangana et al., Dermatology 2010 
Spain 36 21 (58.3%) CM2B4 staining Shuda et al., Int J Cancer 2009 
Netherlands 7 3 (42.8%) PCR and sequence 
analysis (LT) 
Wetzels et al., PLoS ONE, 2009 
Korea 7 7 (100%) PCR (LT) Woo et al., J Plastic Reconstructive and  Aesthetic 
Surg 2010 
Korea 14 12 (85.7%) qPCR (LT and VP1) 
and CM2B4 Staining 
Jung et al., Histol Histopathol 2011 
Japan 11 6 (54.5%) PCR and qPCR (Tag 
and VP1) 
Katano et al., J Medical Virology 2009 
Japan 14 11 (78.6%) PCR (LT) Nakajima et al., J Dermatol Sci 2009 
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Japan 19 11(57.8%) qPCR (LT) and LT Ab 
Staining 
Nakamura et al., Virology 2010 
Japan 26 20 (76.9%) qPCR (LT) and CM2B4 
Staining 
Kuwamoto et al., Human Pathology 2011 
Italy 9 8 (88.8%) PCR (LT and VP1) Paolini et al., Virology Journal 2011 
Italy 70 60 (85.7%) PCR (LT) Asioli et al., Modern Pathology 2011 
Italy 18 18 (100%) PCR (LT) Biase et al., Human Pathology 2011 
Hungary 8 7 (87.5%) PCR (LT) and 
Sequence analysis 
Varga et al., Br J Dermatol 2009 
Austalia 38 33 (86.8%) qPCR (LT and VP1) 
and CM2B4 Staining 
Schrama et al., J Invest Dermatol 2011 
Germany  138 116 (84.1%) qPCR (LT and VP1) 
and CM2B4 Staining 
Schrama et al., J Invest Dermatol 2011 
Germany 39 30 (76.9%) PCR(LT and VP1) and 
sequence analysis 
Kassem et al., Cancer Research 2008 
Germany 53 45 (84.9%) qPCR (LT) Becker et al., J Invest Dermatology 2009 
Germany 39 35(89.7%) PCR (LT) Wieland et al., Emerg Infect Dis 2009 
Germany 98 90 (91.8%) PCR (LT) Helmbold et al., Mol Carcinogenesis 2009 
Germany 33 21 (63.6%) PCR (Tag) and 
Southern 
hybridization 
Andres et al., J Cut Pathol 2010 
Germany 50 43 (86%) PCR (LT) and CM2B4 
staining 
Houben et al., Int J Cancer 2010 
Germany 59 34 (57.6%) PCR (LT and VP1) Handschel et al., Int J Oral and Maxillofacial Surg 2010 
Germany 52 43 (82.7%) qPCR (LT and VP1) Werling et al., Histopathology 2011 
Germany 3 2 (66.7%) Polyomavirus 
genotyping assay 
Schmitt et al., Cancer Epid Biomarker and Prevention 
2011 
Germany 34 22 (64.7%) PCR (Tag) Andres et al., Acta Dermato-Venereologica 2011 
Germany 43 37 (86%) qPCR(LT) Wieland et al., J Am Acad Dermatol 2011 
Germany 142 111 (78.2%) qPCR (LT and VP1) Vlahova et al., Br J Dermatology 2012 
France 9 8 (88.8%) PCR (LT and VP1) Foulogne et al., Emerg Infect Dis 2008 
France 10 10 (100%) PCR (Tag and VP1) Sastre-Garau   et al., J Pathology 2009 
France 32 21 (65.6%) PCR (LT and VP1) Touze et al., Emerg Infec Diseases 2009 
France 18 14 (77.8%) qPCR (LT and VP1) 
and Sequence analysis 
Foulogne et al., Br J Dermatol 2009 
France 43 41 (95.3%) qPCR (LT) Laude et al., PLoS pathogens 2010 
France 68 51 (75%) qPCR (LT) Touze et al., J Clin Oncol 2011 
France 113 70 (61.9%) PCR (LT) and qPCR (sT) Martel-Jantin et al., Virology 2012 
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Finland 114 91 (79.8%) qPCR(LT)and DNA 
sequencing 
Sihto et al., J Natl Cancer Inst 2009 
Finland 3 1 (33.3%) qPCR (LT) Koljonen et al., Nephrology Dialysis Transplantation 
2009 
Finland 5 5 (100%) qPCR (LT) Koljonen et al., Br J Cancer 2009 
Finland 91 61 (67%) qPCR (LT) and CM2B4 
Staining 
Sihto et al., Clin Cancer Research 2011 
Finland 87 67 (77%) qPCR(LT) Waltari et al., Int J Cancer 2011 
Canada 27 17 (62.9%) CM2B4 Staining Ly et al., Human Pathol 2011 
Canada 30 29 (96.7%) CM2B4 Staining Erovic et al., Head and Neck 2012 
Australia 21 5 (23.8%) qPCR (LT) Garneski et al., J Invest Dermatology 2009 
Australia 104 19 (18.3%) CM2B4 Staining Palik et al., Human Pathology 2011 
Total 2354  =1743 (74.04%) 
Methods used were - PCR, qPCR, CM2B4 Staining and Southern blotting 
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Table 15 MCV Presence in non- MCC Disease Tissues (Review of Literature) 
Disease Total 
MCV 
+ve Reference (s) 
Lymphomas  1105 44 Shuda et al., Int J Cancer 2009,Kantola et al., J Clinical Virology 2009, Toracchio 
et al., Emerg Infect Diseases 2010, Andres et al., Am J  Dermatopathology 
2010,  Mirvish et al.,J Am Acad Dermatol 2011 
Myeloid 
disorders 
401 33 Feng et al, Science 2008, Shuda et al., Int J Cancer 2009,Kantola et al., J Clinical 
Virology 2009,Pantulu et al., Blood 2010,Teman et al., Leukemia Research 
2011,Toracchio et al., Emerg Infect Diseases 2010 
Neuroendocrine 
cancers 
196 1 Shuda et al., Int J Cancer 2009,Touze et al., Emerg Infec Diseases 2009, Busam 
et al., Am J Surg Pathol 2009, Touze et al., Emerg Infec Diseases 2009,  
McCluggage et al., Am J Surg Path 2010,Duncavage et al., Am J of Surgical 
Pathology 2009, Lewis et al., Oral Surg, Oral Medicine, Oral Pathol, Oral 
Radiolo and Endodon 2010, , Ly et al., Human Pathol 2011, Schmitt et al., 
Cancer Epid Biomarker and Prevention 2011, Chernock et al., Am J Surg Pathol 
2011 
Skin diseases 
(cancers and 
others) 
1925 329 Feng et al, Science 2008,Katano et al., J Medical Virology 2009,Kassem et al., 
Int J Cancer 2009, Wieland et al., Emerg Infect Dis 2009,Becker et al., J Invest 
Dermatology 2009, Sastre-Garau et al., Journal of Pathology 2009, Andres et 
al., J Cut Pathol 2009, Dworkin et al., J Invest Dermatol 2009, Foulogne et al., 
Br J Dermatol 2009, Garneski et al., J Invest Dermatology 2009, Varga et al., Br 
J Dermatol 2009 , Ridd et al., J Invest Dermatology, 2009, Mangana et al., 
Dermatology 2010, Handschel et al., Int J Oral and Maxillofacial Surg 2010, 
Loyo et al., Int J Cancer 2010, Reisinger et al., J Am Acad Dermatol 2010, 
Andres et al., Am J Dermatopath 2010, Mertz et al., J Investigative Dermatol 
2010, Mertz et al., Human Pathology 2010,Kassem et al., J Dermatolg Science 
2010, Faust et al., J Infect Diseases 2011 ,Rollison et al., Cancer Epid Biomark 
and Prevention 2011, Wieland et al., J Am Acad Dermatol 2011, Ly et al., 
Human Pathol 2011, Murakami et al., J Clin Virol 2011, Mertz et al., 
Dermatology 2011, Jung et al., Histol Histopathol 2011, Ly et al., Human Pathol 
2011,Koburger et al., Experimental Dermatology 2011 
Central Nervous 
System diseases 
291 1 Feng et al, Science 2008, Giraud et al., PLoS ONE 2009,Sastre-Garau et al., 
Journal of Pathology 2009, Katano et al., J Medical Virology 2009, Rubin et al., 
Anticancer Research 2011, Jung et al., Histol Histopathol 2011, Dang et al., 
PLoS ONE 2011 
Other Virus 
related diseases 
146 9 Shuda et al., Int J Cancer 2009, Wieland et al., Emerg Infect Dis 2009, Katano et 
al., J Medical Virology 2009, Sastre-Garau et al., Journal of Pathology 2009 
Mertz et al., Human Pathology 2010, Mertz et al., Dermatology 2011, Dang et 
al., PLoS ONE 2011 
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Other cancers 1807 79 Feng et al, Science 2008, Bhatia et al., Int J Cancer 2009,Giraud et al., PLoS ONE 
2009, Sastre-Garau et al., Journal of Pathology 2009,Bluemn et al., J Clinical 
Virology 2009, Katano et al., J Medical Virology 2009,,Bhatia et al., Int J Cancer 
2009,Kassem et al., Int J Cancer 2009, Joh et al., Exper and Mol Pathol 2010, 
Bhatia et al., J Clinical Virology  2010,  Loyo et al., Int J Cancer 2010,Toracchio 
et al., Emerg Infect Diseases 2010,  Mertz et al., Dermatology 2011, Ly et al., 
Human Pathol 2011, Jung et al., Histol Histopathol 2011, Jung et al., Histol 
Histopathol 2011, Campello et al., J Medical Virology 2011, Helmbold et al., Eur 
J Cancer 2009,Andreas et al., Thorax 2009,Wetzels et al., PLoS ONE, 2009,Ly et 
al., Human Pathol 2011, Biase et al., Human Pathology 2011, Palik et al., 
Human Pathology 2011 
Other diseases 599 55 Wieland et al., Emerg Infect Dis 2009, Ridd et al., J Invest Dermatology 
2009,Kassem et al., Int J Cancer 2009, Katano et al., J Medical Virology 2009, 
Loyo et al., Int J Cancer 2010, Toracchio et al., Emerg Infect Diseases 2010, 
Mertz et al., Human Pathology 2010, Mertz et al., J Investigative Dermatol 
2010, Babakir-Mina et al., J Medical Virology 2010, Dang et al., PLoS ONE 2011, 
Kiasari et al., J Medical Virology 2011 
Total 6470 550 (8.5%) 
Methods used were - PCR, qPCR, CM2B4 Staining. The qPCR copy numbers in the positive cases were 2-4 logs 
lower than that seen in MCC. 
For details of the disease categories see Appendix section A1. 
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Table 16 MCV Presence in Samples from HIV + Individuals (Review of Literature) 
Tissue Total MCV 
+ve 
Method Reference (s) 
Normal skin from HIV Positive 
individual 
1 0 PCR Feng et al, Science 2008 
Kaposi Sarcoma from HIV + individuals 4 0 PCR Feng et al, Science 2008 
Lymph node and spleen tissues from 
HIV +ve individuals with AIDS 
42 0 PCR Sharp et al., J of Infectious Diseases, 2009 
Mucosal samples from HIV +ve MSM 120 37 PCR Wieland et al., Emerg Infect Dis 2009 
Cerebrospinal fluid from HIV+ve MSM 
with nervous problems 
7 0 PCR Wieland et al., Emerg Infect Dis 2009 
Eyebrow hair plucked from HIV + MSM 14 7 PCR Wieland et al., Emerg Infect Dis 2009 
AIDS related Lymphoma 11 0 qPCR Katano et al., J Medical Virology 2009 
HIV associated non small cell lung 
cancer 
8 0 PCR Stebbing et al., AIDS 2010 
Cerebrospinal fluid from HIV +ve 
Individuals 
36 0 qPCR Dang et al., PLoS ONE 2011 
HIV Positive PML tissue 50 0 qPCR Dang et al., PLoS ONE 2011 
HIV+ large cell lymphoma  1 0 PCR Feng et al, Science 2008 
Cutaneous Swabs from HIV Positive 
MSM 
210 124 qPCR Wieland et al., Archives of Dermatol 2011 
PBMC from HIV/AIDS patients 21 2 qPCR Shuda et al., Int J Cancer 2009 
AIDS autopsies below :         
Brain 15 0 qPCR Katano et al., J Medical Virology 2009 
Tongue 5 0 qPCR Katano et al., J Medical Virology 2009 
Submandibular gland 5 0 qPCR Katano et al., J Medical Virology 2009 
Lung 15 0 qPCR Katano et al., J Medical Virology 2009 
Lymph node 12 0 qPCR Katano et al., J Medical Virology 2009 
Heart 9 0 qPCR Katano et al., J Medical Virology 2009 
GI Tract 13 0 qPCR Katano et al., J Medical Virology 2009 
Liver 16 0 qPCR Katano et al., J Medical Virology 2009 
Spleen 19 0 qPCR Katano et al., J Medical Virology 2009 
Pancreas 12 0 qPCR Katano et al., J Medical Virology 2009 
Kidney 14 0 qPCR Katano et al., J Medical Virology 2009 
Adrenal gland 7 0 qPCR Katano et al., J Medical Virology 2009 
Total 667 170 (25.5%)   
The qPCR copy numbers in the positive cases were 2-4 logs lower than that seen in MCC. 
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Table 17 MCV Presence in Healthy Tissue (Review of Literature) 
Tissue Total MCV 
+ ve 
Method 
used 
Reference(s) 
Skin         
Skin 
(normal/healthy) 
618 291 qPCR, PCR 
and LT Ab 
(rabbit 
polyclonal) 
staining, 
rolling circle 
amplification 
Sastre-Garau et al., Journal of Pathology 2009,Sitho et 
al., J Natl Cancer Inst 2009,Helmbold et al., Mol 
Carcinogenesis 2009,Foulogne et al., Br J Dermatol 
2009,Mangana et al., Dermatology 2010,Nakamura et 
al., Virology 2010,Mertz et al., J Investigative Dermatol 
2010,Loyo et al., Int J Cancer 2010,Mogha et al.,PLoS 
ONE 2010,Dworkin et al., J Invest Dermatol 
2009,Wieland et al., Emerg Infect Dis 2009,Feng et al, 
Science 2008,Bhatia et al., Int J Cancer 2009,Schowalter 
et al., Cell Host and Microbe 2010,Foulongne et al., 
Emerg Infect Diseases 2010, Wieland et al., Archives of 
Dermatol 2011,swin swabs from Healthy volunteers 47 
44 qPCR Pastrana et al., Medical Microbio and Immunol 
2011 
Cutaneous swabs 
from MCC patients 
27 29 qPCR Foulongne et al., Emerg Infect Diseases 2010 
Cutaneous swabs 
from patients with 
cutaneous diseases 
58 78 qPCR Foulongne et al., Emerg Infect Diseases 2010 
Infalmmatory skin 3 0   Feng et al, Science 2008 
Total 706 398 (56.4%)   
Digestive System         
Appendix 9 2 PCR, 
southern 
hybridization 
Feng et al, Science 2008 
Buccal Mucosal 
swabs from patients 
with MCC and 
cutaneous disorders 
42 2 qPCR Foulongne et al., Emerg Infect Diseases 2010 
Colon 111 12 PCR and 
qPCR 
Campello et al., J Medical Virology 2011, Sitho et al., J 
Natl Cancer Inst 2009, Feng et al, Science 2008,Loyo et 
al., Int J Cancer 2010 
Esophagus 6 1 qPCR Loyo et al., Int J Cancer 2010 
Saliva from patients 
without cancer 
10 10 qPCR Loyo et al., Int J Cancer 2010 
Small bowel 3 1 PCR, 
southern 
hybridization 
Feng et al, Science 2008 
Stomach 1 0 qPCR Sitho et al., J Natl Cancer Inst 2009 
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Tonsillar tissues 234 8 PCR Feng et al, Science 2008,Kantola et al., J Clinical Virology 
2009 
Mouth, mouthwash 
DNA 
13 2 PCR Feng et al, Science 2008, Dworkin et al., J Invest 
Dermatol 2009 
Mucosa 
(normal/healthy) 
10 2 qPCR Loyo et al., Int J Cancer 2010 
Total 439 40 (9.1%)   
Respiratory System         
Respiratory  tract 
specimens 
612 8 PCR and 
qPCR 
Sharp et al., J Infectious Diseases, 2009,Bialasiewicz et 
al., Emerg Infect Diseases 2009 
Nasopharyngeal 
aspirate samples 
775 30 PCR and 
qPCR 
Kantola et al., J Clinical Virology 2009, Goh et al., Emerg 
Infect Diseases 2009 
Lung 15 1 qPCR Loyo et al., Int J Cancer 2010 
Transbronchial 
biopsies from lung 
transplant patients 
65 22 qPCR Bergallo et al., J Clinical Path 2010 
Total 1467 61 (4.2%)   
Blood         
Whole Blood 317 12 PCR and 
qPCR 
Feng et al, Science 2008,Helmbold et al., Mol 
Carcinogenesis 2009,Campello et al., J Medical Virology 
2011,Helmbold et al., Eur J Cancer 2009,Pantulu et al., 
Blood 2010,Mertz et al., J Investigative Dermatol 
2010,Kassem et al., Cancer Research 2008,Dworkin et 
al., J Invest Dermatol 2009 
Buffy coats 60 13 qPCR Pancaldi et al., Blood 2011 
Sera 725 0 PCR Kantola et al., J Clinical Virology 2009 
PBL 40 2 PCR and 
qPCR 
Bhatia et al., J Clinical Virology  2010,Bhatia et al., Int J 
Cancer 2009 
PBMC 123 0 PCR and 
qPCR 
Shuda et al., Int J Cancer 2009, Duncavage et al., 
Modern Pathology 2009 
Inflammatory 
Monocytes of MCC 
Patients 
2 2 PCR Mertz et al., J Investigative Dermatol 2010 
Total 1267 29 (2.9%)   
Lymphatic System         
Lymph node 143 11 qPCR, 
CM2B4 
staining 
Feng et al, Science 2008, Sitho et al., J Natl Cancer Inst 
2009 ,Shuda et al., Int J Cancer 2009, Toracchio et al., 
Emerg Infect Diseases 2010 
Bone marrow 2 0 qPCR Sitho et al., J Natl Cancer Inst 2009 
Total 145 11 (7.6%)   
Urinary System         
Bladder 2 0 qPCR Loyo et al., Int J Cancer 2010 
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Kidney 1 0 PCR Feng et al, Science 2008 
Urine 69 10 PCR and 
qPCR 
Wieland et al., Emerg Infect Dis 2009,Bofil-Mas et al., 
Virology Journal 2010,Husseiny et al., J Clin Virol 
2010,Mertz et al., J Investigative Dermatol 2010 
Total 72 10 (13.9%)   
Other Tissues         
Brain tissues 300 0 PCR Lam et al., J Clinical Virology 2010 
Fetal autopsy 535 1 qPCR and 
Sequence 
analysis 
Sadeghi et al., Virology Journal 2010 
Fibrous tissue  2 0 PCR Feng et al, Science 2008 
Fistula track  1 0 PCR Feng et al, Science 2008 
Gall Bladder 7 1 PCR, 
southern 
hybridization 
Feng et al, Science 2008 
Heart 1 0 PCR Feng et al, Science 2008 
Hemorrhoid 1 1 PCR, 
southern 
hybridization 
Feng et al, Science 2008 
Hernia 2 0 PCR Feng et al, Science 2008 
Liver 15 5 qPCR Loyo et al., Int J Cancer 2010 
Prostate 29 0 PCR and 
qPCR 
Feng et al, Science 2008, Bluemn et al., J Clinical Virology 
2009 
Prostate tumor 
adjacent stroma 
6 0 qPCR Bluemn et al., J Clinical Virology 2009 
Skeletal muscle 1 0 qPCR Sitho et al., J Natl Cancer Inst 2009 
Total 900 8 (0.9%)   
The qPCR copy numbers in the positive cases were 2-4 logs lower than that seen in MCC. 
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4.0  SURVIVIN AND MERKEL CELL CARCINOMA 
4.1 THE DUAL ROLE OF SURVIVIN 
 
In response to a variety of different stimuli including UV radiation, toxins, cytokines, and 
DNA damage cells usually initiate an evolutionary conserved process of autodestruction called 
apoptosis. Both intracellular and extracellular factors exist that control apoptosis, triggering the 
intrinsic and/or the extrinsic pathways respectively. Extracellular activators of apoptosis include 
death receptors such as Fas and tumor necrosis factor receptors, whereas intracellular 
activators include stress-activated factors controlling mitochondrial activity. Proteolytic 
caspases, activated upon cleavage, are the main effectors of apoptosis. Both caspase-8 
(extrinsic pathway) and caspase-9 (intrinsic pathway) stimulate the effector serine protease- 
caspase 3, which activates a DNAse that eventually degrades cellular DNA and kills the cells. 
Due to the importance of apoptosis in both normal and diseased tissues, the process is 
intricately regulated by a number of anti- and pro- apoptotic molecules. One such group is 
called the inhibitor of apoptosis (IAP) family; one of its most important members is survivin 
[460-462].   
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The IAP family is comprised of structurally different proteins, sharing one or more copies 
of a domain called the BIR (baculovirus IAP repeat), which binds and blocks caspase activity. The 
BIR domain containing proteins include Bruce, ILP2, Livin, survivin, NAIP, c-IAP1, c-IAP2, and 
XIAP (X-linked IAP) (Figure 20). Unlike other IAP members, the smallest member, survivin also 
plays an important role in the regulation of mitosis. This dual nature of survivin can be 
attributed to its unique distinguishing structure. Survivin has only one BIR domain, which it uses 
 
Figure 20 The inhibitor of apoptosis (IAP) family members and survivin isoforms.  
The IAP family comprises of eight members: XIAP (X-linked IAP), c-IAP1, c-IAP2, ILP2 (IAP-like protein-2), ML-IAP 
(melanoma IAP)/Livin, NAIP (neuronal apoptosis-inhibitory protein), and survivin. All these proteins exert 
antiapoptotic functions. Survivin is an exception as it also regulates the cell cycle. Alternative splicing of survivin 
transcript generates five major isoforms characterized by different functions. BIR, baculovirus inhibitor of 
apoptosis repeat; CARD, caspase recruitment domain; RING, really interesting new gene; 3′UTR, 3′ untranslated 
region; WT, wild type. (Reproduced from Dallaglio et al., JID 2012) 
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to homodimerize, and interact with other chromosome passenger proteins (phosphorylation of 
threonine 48 in the BIR domain is essential for this)[460, 461, 463]. In addition, survivin also has 
a coiled-coil α-helix C-terminal domain. Unlike other IAPs, survivin lacks a caspase recruitment 
domain (CARD) [344] and does not directly bind caspases in vivo. It primarily forms a complex 
with XIAP, stabilizes it and thereby increases XIAP’s ability to inhibit caspases and thus 
apoptosis[464, 465]. In addition, survivin also interacts with Smac/DIABLO (second 
mitochondria-derived activator of caspases expressed from the DIABLO gene) and thus 
prevents it from activating caspases at the postmitochondiral level[466]. Finally, survivin is 
dynamically regulated by multiple post-translational mechanisms, and its various functions are 
also spatially and temporally regulated[467]. There are several other molecules that have been 
identified in complex with survivin, but their significance and functions are still under 
evaluation. The gene encoding for the 16.5kD (142 amino acids) wild type survivin, called BIRC5, 
spans 14.7 kb at the telomeric end of chromosome 17. It generates five major transcripts by 
alternative splicing: wild-type [75]-survivin, survivin-2B, survivin-ΔEx3, survivin-3B, and survivin-
2α (Figure 20). Survivin-2α and survivin-2B favor induction of apoptosis, whereas WT-survivin, 
survivin-ΔEx3, and survivin-3B appear to be antiapoptotic and cytoprotective[461, 467]. More 
studies are still needed to determine the expression, localization and functions of all these 
different isoforms. Analysis of human survivin protein on NCBI website shows that it shares 84% 
and 91.5% sequence identity with mouse and canine survivin respectively, suggestive of a 
conserved function in the mammalian species.  
Survivin is unique in its ability to regulate mitosis. One of the ways in which it mediates 
this is by binding to microtubules through its C-terminal domain and ensuring correct cell 
division. Survivin also associates with the chromosome passenger proteins Aurora B, INCENP, 
and Borealin, and the complex is recruited to the mitotic centromeres to assist and ensure 
proper chromosomal segregation[468, 469]. Additionally, survivin localizes to the centrosomes 
of dividing cells. It is here that it binds to cyclin dependent kinase 1 (Cdk1), the activation of 
which allows the cells to enter mitosis (specifically S phase)[470]. 
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Within a cell, survivin exists in different subcellular compartments where it interacts 
with various effector molecules and executes its functions. Nuclear, cytoplasmic, and 
mitochondrial pools of survivin protein have been reported. Scientists have linked nuclear 
localization with its mitotic regulation function and mitochondrial survivin with its inhibition of 
apoptosis function. Cytoplasmic survivin on the other hand, loses its cytoprotective ability after 
exiting from the mitochondria once apoptosis is initiated[471, 472]. Survivin induced by stress 
stimuli, is also found in the extracellular space. This pool seems to retain both antiapoptotic and 
proliferative activities[473]. A role in for survivin in the pathogenesis of rheumatoid arthritis is 
being explored [474]. 
 Although regulatory mechanisms of survivin are not yet fully understood at the 
transcriptional level, survivin levels has been demonstrated to be cell cycle dependent. The 
BIRC5 promoter possesses a cell-cycle dependent element/ cell cycle gene homology region 
(CDE/CHR) G1 repressor element. Furthermore, Raj et al. reported that survivin expression in 
melanocytes is cell cycle dependent and regulated by both p53 and Rb. In particular, wild-type 
p53 is able to repress mitochondrial apoptosis-preventing survivin (both mRNA and protein) 
[475]. The stabilization of p53 following DNA damage leads to subsequent repression of survivin 
and the activation of cell cycle checkpoints. Conversely, overexpression of survivin is able to 
rescue cells from p53-induced apoptosis. The loss of p53 is often observed in cases of 
protracted UV irradiated skin (sun-exposed skin). This results in uncontrolled survivin 
expression, impaired checkpoint control and accumulation of genomic mutations that 
eventually lead to the development of a neoplasm [476, 477].    
 Among the interactor proteins of survivin, another worth mentioning is the heat shock 
protein 90 (Hsp90). The interaction and formation of the survivin-Hsp90 complex appears to 
stabilize survivin and prevent its proteasomal degradation [478].  
Survivin tissue expression is ubiquitous and abundant in embryonic and fetal 
development; and in a variety of malignant tumors including melanomas, gastric, colon, 
uterine, pancreatic, ovarian and bladder carcinomas [476, 479-489]. However, it is almost 
undetectable in most adult, differentiated tissues. Overexpression in most tumor tissues and 
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cell lines, independent of mitotic index, is what has earned survivin the status of a putative “ 
tumor-specific antigen”. Although, survivin has been detected, and postulated to play a role, in 
some adult tissues  (epidermal stem cells, keratinocyte stem cells, neural stem cells, 
mesenchymal stem cells, CD34+ haematopoietic progenitors, thymocytes, adult colonic 
epithelium, pancreatic beta cells, outer root sheeth and matrix cells of hair follicles, etc.) its 
level of expression is much lower compared to levels in cancer cells [460, 467].   
 Studies of tumor viruses have shown interesting links between important viral proteins 
and survivin. Hepatitis B X-interacting protein forms a complex with survivin, which in turn 
binds to pro-caspase-9, preventing the activation of apoptosis [490]. Human papillomavirus E6 
oncoprotein transactivates the survivin promoter in HeLa and human embryonic fibroblast 
cells. This transactivation effect of E6 on survivin seems to be dependent on E6’s ability to 
interact with p53 and causes its ubiquitination-dependent degradation. The downregulation of 
p53 directly derepresses survivin expression [491]. Consistent with this, high levels of survivin 
protein have also been found in HPV-induced warts [492]. Other than that, upregulated survivin 
was found in oligodendrial and astrocytic cultures infected with JCV and in JCV positive PML 
(progressive multifocal leukoencephalopathy) cases. Gualco et al. recently showed that this 
effect might be insulin-like growth factor-1 receptor (IGF-IR) dependent [493]. Induction of JCV 
T antigen expression caused an increase in survivin expression in wild type IGF-IR embryo 
derived neural progenitors, but not in IGF-IR knockout embryo derived cells. A single study by 
Raj et al. also explored the increase in survivin by SV40 large T antigen overexpression [475]. 
Chapter 5 describes the newfound link between MCV large T antigen and survivin. 
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4.2 SURVIVIN	  EXPRESSION	  IN	  MERKEL	  CELL	  CARCINOMA	  
To	  clinical	  investigators	  survivin	  has	  become	  a	  diagnostic	  cancer	  biomarker	  and	  also	  a	  molecular	  
signature	  of	  poor	  disease	  outcome	  in	  a	  majority	  of	  human	  cancer	  cases.	  Two	  separate	  groups	  
have	   validated	   survivin	   as	   a	   prognostic	   biomarker	   in	   Merkel	   cell	   carcinomas	   as	   well.	   Both	  
nuclear	   and	   cytoplasmic	   survivin	  was	   detected	   in	  MCC,	  with	   higher	   expression	   correlating	   to	  
tumor	   recurrence	  and	  metastasis.	  Kim	  et	  al.	   reported	   that	   in	   the	  nucleus,	   survivin	  colocalizes	  
with	  the	  mitotic	  spindle	  markers.	  On	  the	  other	  hand,	  cytoplasmic	  survivin	  is	  also	  detected	  and	  
found	   in	   large	  cell	   foci	  but	  predicts	  better	  outcome	   (Figure	  21).	  We	  also	  analyzed	  5	  MCC	  cell	  
lines	  and	  found	  nuclear	  localization	  of	  survivin	  expression	  (Figure	  22).	  Small	  case	  numbers	  and	  
short	   clinical	   follow	   up	   periods	   limited	   these	   studies.	  More	   evaluations	   are	   thus	   required	   to	  
make	  any	  stronger	  correlation	  [494,	  495].	  	  
	  
	  
	  
Figure	  21	  Immunohistochemical	  staining	  for	  survivin	  expression	  in	  Merkel	  cell	  carcinoma.	  
(A	   and	   B)	   Survivin	   localization	   in	   the	   nuclear	   compartment.	   (C	   and	   D)	   Survivin	   localization	   in	   the	   cytoplasmic	  
compartment.	  Original	  magnification	  200X.	  (Kim	  et	  al.	  Modern	  Pathology	  2008)	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Figure 22 Nuclear localization of survivin in MCC cell lines.  
Immunofluorescence analysis of MCC cell lines, both MCV positive (MKL-1, MKL-2, MS-1, WaGa) 
and MCV negative (UISO) reveals nuclear staining of survivin. Survivin antibody (Cell signaling) 
was used at a 1:250 dilution and anti-rabbit Alexa 568 (red) was used as secondary antibody. 
DAPI was used as a counter stain for the nucleus.  
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4.3 SURVIVIN AS A CHEMOTHERAPEUTIC TARGET 
Survivin is a promising chemotherapeutic target in multiple cancers for several reasons. First, 
this small inhibitor of apoptosis protein is differentially over-expressed in cancer. Other than 
inhibiting apoptosis it is also actively involved in cell cycle progression and proliferation. Most 
importantly, it involved in multiple signaling mechanisms in tumor maintenance (considered a 
nodal protein), and most of the survivin-binding partners are oncoproteins themselves, as 
either they are mutated, overexpressed or functionally altered in cancer. Hence, targeting 
survivin for treatment confers the advantage of eliminating tumor cells while sparing normal 
tissues. Targeting this nodal protein also yields the benefit of avoiding resistance to single 
molecule/pathway directed therapy that often develops in heterogenous cancers. Further, 
survivin promotes tumor-associated angiogenesis, considered a hallmark of cancer[185], and 
acts as a resistance factor to various anticancer therapies. Lastly, retrospective analyses of 
patient cohorts have consistently found that an increased level of survivin expression predicts 
poor prognosis and recurrence[476, 480, 496, 497]. 
Survivin, has thus, emerged as an important target for cancer drug discovery. 
Unfortunately, despite the enormous amount of knowledge gained and the interest generated 
in survivin, the portfolio of survivin antagonists available for clinical testing is small. Currently 
used survivin antagonists and their respective clinical trial information are summarized in the 
following table. 
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Compound(Name
Therapeutic(
approach Reference(s) Clinical(Development(((Identifier#(from(clinicaltrials.gov)
LY2181308 Antisense.
oligonucleotide
Tanioka,.M.,.et.al..Cancer.chemotherapy.
and.pharmacology,.2011.......................................................................................
(Developed.by.Elli.Lilly.and.Company)
1....Phase.II.for.relapsed.or.refractory.acute.myeloid.
leukemia.(NCT00620321).................................................................................
2....Phase.II.in.combination.with.docetaxol.for.nonNsmall.
cell lung cancer (NCT01107444).................................................................
3....Phase.II.in.combination.with.docetaxol.and.
prednisone.for.hormone.refractory.prostate.cancer.
(NCT00642018)
SPC3042./.EZNN3042
Antisense.
oligonucleotide
.N.Hansen,.J..B.,.et.al..Molecular.cancer.
therapeutics,.2008........................................................................................................................
N.Sapra,.P.,.et.al..Nucleosides,.nucleotides.
&.nucleic.acids,2010...............................................................................................
(Developed.at.Santaris.and.Enzon.
Pharmaceuticals.Inc.)
At.preclinical.stage.completed........................................................
Phase.I.for Leukemia
Shepherdin
Peptidomimetic.
(combined.survivin.
and.HSP90.
antagonist)
Plescia,.J.,.Cancer.cell,2005 At.preclinical.stage
Dominant.
interfering.mutants.
(C84A,.T34A.and.
TC34,84AA)
Gene.Therapy
.N.Mesri,.M.,.The.Journal.of.clinical.
investigation,.2001..............................................................................................................................
N.Tu,.S..P.,.Cancer.research..2003...................................................................................................................................................................
N.Zhang,.R.,.Cancer.biology.&.therapy.2008
At.preclinical.stage
BIRC5.promoter.for.
tumorNspecific.
transcription.of.
cytotoxic.genes
Gene.Therapy Chen,.J..S.,Cancer.gene.therapy,.2004 At.preclinical.stage
Table	  18	  Survivin	  antagonists	  and	  their	  clinical	  development	  
	  
Ribozyme)RNA)
Interference)))))))))))))))))))))))))))))))))))))
(RZ41,)RZ42)
Molecular)
antagonist
Choi,)K.)S.,))Cancer)gene)therapy,)2003 At)preclinical)stage
YM155
Small)molecule)
transcriptional)
repressor
Nakahara,)T.,)Cancer)research,)2007))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
(Developed)by)Astellas)Pharmaceuticals)
Inc)
1.)))Phase)II)for)Lung)cancer)(NCT00328588))))))))))))))))))))))))))))))))))))))
2.)))Phase)II)for)prostrate)cancer)(NCT00257478)))))))))))))))))))))))))))))))
3.)))Phase)II)for)Melanoma)(NCT00281541))))))))))))))))))))))))))))))))))))))))))
4.)))Phase)II)in)combination)with)docetaxel)and)
prednisone)for)prostrate)cancer.)(NCT00514267)))))))))))))))))))))))))))))))))))))))))))))))))))))))
5.)))Phase)II)for)Diffuse)large)B4cell)lymphoma)
(NCT00498914))6.)))Phase)II)in)combination)with)
paclitaxel and)carboplatin for)non4small cell lung
carcinoma.)(NCT01100931))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
7.)))Phase)II)in)combination)with)docetaxel)for)breast)
cancer.)(NCT01038804)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
8.)))Phase)II)in)combination)with)rituximab)for)Non4
hodgkin’s)lymphoma.)(NCT01007292))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
9.)))Phase)II)in)combination)with)docetaxel)for)melanoma.)
(NCT01009775)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
10.)))Phase)II)for)advanced)cancer.)(NCT01023386)and)
NCT00818480)
EM41421)
(Terameprocol)
Small)molecule)
transcriptional)
inhibitor
Heller,)J.)D.,Cancer)research.)2001))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
(Developed)by)Erimos)Pharmaceuticals)
1.))))Phase)I)for)refractory)solid)tumors,)leukemias)and)
lymphomas)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
2.)Phase I and II for)Cervical)Intraepithelial Neoplasia)
(NCT00154089)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
3.))Phase)I)and)II)for)Brain)and)central)nervous)system)
tumors)(NCT00404248)
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Autologous.
Cytotoxic.T.cells.
with.survivinNprimed.
dendritic.cells
Immunotherapy
Svane,.I..M.,.Cancer.immunology,.
immunotherapy,.2004
1....Phase.I.and.II.in.Melanoma.(NCT00197912)...............................
2....Phase.I.and.II.in.renal.cell.carcinoma..(NCT00197860)...............
3....Phase.II.in.combination.with.docetaxel.for.prostrate.
cancer..(NCT01446731).......................................................................................
4....Phase.I.and.II.in.combination.with.hTERT.tumor.
vaccine.for.multiple.myeloma..(NCT00834665)......................................................
5....Phase.I.and.II.for.Multiple.myeloma.and.plasma.cell.
neoplasm..(NCT00499577)...................................................................
6....Phase.I.and.II.for.prostrate.cancer..(.NCT01197625)..................
7....Phase.I.and.II.for.Melanoma..(NCT00074230)..............................
8....Phase.I.and.II.for.ovarian.cancer..(NCT01334047)
DPXNSurvivac Immunotherapy
Karkada,.M.,..Journal.of.immunotherapy.
2010...................................................................................................................................
(Developed.by.ImmunoVaccine.
Technologies.Inc.)
Phase.I.and.II.in.combination.with.cyclophosphamide.for.
ovarian,.fallopian.tube.and.peritoneal.cancer..
(NCT01416038)
Sequence.data.and.chemical.structures.were.not.publically.available.for.most.of.the.drugs.enlisted.and.hence.are.not.included.in.this.table.
The.Clinical.Development.column.is.mainly.focussed.on.Phase.II.trials.and.all.the.information.is.from.www.clinicaltrials.gov.and.
www.cancer.gov..The.table.includes.a.summary.of.trials.only.in.the.USA,.and.hence.is.not.an.exhaustive.list.
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5.0  VIRAL RNAI KNOCKDOWN AND RATIONAL DRUG SCREENING REVEALS SURVIVIN AS A 
THERAPEUTIC TARGET FOR MERKEL CELL CARCINOMA 
 
Work described in this section is in press in Science Translational Medicine Journal 
 
with authors Reety Arora, Masahiro Shuda, Anna Guastafierro, Huichen Feng, Tuna Toptan, 
Yanis Tolstov, Daniel Normolle, Laura L. Vollmer, Andreas Vogt, Alexander Dömling, Jeffrey L. 
Brodsky, Yuan Chang and Patrick S Moore 
 
R.Arora and M.Shuda performed the T antigen and survivin knock down experiments and 
immunoblots as well as cell cycle analysis. H.Feng performed the DTS analysis. T.Toptan and 
R.Arora created BJ stable cell lines and tested for survivin, cyclin E, E2F1 and MCV T Ag 
expression. R.Arora, Y.Tolstov and L.Vollmer performed the drug screen. R.Arora tested 
individual drugs and performed cell titer glo studies. A.Guastafierro and R.Arora performed 
mouse xenograft experiments and qRT-PCR studies. D.Normolle performed xenograft tumor 
volume analysis. A.Vogt, J.Brodsky, A.Domling provided compounds and supervision on drug 
screen. R. Arora, Y.Chang , and P.S.Moore interpreted the data and wrote the manuscript. 
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Merkel cell carcinoma is an aggressive, often lethal cancer. There is no optimal therapy for MCC 
beyond surgery. Also, MCC are highly chemoresistant tumors and either respond poorly to 
standard chemotherpies or lose sensitivity within a few treatment rounds.  
Before the discovery of MCV, the prospects of this cancer seemed dismal as MCC based 
mortality was increasing; however no pathway or important target had been identified. The 
discovery of MCV changed that perception and revealed the integrated virus as a target for 
therapy.  
To seek for a treatment module for this cancer, post the discovery of MCV, we 
experimentally exploited the molecular biology of this virus. By comparing digital transcriptome 
subtraction (DTS) deep-sequencing profiles, we found cellular survivin oncoprotein (BIRC5a) 
transcripts upregulated seven-fold in virus-positive compared to virus-negative MCC tumors.  
We also knocked down MCV T antigen in MCV positive MCC cell lines and found an associated 
decrease in survivin mRNA and protein expression.  
To follow this up we exogenously expressed MCV large T antigen (LT) in non-MCC 
primary cells. This caused an increase in survivin protein expression and required an intact 
retinoblastoma (RB) protein-targeting domain in MCV T antigen. This RB binding domain not 
only activated surivivin gene transcription but also increased expression of other G1/S-phase 
proteins including E2F1 and Cyclin E. Also shRNA based knockdown of survivin alone caused cell 
death in MCV positive MCC cells.  
We next tested an experimental drug called YM155, known to target survivin, on MCV 
positive MCC cells. YM155 selectively initiated irreversible, non-apoptotic MCV-positive MCC 
cell death. A compound library screen of 1360 other chemotherapeutic and pharmacologically-
active compounds in vitro, resulted in only one compound named bortezomib (Velcade) with 
similar potentcy. Bortezomib however was not selective for killing MCC cells. 
We created an MCC xenograft model by injecting MCV positive MCC cell line MKL-1 
subcutaneously in NSG mice, and used it for YM155 and bortezomib preclinical evaluation. 
YM155 was nontoxic and halted MCV-positive MCC xenograft tumor growth in mice. On the 
other hand, bortezomib was significantly toxic and was not active in vivo. Xenograft tumors 
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resumed growth once YM155 treatment ended suggesting that YM155 may be cytostatic rather 
than cytotoxic in vivo. 
Collectively, this study identified an important pathway (survivin) targeted by MCV T 
antigen to initiate tumor formation. Using this protein we were able to rationally design a 
precisely targeted, less-toxic therapy for MCC in less than four years. Thus, identifying the 
cellular circuits, such as survivin, that are targeted by tumor viruses can lead to rapid and 
rational identification of drug candidates for viral cancers that are otherwise difficult to treat. 
Multicenter clinical trials for these drugs are scheduled to open soon in the USA. 
5.1 MATERIALS AND METHODS 
5.1.1 Cell culture 
Seven Merkel cell carcinoma cell lines: MKL-1, MKL-2, MS-1, UISO, MCC13, MCC26 and WaGa 
(kind gift of Jurgen Becker [405, 498, 499]; NCI-H69 small cell lung cancer cell line (ATCC); 293 
human embryonic kidney cells (ATCC); U2OS osteosarcoma cell line (kind gift of Ole Gjoerup); 
BJhTERT immortalized foreskin fibroblast cell line (kind gift of Ole Gjoerup); and BJ primary 
foreskin fibroblasts (ATCC) were used to screen and evaluate the small molecules examined in 
this study [405, 498, 499]. The Merkel cell lines and NCI-H69 were grown in RPMI 1640 
supplemented with 10% fetal calf serum, penicillin and streptomycin at 37 °C in humidified air 
containing 5% CO2. The remaining cell lines were grown in DMEM supplemented with 10% fetal 
calf serum. 
 
5.1.2 Compounds 
A total of 1,360 compounds were used in the screening survey and are listed in Appendix A- 
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Table	   22:	   1,280	   compounds	   from	   LOPAC1280	   library	   (Sigma	   Aldrich,	   accessed	   through	  
University	   of	   Pittsburgh	   Drug	   Discovery	   Institute),	   89	   compounds	   from	   NCI’s	   Approved	  
Oncology	  Drug	  Set	  II	  (from	  The	  NCI/DTP	  Open	  Chemical	  Repository,	  http://dtp.cancer.gov),	  6	  LT	  
ATPase	   inhibitors	  (MAL2-­‐11B,	  MAL3-­‐101,	  MAL2-­‐51,	  DMT3084,	  bithionol	  and	  hexachlorophene	  
[500,	  501])	  and	  4	  compounds	  that	  target	  and	  inhibit	  p53	  and	  MDM2	  binding	  (Nutlin-­‐3,	  YH264A,	  
Y2H265A	   and	   KK_NW_16A	   [502,	   503]).	   19	   compounds	   that	   were	   in	   common	   between	   the	  
LOPAC	   1280	   and	   the	   NCI	   Approved	   Oncology	   Drug	   Set	   II	   library	   were	   screened	   twice	   with	  
comparable	  results.	  NCI	  Approved	  Oncology	  Drug	  Set	  II,	  SV40	  LT	  ATPase	  inhibitors	  and	  MDM2	  
inhibitors	   were	   reconstituted	   as	   recommended	   by	   supplier.	   YM155	   (4,9-­‐Dihydro-­‐1-­‐(2-­‐
methoxyethyl)-­‐2-­‐methyl-­‐4,9-­‐dioxo-­‐3-­‐(2-­‐pyrazinylmethyl)-­‐1H-­‐naphth[2,3-­‐d]imidazolium	  
bromide)	  was	  purchased	  from	  Active	  Biochemicals	  Co.	  Ltd.	   (Hong	  Kong,	  China).	  Reconstituted	  
compounds	  were	   diluted	   in	   cell	   culture	  media	   to	   obtain	   a	   100x	   stock	   concentration	   prior	   to	  
addition	   to	   cells.	   Doxorubicin	   (positive	   control)	   was	   obtained	   from	   Sigma-­‐Aldrich	   and	   DMSO	  
(negative	  control)	  was	  obtained	  from	  Fisher	  Bioreagents.	  
	   For	   EC50	  measurements,	   dose-­‐response	   curves	  were	   established	   for	   17	   drugs	   obtained	  
individually	   in	   bulk	   stocks.	   Iodoacetamide	   (I1149),	   sanguarine	   chloride	   (S5890),	   NSC95397	  
(N1786),	   chelerythrine	   chloride	   (C2932),	   calmidazolium	   chloride	   (C3930),	   tetraethylthiuram	  
disulfide	  (T1132),	  bay	  11-­‐7085	  (B5681),	  quinacrine	  dihydrochloride	  (Q3251),	  ellipticine	  (E3380),	  
amsacrine	   hydrochloride	   (A9809)	   and	   nutlin-­‐3	   (N6287)	   were	   purchased	   from	   Sigma	   Aldrich,	  
USA.	   Mitoxantrone	   (NSC279836),	   daunorubicin	   HCl	   (NSC82151),	   valrubicin	   (NSC246131),	  
topotecan	  HCl	  (NSC609699),	  teniposide	  (NSC122819)	  and	  bortezomib	  (NSC681239)	  were	  kindly	  
provided	  by	  the	  NCI/DTP	  Open	  Chemical	  Repository,	  http://dtp.cancer.gov.	  	  
5.1.3 MKL-­‐1	  cytotoxicity	  screen	  
MKL-­‐1	  cells	  were	  seeded	  at	  a	  density	  of	  6000	  cells	  in	  50	  ml	  of	  medium	  per	  well	  (120	  cells/ml)	  in	  
opaque	  polypropylene	  384-­‐well	  microplates	  (#781080,	  Greiner	  Bio-­‐One,	  Germany).	  Cells	  were	  
incubated	   at	   37°C	   in	   humidified	   air	   containing	   5%	   CO2	   for	   24	   hours.	   Thereafter,	   25	   ml	   of	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medium	   containing	   3X	   drug	   per	  well	   was	   added	   to	   the	   plates,	  which	  were	   incubated	   for	   an	  
additional	   48	   hours.	   Cell	   viability	   was	   measured	   using	   Cell	   Titer	   Glo	   (Promega)	   following	  
manufacturer’s	  instructions.	  The	  validity	  of	  Cell	  Titer	  Glo	  results	  in	  measuring	  cell	  viability	  was	  
confirmed	  by	  trypan	  blue	  exclusion	  staining	  and	  WST-­‐1	  assays	  (Roche)	  in	  pilot	  studies.	  
	   The	   LOPAC1280	   library	   was	   screened	   at	   a	   final	   concentration	   of	   10	   mM	   for	   each	  
compound	   and	   the	   NCI	   library	   was	   screened	   at	   a	   final	   concentration	   of	   1	   mM	   for	   each	  
compound.	  MAP-­‐C	   (Titertek	   Instruments	   Inc)	  and	   Janus	  MDT	   (PerkinElmer	   Inc)	  were	  used	   for	  
automated	   resuspension	   and	   the	   addition	  of	   LOPAC	   library	   drugs	   to	   assay	   plates.	  NCI	   library	  
compounds	  were	  added	  to	  wells	  by	  manual	  pipetting.	  	  
	   Cell	  Titer	  Glo	  assays	  were	  performed	  in	  duplicate	  using	  384	  well	  plates,	  each	  containing	  
24	   wells	   with	   1%	   DMSO	   (negative	   control)	   and	   32	   wells	   with	   200	  mM	   doxorubicin	   (positive	  
control).	  Screening	  results	  were	  evaluated	  on	  the	  basis	  of	  percentage	  cell	  survival	  normalized	  to	  
the	  DMSO	  control	  (100%).	  Positive	  candidates	  were	  identified	  using	  a	  cut-­‐off	  value	  of	  <10%	  cell	  
survival.	  The	  average	  Z	  factor	  was	  0.61	  (range	  0.34-­‐0.74)	  for	  the	  LOPAC	  library	  screen	  and	  0.82	  
for	  the	  NCI	  library	  screen	  (range	  0.75-­‐0.91).	  
5.1.4 Dose-­‐response	  studies	  
Compounds	   that	  met	   the	  selection	  criteria	  <	  10%	  cell	   survival	  were	  purchased	  or	  obtained	   in	  
bulk	   from	  NCI/NIH	  Developmental	  Therapeutics	  Program.	  Serial	  drug	  dilutions	   from	  10-­‐4	  M	  to	  
10-­‐9	  M	  were	  used	  on	  MCC	  and	  non-­‐MCC	  cell	   lines.	  Cells	  were	   seeded	   into	  384-­‐well	   plates	  at	  
6000	   cells	   in	   50	   ml	   of	   medium	   per	   well.	   After	   24	   hours,	   25	   ml	   of	   3X	   drugs	   were	   added	   at	  
increasing	   concentration	   to	   each	   well.	   Cell	   viability	   was	   then	   measured	   using	   Cell	   Titer	   Glo	  
(Promega)	   kit	   following	   manufacturer’s	   instructions	   as	   described	   previously.	   Each	   drug	  
concentration	  was	  tested	  in	  triplicate	  for	  each	  cell	   line	  and	  experiments	  were	  repeated	  twice.	  
EC50	  doses	   for	   the	  drugs	  were	   calculated	  using	  a	   four	  parameter	   logistic	   equation	   (GraphPad	  
Prism).	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5.1.5 Trypan	  blue	  dye	  exclusion	  assay	  
Cells	  were	  equally	  seeded	  and	  treated	  with	  YM155	  for	  48	  hours.	  To	  quantitate	  cell	  death,	  cells	  
were	   treated	   with	   Accutase	   (Millipore),	   collected,	   resuspended	   in	   PBS,	   mixed	   with	   equal	  
volume	   of	   Trypan	   blue	   (Lonza,	   0.4%)	   and	   counted	   using	   a	   hemocytometer	   under	   the	  
microscope.	  Counting	  was	  performed	  three	  times,	  in	  triplicate.	  
5.1.6 Expression	  and	  shRNA	  lentivirus	  construction	  
To	   express	   codon	   optimized	   full-­‐length	   MCV	   large	   T	   antigen,	   the	   gene	   was	   synthesized	  
(DNA2.0)	   from	   the	   MCV-­‐HF	   strain	   large	   T	   antigen	   sequence	   template	   [360]	   (GenBank	   ID:	  
JF813003)	   and	   cloned	   into	   the	   lentiviral	   pLVX	   EF	   puro	   vector	   [504].	   Truncated	   tumor	   LT339	  
(representing	   the	   MCV339	   strain,	   amino	   acid	   1-­‐455)	   and	   LT339.LFCDK	   were	   cloned	   by	   site-­‐
directed	  mutagenesis	  from	  the	  codon-­‐optimized	  full-­‐length	  LT	  into	  pSMPUW-­‐hygro	  vector	  (Cell	  
Biolabs	   Inc.)	   [504].	  MCV	   small	   T	   codon	   optimized	  was	   also	   cloned	   into	   the	   lentivirus	   vector.	  
Cells	   were	   infected	   with	   lentiviruses	   in	   the	   presence	   of	   1-­‐4	   mg/ml	   polybrene	   for	   24	   hours,	  
followed	   by	  media	   change.	   Stable	   selection	  with	   either	   puromycin	   (1	  mg/ml)	   or	   hygromycin	  
(200	  mg/ml)	  was	  initiated	  48	  hours	  after	  infection.	  	  	  
shRNA	  for	  MCV	  T	  antigen	  knockdown	  was	  generated	  and	  used	  as	  previously	  described	  
[498,	  505],	  we	  renamed	  shT1	  and	  shScr	  in	  Houben	  et	  al.	  to	  panT1	  and	  shCntrl	  in	  this	  study.	  To	  
knockdown	   survivin	   gene	   expression,	   shRNA	   sequence	   (shsur1-­‐5’	  
ccggCCGCATCTCTACATTCAAGAACTCGAGTTCTTGAATGTAGAGATGCGGtttttg-­‐3’	   and	   shsur2-­‐	   5’	  
ccggCCTTTCTGTCAAGAAGCAGTTCTCGAGAACTGCTTCTTGACAGAAAGGtttttg-­‐3’	   (Lower	   cased	  
nucleotides	  indicate	  linker	  sequences	  used	  for	  cloning))	  was	  cloned	  into	  a	  pLKO.1puro	  lentiviral	  
vector.	   shCntrl	   is	   a	   nontargeting	   shRNA	   negative	   control	   [498].	   	   Cells	   were	   infected	   with	  
lentiviruses,	   washed	   after	   24	   hours	   and	   then	   harvested	   for	   immunoblotting	   six	   days	   after	  
infection.	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5.1.7 Immunoblotting 
Cells were lysed in buffer (RIPA or 10mM Tris-HCl pH 8.0, 0.6% SDS) containing protease 
inhibitor cocktail (Roche). Lysates were electrophoresed in 10% SDS-PAGE, transferred to 
nitrocellulose membrane (Amersham) and reacted with specific antibodies CM2B4 (1:5000 
dilution) [506], CM8E6 (1:500 dilution), cleaved PARP, cleaved caspase3, survivin, XIAP, p53, 
Bcl-2, Bax (1:1000 dilution, Cell Signalling Technologies), E2F1, cyclin E (1:1000 dilution, Santa 
Cruz Biotechnology), LC3 (1:1000 dilution, Novus Biologicals) or α-tubulin (1:5000 dilution, 
Sigma)) overnight at 4°C, followed by anti-mouse (1:5000 dilution, Amersham) or anti-rabbit 
IgG-HRP conjugates (1:3000 dilution, Cell signaling) for 1 hour at room temperature. Peroxidase 
activity was detected using Western Lightning plus-ECL reagent (Perkin Elmer). For quantitative 
immunoblotting, Odyssey Infrared Imaging system (LI-COR) was used with IRDye 800-
conjugated secondary antibodies (1:5000 dilution, Rockland Immunochemicals). 
5.1.8 qRT-PCR 
RNA was extracted from cell lysates using Trizol reagent (Invitrogen) and cDNA was synthesized 
using SuperScript III First Strand Synthesis (Invitrogen). Quantitative real-time PCR for survivin 
was performed on cDNA using the SYBR green method (based on manufacturer’s protocol, 
Applied Biosystems). Primers used were 5’-CTGCCTGGCAGCCCTTT-3’ (Forward) and 5’-
CCTCCAAGAAGGGCCAGTTC-3’ (reverse) for surviving [507] and 5’-CACTGGCTCGTGTGACAAGG-
3’ and 5’-CAGACCTACTGTGCGCCTACTTAA-3’ for β-actin. The relative change in expression was 
calculated using the Pffal method [508]. Experiments for MCC cell lines were repeated six times 
(2 biological repeats done in triplicate). Experiments for BJ cell lines were repeated six times (3 
biological repeats done in duplicate). Mean and standard error of mean was calculated and 
plotted as column graphs for comparison. 
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5.1.9 Cell	  cycle	  analysis	  
MKL-­‐1	  cells	  were	   treated	  with	  Accutase	   (Millipore)	   to	  break	  clumps	  and	   then	   resuspended	   in	  
fresh	   medium	   containing	   drug	   and	   treated	   for	   12	   hours.	   Bromodeoxyuridine	   (10	   μM	  
concentration)	  was	  added	  three	  hours	  before	  harvesting.	  	  Cells	  were	  then	  harvested	  and	  fixed	  
in	   chilled	  70%	  ethanol	  overnight.	   The	   cells	  were	   then	  washed,	   resuspended	   in	  200	  ml	  of	   2M	  
HCl/Triton	  X	   (1%)	  and	   incubated	   for	  30	  mins	  at	   room	   temperature.	  Cells	  were	   centrifuged	  at	  
2000	  rpm	  for	  10	  mins	  and	  neutralized	  in	  200ml	  of	  0.1M	  sodium	  tetraborate	  (pH	  8.5).	  Cells	  were	  
then	  washed,	  suspended	  in	  20ml	  of	  PBS	  containing	  0.5%	  tween20,	  1%	  donkey	  serum	  and	  2ml	  of	  
anti-­‐BrdU	  antibody	   (1:10	  diution,	  BD	  Biosciences)	   and	   incubated	  overnight	   at	   4°C.	   Cells	  were	  
washed	  and	   incubated	  with	   secondary	   anti-­‐mouse	   IgG	  Alexa488	   (1:1000)	   for	   1	  hour	   at	   room	  
temperature.	  Cells	  were	  washed,	  suspended	  in	  PBS	  containing	  100mg/ml	  of	  RNase	  A,	  50mg/ml	  
of	  PI	  (propidium	  iodide)	  and	  0,05%	  Triton	  X	  and	  incubated	  for	  30	  mins	  at	  37°C	  in	  the	  dark	  and	  
then	  analyzed	  using	  an	  Accuri	  C6	  flow	  cytometer.	  
5.1.10 Cell	  death	  evaluation	  by	  CFDA	  and	  PI	  staining	  
After	   harvesting,	   cells	   were	   resuspended	   in	   2	   ml	   of	   PBS	   containing	   4mg/ml	   PI	   (propidium	  
iodide,	  Sigma)	  and	  10	  mM	  CFDA	  (Carboxy	  fluorescin	  diacetate,	  Invitrogen)	  at	  room	  temperature	  
for	  10	  mins.	  Cells	  were	  then	  rinsed	  in	  1X	  PBS	  and	  examined	  under	  the	  microscope.	  Quantitation	  
was	  performed	  using	  ImageJ	  software.	  
5.1.11 Mouse	  xenograft	  studies	  
Compounds	  
For	   in	   vivo	   experiments,	   clinical-­‐grade	   bortezomib	   (Velcade)	   was	   purchased	   from	   the	  
University	   of	   Pittsburgh	   Cancer	   Institute	   Pharmacy	   and	   YM155	   was	   purchased	   from	   Active	  
Biochemicals	   Ltd.	   (Hong	   Kong,	   China).	   	   Compounds	   were	   dissolved	   in	   sterile	   0.9%	   saline	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solution for administration to animals. 
 
Animals 
Six-week-old female triple immune-deficient NSG (NOD scid gamma) mice (Jackson 
Laboratory) were maintained in a specific pathogen-free environment at the Hillman Cancer 
Center Mouse Facility, University of Pittsburgh. All animal studies were conducted according to 
protocols approved by the Animal Ethics Committee of the University of Pittsburgh (IACUC 
Protocol # 1102226). 
 
Xenograft Drug Treatments 
MCC cells were checked for viability >90% by trypan blue staining resuspended in PBS (2 × 107 
cells in 100 μl) and inoculated subcutaneously into the right flank of mice. Once tumors were 
palpable (2-4 weeks after injection), mice were assigned sequentially into receiving either 
bortezomib, YM-155 or saline treatment arms.  
All treatments were delivered for three consecutive weeks. Bortezomib treatment was 
delivered subcutaneously twice weekly at 1 mg/kg per mouse. To avoid previously observed 
side effects, mice were given hydrogel (ClearH2O) and kept at 30°C (using a heating blanket to 
heat up half of the cage) during bortezomib treatment. YM-155 (2 mg/kg) was given 
intraperitoneally on five consecutive days, followed by a two-day treatment-free interval. The 
control group received saline alone (21 mice on the same dosing schedule as bortezomib and 
10 mice on the same dosing schedule as YM155). Day 19 was the last day of drug delivery for 
both schedules and hence the end of treatment. Caliper measurements of the longest 
perpendicular tumor diameters were performed every other day and tumor volumes were 
calculated using the formula: (width) 2 × (length/2). Animals were sacrificed when tumors 
reached 2 cm in any dimension, >20% weight loss or when they became moribund. Survival 
was defined as time from the first day of treatment until death/sacrifice.    
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5.1.12 Statistical analysis  
Two-tailed paired Student’s t test was used to analyze statistical differences in qRT-PCR 
results. Mouse survival curves were estimated using the Kaplan–Meier product-limit method 
and were compared using the log-rank test (GraphPad Software, La Jolla, CA). A piecewise 
linear hierarchical Bayesian model [509] was used to characterize differences in tumor 
volumes and growth between treatments.     
5.1.13 Immunohistochemistry 
Immunohistochemical staining of mouse tumor tissues was performed as previously described 
in Shuda et al. 2009 [506]. 
 
 
 
 
5.2 RESULTS 
5.2.1 Survivin expression in MCV-positive MCC 
To identify pathways perturbed by MCV infection in MCC, we analyzed DTS datasets to identify 
cellular genes differentially regulated between MCV-positive and MCV-negative MCC [74]. We 
compared 400,000 cellular transcripts from MCV-positive and MCV-negative MCC tumors and 
found 1096 of 11,531 (9.5%) genes elevated >3 fold for the MCV-positive compared to the 
MCV-negative library.  
 We next identified sixty-four genes using Gene Ontology (GO) gene definitions [510] 
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directly involved in programmed cell death or cell cycle regulation (Table 19 and Figure 23A). 
BIRC5a (Baculoviral inhibitor of apoptosis repeat-containing 5) mRNA encoding the survivin 
oncoprotein were increased 7 fold (p=2.90xe-10) for virus-positive compared to virus-negative 
MCC tumors (Figure 23A and Table 19). Other genes regulating programmed cell death, 
including TP53, cIAP2, XIAP, BAX, BCL2 and Caspase 3/6 transcripts, were not differentially 
expressed (Figure 23A and Table 19). Notably, some genes including TRAF2 and PI3K were 
significantly reduced in virus-positive compared to virus-negative MCC tumor libraries. 
5.2.2 MCV large T induces survivin through retinoblastoma protein targeting  
To determine if MCV T antigen increases survivin expression in MCC, we used a short-hairpin 
(shRNA) lentivirus (panT1) to perform RNAi targeting of the MCV T antigen exon1 sequence that 
selectively knocks down all MCV T antigen isoforms in MCC cells [498]. MCV-positive MCC cells 
infected with this lentivirus undergo non-apoptotic cell death (necroptosis) when MCV 
oncoprotein expression is inhibited [498]. MCV T antigen reduction correlated with survivin 
reduction in all MCV-positive MCC cell lines, but not in any of the MCV-negative cell lines 
(Figure 23B). The degree of survivin decrease with T antigen knockdown ranged from modest in 
MS-1 to near complete in WaGa cell lines (Figure 23B). This effect is at the level of  
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Table&S1.&Gene&expression&pattern&in&MCC&libraries&using&DTS&comparision
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
Gene&symbol Gene&name NCBI&Accession
MCC347&&&
Library
MCC337.343.
346&&Library
Normalized&
ratio Log2&value&#
(MCV%+ve)* %(MCV%+ve)* (MCV%+ve%/%
MCV%+ve)
Apotosis+associated%genes
BIRC5 Baculoviral%IAP%repeat%containing%5 NM_001012271 17 2 6.79 2.76
DFFB DNA%fragmentation%factor,%40kDa,%beta%polypeptide%(caspase+activated%DNase) NM_004402 7 1 5.59 2.48
CHUK Conserved%helix+loop+helix%ubiquitous%kinase NM_001278 7 1 5.59 2.48
ENDOG Endonuclease%G NM_004435 6 1 4.79 2.26
AIFM1 Apoptosis+inducing%factor,%mitochondrion+associated,%1 NM_145813 9 2 3.59 1.85
PPP3CA Protein%phosphatase%3,%catalytic%subunit,%alpha%isozyme NM_000944 36 8 3.59 1.85
BIRC2 Baculoviral%IAP%repeat%containing%2 NM_001166 8 2 3.19 1.68
CASP10 Caspase%10,%apoptosis+related%cysteine%peptidase NM_032977 8 2 3.19 1.68
ATM Ataxia%telangiectasia%mutated NM_138292 37 10 2.96 1.56
TNFRSF1A Tumor%necrosis%factor%receptor%superfamily,%member%1A NM_001065 19 6 2.53 1.34
IRAK2 Interleukin+1%receptor+associated%kinase%2 NM_001570 3 1 2.40 1.26
MYD88 Myeloid%differentiation%primary%response%gene%(88) NM_002468 6 2 2.40 1.26
PRKAR2B Protein%kinase,%cAMP+dependent,%regulatory,%type%II,%beta NM_002736 3 1 2.40 1.26
PIK3R3 Phosphoinositide+3+kinase,%regulatory%subunit%3%(gamma) NM_003629 15 6 2.00 1.00
CHP Calcium%binding%protein%P22 NM_007236 12 5 1.92 0.94
BCL2 B+cell%CLL/lymphoma%2 NM_000657 2 1 1.60 0.68
CASP3 Caspase%3,%apoptosis+related%cysteine%peptidase NM_032991 4 2 1.60 0.68
TRADD TNFRSF1A+associated%via%death%domain NM_003789 2 1 1.60 0.68
ENDOD1 Endonuclease%domain%containing%1 NM_015036 11 6 1.46 0.55
MAP3K14 Mitogen+activated%protein%kinase%kinase%kinase%14 NM_003954 8 5 1.28 0.35
PRKAR1A Protein%kinase,%cAMP+dependent,%regulatory,%type%I,%alpha NM_212472 48 30 1.28 0.35
PRKX Protein%kinase,%X+linked NM_005044 8 5 1.28 0.35
CAPN1 Calpain%1,%(mu/I)%large%subunit NM_005186 18 12 1.20 0.26
PIK3R2 Phosphoinositide+3+kinase,%regulatory%subunit%2%(beta) NM_005027 61 43 1.13 0.18
CYCS Cytochrome%c,%somatic NM_018947 51 40 1.02 0.03
DFFA DNA%fragmentation%factor,%45kDa,%alpha%polypeptide NM_213566 23 18 1.02 0.03
RIPK1 Receptor%(TNFRSF)+interacting%serine+threonine%kinase%1 NM_003804 12 10 0.96 +0.06
AKT2 v+akt%murine%thymoma%viral%oncogene%homolog%2 NM_001626 23 20 0.92 +0.12
APAF1 Apoptotic%peptidase%activating%factor%1 NM_013229 8 7 0.91 +0.13
PRKY Protein%kinase,%Y+linked,%pseudogene NM_002760 9 8 0.90 +0.15
AKT1 v+akt%murine%thymoma%viral%oncogene%homolog%1 NM_001014432 36 34 0.85 +0.24
CASP7 Caspase%7,%apoptosis+related%cysteine%peptidase NM_033338 2 2 0.80 +0.32
EXOG Endo/exonuclease%(5'+3'),%endonuclease%G+like NM_005107 1 1 0.80 +0.32
IRAK4 Interleukin+1%receptor+associated%kinase%4 NM_016123 5 5 0.80 +0.32
NTRK1 Neurotrophic%tyrosine%kinase,%receptor,%type%1 NM_001012331 1 1 0.80 +0.32
PIK3CB Phosphoinositide+3+kinase,%catalytic,%beta%polypeptide NM_006219 4 4 0.80 +0.32
PPP3CB Protein%phosphatase%3,%catalytic%subunit,%beta%isozyme NM_021132 15 15 0.80 +0.32
TNFRSF10B Tumor%necrosis%factor%receptor%superfamily,%member%10b NM_147187 2 2 0.80 +0.32
cIAP2 Cellular%inhibitor%of%apoptosis%2 NM_001165 1 1 0.80 +0.32
IKBKG Inhibitor%of%kappa%light%polypeptide%gene%enhancer%in%B+cells,%kinase%gamma NM_001099857 8 9 0.71 +0.49
BCL2L1 BCL2+like%1 NM_138578 24 28 0.68 +0.55
PRKACB Protein%kinase,%cAMP+dependent,%catalytic,%beta NM_002731 11 13 0.68 +0.57
PRKACA Protein%kinase,%cAMP+dependent,%catalytic,%alpha NM_207518 25 31 0.64 +0.63
CFLAR CASP8%and%FADD+like%apoptosis%regulator NM_003879 5 8 0.50 +1.00
PIK3CA Phosphoinositide+3+kinase,%catalytic,%alpha%polypeptide NM_006218 3 4 0.60 +0.74
PPP3R1 Protein%phosphatase%3,%regulatory%subunit%B,%alpha NM_000945 6 8 0.60 +0.74
TP53 Tumor%protein%p53 NM_000546 15 21 0.57 +0.81
BAX BCL2+associated%X%protein NM_138761 2 3 0.53 +0.91
PIK3CD Phosphoinositide+3+kinase,%catalytic,%delta%polypeptide NM_005026 2 3 0.53 +0.91
PRKAR1B Protein%kinase,%cAMP+dependent,%regulatory,%type%I,%beta NM_002735 3 5 0.48 +1.06
XIAP X+linked%inhibitor%of%apoptosis%protein NM_001167 10 18 0.44 +1.17
CASP9 Caspase%9,%apoptosis+related%cysteine%peptidase NM_032996 1 2 0.40 +1.32
BID BH3%interacting%domain%death%agonist NM_197967 1 2 0.40 +1.32
CHP2 Calcineurin%B%homologous%protein%2 NM_022097 1 2 0.40 +1.32
NFKBIA Nuclear%factor%of%kappa%light%polypeptide%gene%enhancer%in%B+cells%inhibitor,%alpha NM_020529 10 22 0.36 +1.46
IL1R1 Interleukin%1%receptor,%type%I NM_000877 3 7 0.34 +1.55
IKBKB Inhibitor%of%kappa%light%polypeptide%gene%enhancer%in%B+cells,%kinase%beta NM_001556 5 12 0.33 +1.59
AKT3 v+akt%murine%thymoma%viral%oncogene%homolog%3%(protein%kinase%B,%gamma) NM_005465 2 5 0.32 +1.65
CASP6 Caspase%6,%apoptosis+related%cysteine%peptidase NM_001226 2 5 0.32 +1.65
BAD BCL2+associated%agonist%of%cell%death NM_032989 5 13 0.31 +1.70
IRAK1 Interleukin+1%receptor+associated%kinase%1 NM_001025243 9 24 0.30 +1.74
NFKB1 Nuclear%factor%of%kappa%light%polypeptide%gene%enhancer%in%B+cells%1 NM_003998 1 3 0.27 +1.91
PIK3R1 Phosphoinositide+3+kinase,%regulatory%subunit%1%(alpha) NM_181504 3 9 0.27 +1.91
PPP3CC Protein%phosphatase%3,%catalytic%subunit,%gamma%isozyme NM_005605 2 9 0.18 +2.49
CAPN2 Calpain%2,%(m/II)%large%subunit NM_001748 3 21 0.11 +3.13
TRAF2 TNF%receptor+associated%factor%2 NM_021138 1 11 0.07 +3.78
Control%genes
ACTB Actin,%beta NM_001101 544 668 0.65 +0.62
B2M Beta+2+microglobulin NM_004048 94 60 1.25 0.32
CK20 Keratin%20 NM_019010 15 13 0.92 +0.12
GAPDH Glyceraldehyde+3+phosphate%dehydrogenase NM_002046 438 228 1.53 0.62
HPRT1 Hypoxanthine%phosphoribosyltransferase%1 NM_000194 7 9 0.62 +0.69
PPIA Peptidylprolyl%isomerase%A%(cyclophilin%A) NM_021130 143 75 1.52 0.61
*B"MCVB+ve"BstandsBforBMCVBpositiveBinBtheBMCC347BlibraryBwithB143,373BgeneBreads;BB"MCVBZve"BstandsBforBMCVBnegativeBinBtheBMCC337.343.346BlibraryBwithB114,514BgeneBreads
#%"+"%stands%for%gene%upregulation%in%the%"MCV%+ve"%library%compared%with%the%"MCV%+ve"%one;%"+"%stands%for%gene%downregulation%ratios.%
%(Feng%et%al.%Science%319:1096+100,%2008).%
Table	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Figure 23 Survivin oncoprotein mRNA expression is increased in MCV-positive MCC.  
(A) DTS comparison of 64 genes involved in programmed cell death and cell cycle regulation, showing that survivin 
(BIRC5) mRNA transcripts (highlighted in bold) were seven-fold higher in a MCV-positive than an MCV-negative MCC 
DTS cDNA library. The relative expression of genes was normalized to total sequence reads for each MCC library (also 
see Table 19 for more details). (B) MCV T antigen is required for survivin expression. Lentiviral MCV T antigen exon1 
knockdown (panT1) decreased survivin protein expression among four MCV-positive MCC cell lines (left panel). 
shCntrl is a scrambled shRNA control lentivirus. No consistent changes in XIAP, BCL-2, Bax or p53 protein levels are 
seen after MCV T antigen knockdown among MCC cell lines (right panel). MKL-1, MKL-2, MS-1 and WaGa are MCV 
positive and UISO is MCV negative. (C) MCV T antigen is required for survivin transcription.  Survivin mRNA levels were 
reduced in MKL-1 but not UISO cells after T antigen knockdown indicating that T antigen acts survivin transcription. 
Survivin mRNA was measured by qRT-PCR and normalized to β-actin mRNA. The experiments were performed in 
triplicate and repeated two times (mean+SEM). (D) Survivin expression is required for MCV-positive MCC cell survival. 
Survivin was targeted for knock down with two shRNA lentiviral vectors, shsur1 and shsur2 in MKL-1 cells and UISO 
cells. MKL-1 cells initiate apoptosis after survivin knockdown, with increased expression of cleaved polyADP ribose 
polymerase (cPARP) and caspase 3 (cCasp3), whereas UISO cells are resistant to survivin knock down-induced 
apoptosis. -Tubulin is used as a loading control. 
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transcription rather than translation since BIRC5a mRNA is significantly reduced by T antigen 
knockdown (Figure 23C). Use of an shRNA lentivirus that selectively targets only the small T 
antigen isoform [504], however, did not affect survivin expression (Figure 24), indicating that 
increased survivin transcription was dependent on MCV LT but not small T antigen (knockdown 
of LT alone is difficult due to the overlapping structure of the T antigen cistron). In contrast to 
Figure 25. T antigen knockdown does not affect caspase and PARP cleavage.  
UISO and MKL-1 cells with panT1 knockdown were tested for immunoblotting for cleaved caspase 3 and 9, cleaved 
PARP and α- tubulin. Also see Figure 20. 
 
Figure 24. MCV sT antigen knockdown does not affect survivin expression 
UISO and MKL-1 cells infected with sT1, which knockdown sT alone (Shuda et al., JCI 2011) as well as panT1 shRNA 
lentiviruses were tested for immunoblotting for survivin and  α- tubulin. Lanes were run on the same gel, but were 
not contiguous. 
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survivin, no consistent changes in protein expression for p53, XIAP, Bcl-xL, Mcl-1, Bad, Bik, Bmf, 
Bim, Puma, Bcl-2 or Bax proteins (Figure 23B and [498]) or for cleaved polyADP ribose 
polyomerase (PARP), cleaved caspase 3 or cleaved caspase 9 proteins (Figure 25) were seen 
after panT1 knock down in MCV-positive cells. These results are consistent with our DTS 
findings suggesting that MCV T antigen selectively activates BIRC5a transcription. We next 
sought to determine the importance of survivin expression to survival of MCV-positive and 
MCV-negative MCC cells. Although only partial suppression of survivin expression was achieved 
by shRNA BIRC5a targeting, MCV-positive MKL-1 cells, but not MCV-negative UISO cells, 
underwent apoptosis (Figure 23D).  
 To confirm that LT is the MCV T antigen isoform responsible for survivin activation, we 
cloned and transduced a tumor-derived LT (LT339) cDNA into nontransformed, primary human 
BJ fibroblasts. Survivin protein levels increased three-fold when LT was expressed compared to 
the empty vector control (as measured by quantitative LICOR immunoblotting, Figure 26 A and 
26 B). Also consistent with our knockdown experiments (Figure 23C), LT directly activates 
BIRC5a promoter transcription in BJ cells (Figure 26C). This is mediated by a specific domain 
(LXCXE) in LT responsible for sequestration of RB1. Both cyclin E and E2F1, required for cell 
cycle S phase entry [511], are repressed by active RB1 and were used as markers for RB-
regulated gene expression. MCV LT339 activates expression of both cyclin E and E2F1 proteins 
in BJ cells whereas LT339, having a point mutation that prevents RB1 binding (changing LFCDE 
to LFCDK) [368], abolishes induction of cyclin E, E2F1 and survivin (Figure 26 A). MCV small T 
expressed alone in BJ cells did not increase survivin oncoprotein expression (Figure 27). In 
contrast to primary BJ fibroblasts, we did not find that MCV LT markedly increased survivin 
expression in cell lines that had been already transformed, including 293HEK and U2OS cells 
(Figure 28). 
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Figure 26 MCV LT protein isoform induces survivin oncoprotein expression in human BJ cells by targeting 
retinoblastoma protein (RB)  
(A) BJ cells were transduced with either empty vector, a tumor-derived LT cDNA (LT.339) or an LT cDNA with an 
inactive RB binding domain (LT.339LFCDK).  Immunoblotting reveals that MCV LT.339 induces survivin expression 
but LT.339LFCDK does not.  A similar pattern is seen for other S phase cell cycle proteins such E2F1 and cyclin E 
that are also transcriptionally repressed by RB. (B) LICOR quantitative immunoblotting for survivin in (A), 
normalized to -tubulin (arbitrary units). (C) Survivin mRNA levels increased in BJ cells expressing LT.339 protein 
but not in cells expressing the RB1 binding mutant LT.339LFCDK. BJ cells expressing either empty, LT.339 or 
LT.339LFCDK were serum starved for 48 hours and then harvested for RNA. Survivin mRNA was measured by qRT-
PCR and normalized to β-actin mRNA. The experiments performed three times in duplicate (mean+SEM). 
 
Figure 27 MCV sT isoform doe not induce survivin expression in BJ cells.  
BJ cells were transduced with either empty vector, tumor derived LT cDNA (LT.339) or small T antigen cDNA and 
immunoblotted for (A) survivin and α-tubulin (B) CM8E6 (MCV T antigen exon 1). Lanes were run on the same 
gel, but were not contiguous. 
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5.2.3 Survivin as a target for MCC chemotherapy 
Given the apparent importance of MCV-induced survivin expression to MCC cell survival, we 
examined YM155, an imidazolium small molecule inhibitor (Figure 29) of the survivin promoter 
that is currently undergoing Phase II trials for prostate cancer [507, 512, 513]. YM155 is both 
highly active and selective for inhibiting MCV-positive MCC cell growth in vitro as measured by 
Cell-Titer Glo assays (EC50 1.34 nM to 12.2 nM) (Figure 30A). MCV-negative MCC cell is also 
inhibited by YM155 but this occurs at concentrations 1-2 orders of magnitude higher than for 
MCV-positive MCC cells. YM155 treatment for 48 hours at 10-100 nM preferentially killed MCV- 
positive MKL-1 compared to MCV-negative UISO cells as measured by trypan blue staining 
(Figure 30B). Survivin protein was reduced in MKL-1 cells after YM155 treatment, consistent 
with  YM155’s proposed mechanism of action in inhibiting the BIRC5 prmoter (Figure 30C). 
Figure 29 YM155 chemical structure. Scanned from MSDS sheet of YM155  
(Activebiochemicals Inc.) 
Figure 28 MCV LT protein does not affect survivin oncoprotein expression in U2OS cells.  
U2OS cells were transduced and stably selected with empty vector, tumor derived LT cDNA (LT.339) or an LT cDNA 
with an inactive RB binding domain (LT.339.LFCDK) and immunoblotted for (A) survivin and α-tubulin (LICOR) (B) 
MCV LT (using CM2B4 antibody). Lanes were run on the same gel, but were not contiguous. 
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Figure 30 The survivin promoter inhibitor YM155 inhibits MCV-positive MCC cell line growth.  
(A) Dose-dependent growth curves at 48 h for YM155-treated cell lines. MCV-negative MCC13, BJ and BJhTERT cells 
showed relative resistance to YM155 treatment, whereas all MCV-positive cell lines (MKL-1, MKL-2, MS-1 and WaGa) 
were sensitive to YM155.  MCV-negative UISO and MCC26 had intermediate sensitivity to the YM155. (B) Trypan blue 
vital dye exclusion assay showed dose-dependent cell killing at 48 h for MKL-1 cells (blue bars) whereas UISO cells (red 
bars) are relatively less sensitive and BJ cells (green bars) are resistant to YM155. (C) Dose-dependent decrease in MKL-
1 cell survivin protein expression after 12 h YM155 treatment.  
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 Figure 31 Cell death phenotype of YM155-treated MCV-positive MCC.  
(A) Cell cycle analysis reveals YM155 treated cells do not undergo mitotic catastrophe. MKL-1 cells were treated 
with DMSO, YM155 (100nM) and camptothecin (CPT, 1              
BrdU staining (lower panel). Boxes show S phase BrdU incorporation without treatment, accumulation at G1 and 
G2/M/G1 tetraploid during CPT treatment, and near-complete loss of BrdU incorporation during YM155 
treatment. Box a represents G1 phase, box b represents S phase and box c represents G2/M phase and M1-M4 
describe the corresponding percentages of cells in these phases (B) YM155 induces nonapoptotic cell death 
associated with autophagy in MKL-1 cells. MKL-1 cells were treated with DMSO, YM155 (100nM) or bortezomib 
(100nM) and immunoblotted for (c) cleaved PARP, cCaspase 3, LC3 and -tubulin. In contrast to YM155, the 
bortezomib proteasome inhibitor activates MKL-1 cell apoptosis (also see Fig S2). (C) YM155 treatment initiates 
programmed cell death within 12-24 hours after treatment. MKL-1 cells were co-stained with CFDA (green, live) 
and PI (red, dead). Column graphs (right panel) represent mean and range of % CFDA-positive (green) and % PI-
positive cells (red). 
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We next examined mechanisms of cell killing by YM155 in MCV-positive MCC cells (Figure 31). 
Survivin plays a role in mitotic progression and loss of survivin can lead to cell death through 
mitotic catastrophe in some tumor cells [514, 515]. MCV-positive MCC, however, are slowly 
cycling cells (doubling time of 3 days, [498]) and do not undergo G1 arrest or G2/M pileup as 
would occur with mitotic checkpoint activation in rapidly cycling cells (Figure 31A, top panels). 
Instead, bromo-deoxyuridine (BrdU) incorporation into DNA reveals a profound inhibition of 
DNA synthesis by YM155. Figure 31 A (boxes, bottom left panel) shows the normal inverted-U 
pattern for BrdU incorporation during S phase DNA synthesis in MKL-1 cells. When the 
topoisomerase I inhibitor camptothecin is added (Figure 31A, bottom right panel), 
accumulation of BrdU-positive cells in G1 and G2/M/G1-tetraploid becomes evident, and S 
phase incorporation is lost, consistent with repair polymerase activation during DNA damage 
response signaling. YM155 treatment, however, ablates BrdU incorporation (Figure 31A, center 
panel), most consistent with disruption of DNA replication forks and inhibition of new S phase 
and repair DNA synthesis, but not mitotic catastrophe.   
Figure 32 Bortezomib induces apoptotic cell death in MCC cells.  
(A) MKL-1 cells were treated with Bortezomib (1,10,100,1000 and 10,000 nM) for 48 h or (B) MKL-1 cells treated 
with 100nM bortezomib for different time points, or (C) other MCC cell lines (MKL-1, MKL-2, MS-1, WaGa and 
UISO) treated with 100nM bortezomib for 48 h were treated for immunoblotting for cleaved caspase 3, cleaved 
PARP apoptotic markers and α-tubulin. 0.01% DMSO was used for mock-treated control.  
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 YM155 treatment results in early commitment to nonapoptotic programmed cell death. 
No evidence of apoptosis was present, measured by caspase 3 and PARP cleavage (Figure 31B), 
when MKL-1 cells were treated with 100 nM YM155 for 48 hours, but YM155 did initiate LC3-II 
accumulation, a marker for cell autophagy [516]. This is not due to loss of apoptosis pathway 
signaling since treatment with the proteasome inhibitor bortezomib (Velcade) activated PARP 
and caspase cleavage (Figure 31B and Figure 32). Commitment to YM155-dependent cell death 
occurs relatively quickly and irreversibly: when MKL-1 cells were treated with 100 nM YM155 
for 3, 6 or 12 hours, followed by wash out with complete cell culture medium, only 51%, 3% and  
1.8% of cells respectively, remained viable at 48 hours, as measured by trypan blue dye 
exclusion. This was confirmed by a cell viability assay using propidium iodide (PI, dead) and 
carboxyfluorescein diacetate (CFDA, alive) co-staining (Figure 31C). Twelve to 24 hours of 100 
nM YM155 treatment causes MKL-1 cells to lose membrane integrity, becoming positive for PI 
and negative for CFDA staining. 
 To search for other MCC chemotherapeutics, we performed a two-stage cytotoxicity 
library screen on 1,360 pharmacologically-active drug compounds (see Table 22 and Figures 
33A and 33B) including 1,280 drugs from the Library of Pharmacologically Active Compounds 
(LOPAC) (Sigma Aldrich), 89 drugs from the National Cancer Institute’s Approved oncology drug 
set II (19 compounds in common with LOPAC1280), 6 compounds targeting SV40 LT ATPase 
activity [500, 501] and 4 compounds targeting MDM2 to activate p53 [502, 503]. These 
compounds were screened at 10-5 M for >90% inhibition of MKL-1 cell growth in a Cell-Titer Glo 
assay (Promega). Notably, mTOR inhibitors (everolimus, rapamycin etc), antiviral compounds 
(ribavirin, acyclovir) and MDM-2 inhibitors active in other viral cancers (e.g., nutlin-3 [517, 518]) 
were not active in our screen. This is consistent with previous findings that MCV loses 
replication activity [368] and activates cap-dependent translation downstream of mTOR [504] 
in MCC tumor cells.  
Eighteen (1.3%) of these 1360 drugs met our initial screening criterion for anti-MCC 
activity and were selected for secondary dose-dependent screening on MCV-positive and MCV-
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negative	   cell	   lines	   (Table	   20).	   Only	   the	   proteasome-­‐inhibitor	   bortezomib	   [519]	   was	   active	   in	  
vitro	  at	  low	  doses	  (EC50	  1.3-­‐13.2	  nM,	  Figure	  33C	  and	  Figure	  32).	  This	  activity,	  however,	  was	  not	  	  
selective	   for	  MCV-­‐positive	   cells	   (Figure	   33).	  Other	   agents,	   particularly	   topoisomerase	   I	   and	   II	  
inhibitors,	   also	   inhibited	  MCC	   cell	   growth	   but	  were	   generally	   far	   less	   potent	   or	   had	   variable	  
activity	  among	  different	  MCC	  cell	  lines	  (Table	  20	  and	  Figures	  33A	  and	  33B).	  	  
	  
	  
! 1!
Table&1&
!
EC50&(μM)&concentrations&for&MCC&cell&lines&
&
Drugs! MKL=1! MKL=2! MS=1! WaGa! UISO!
PROTEASOME&INHIBITOR!
! ! ! ! !Bortezomib! 0.013!! 0.005!! 0.002!! 0.001! 0.003!
TOPOISOMERASE&INHIBITORS!
! ! ! ! !Ellipticine! 3.2! 6.5! 6.9! 3.0! 1.1!
Amsacrine!hydrochloride! 0.11! 3.0! 7.5! 0.25! 2.6!
Teniposide! 0.010! 2.8! 3.0! 0.026! 7.3!
Valrubicin! 0.23! 2.8! 9.9! 0.32! 4.0!
Mitoxantrone! 0.006! 1.3! 1.6! 0.014! 0.97!
Daunorubicin! 0.015! 0.086! 0.15! 0.018! 1.4!
Doxorubicin! 0.21! 0.022! 0.37! 0.022! 0.25!
Topotecan! 0.028! 0.43! 0.62! 0.015! 0.17!
OTHERS!
! ! ! ! !Iodoacetamide! 0.29! 0.30! 0.64! 0.37! 2.5!
Sanguinarine!chloride! 5.3! 8.4! 4.9! 2.5! 6.5!
NSC!95397! 1.2! 1.5! 1.8! 0.73! 2.8!
Chelerythrine!chloride! 0.60! 0.65! 0.52! 0.70! 3.7!
Calmidazolium!chloride! 2.2! 1.7! 2.1! 2.1! 2.0!
Tetraethylthiuram!disulfide! 0.49! 0.19! 6.3! 1.1! 13!
Bay!11M7085! 1.4! 1.7! 2.7! 1.2! 4.5!
Quinacrine!dihydrochloride! 5.1! 4.6! 4.9! 5.2! 7.1!
&!1!
Table	  20	  EC50	  (μM)	  concentrations	  for	  MCC	  cell	  lines	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Figure 33 Dose response curves for drug screen candidates.  
MCC cell lines and other human cancer cell lines were treated with compounds identified from the 
screen at increasing doses. Cell viability was normalized to no drug conditions (%survival=100). Shown 
is the average and standard deviation for 2 independent experiments tested in triplicate. (A) 
Topoisomerase inhibitors (B) other drugs (C) Bortezomib and (E) YM155 tested on NCI-H69 and U2OS 
cells. 
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5.2.4 Effect of YM155 on Human MCC Xenografts in Mice 
We developed an MKL-1 xenograft model to test the in vivo efficacy of YM155 and bortezomib 
on human MCC in NOD scid gamma (NSG) mice. Subcutaneous injection of MKL-1 cells 
generates tumors that are positive for MCV LT and the MCC diagnostic marker CK20 (Figure 
34A), and progress to endpoint (2 cm tumor diameter) within 2-4 weeks after tumors are first 
detected. We treated these mice with bortezomib, YM155 or saline for three weeks once 
tumors became palpable. Bortezomib was administered at levels effective on multiple myeloma 
xenografts [520] (1 mg/kg, twice-weekly subcutaneous injections). This did not significantly 
affect MCC tumor progression or volume compared to treatment with saline alone (p=0.53, log-
rank test). Bortezomib administration at this level was associated with mouse lethargy and 
weight loss, requiring temporary use of heat blankets and Hydrogel (ClearH2O) to prevent 
animal loss during initial treatment.  
 In contrast to bortezomib, YM155 (2 mg/kg, subcutaneous 5 times weekly [507, 521]) 
markedly delayed MKL-1 xenograft growth and significantly prolonged survival compared to 
either saline or bortezomib (p<0.0001, log-rank test, Figures 34B and 34C). This YM155 
treatment regimen is the standard dosing for mouse xenograft experiments based on 
pharmacokinetic and treatment response studies of Nakahara et al. on six different human 
cancer xenografts (prostate, bladder, melanoma, breast and lung cancer) in mice and >100 
human tumor cell lines [522, 523]. While 66.7-74.2% of bortezomib or saline-treated mice 
reached the euthanasia endpoint during the three-week treatment period, none of the YM155-
treated mice reached this endpoint during treatment. Partial tumor regression occurred among 
some YM155-treated mice but all tumors resumed growth once YM155 was stopped, indicating 
that a single 3-week treatment course was insufficient for tumor eradication (Figure 34B). For 
the majority of the mice, MKL-1 tumor volumes were unchanged or showed delayed growth 
during YM155 treatment, suggesting this drug may be cytostatic rather than cytocidal for MKL-1 
xenografts (Figure 34C and Appendix B). YM155 was well-tolerated and no adverse effects or 
acute toxicities were noted. In smaller cohorts of mice bearing MS-1 (MCV-positive) and UISO 
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Figure 34 YM155 inhibits growth of human MKL-1 MCC xenografts in NSG mice.  
(A) MKL-1 xenograft tumors stained with hematoxylin and eosin, MCV LT (CM2B4 antibody) and CK20 
(magnification 40X). (B) MKL-1 xenograft survival curves after drug treatment. Mice were subcutaneously 
injected with 20 million MKL-1 cells and assigned to a three-week drug treatment after tumors became 
palpable (see text). No significant difference was found between saline and bortezomib treatment. Tumor 
progression was significantly delayed by YM155, with none of the YM155-treated mice dying during 
treatment (up to day 19) compared to 23 of 31 (74%) saline and 14 of 21 (67%) bortezomib-treated mice. 
Tumor progression recurred for all YM155-treated mice once treatment was stopped. (C) Piecewise linear 
hierarchical Bayesian model for tumor volumes in treated mice (see supplemental appendix for details). 
Colored lines show estimated central population tumor volumes with shaded regions representing 95% 
credible intervals. Actual tumor volumes (grey lines) for each mouse are shown for comparison. YM155 
treatment retards tumor growth compared to saline or bortezomib treatment. (D) Table showing day of 
termination and tumor volumes for MS-1 and UISO xenograft mice treated with YM155 or saline.  
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(MCV-negative) cell xenografts, final tumor volumes for YM155-treated mice were 43-55% 
(median) of saline-treated control mice at the end of the three-week treatment period (Figure 
34D).   
5.2.5 DISCUSSION 
We show here that discovery of a viral cause for most MCC in February 2008, followed by the 
description of the virus’ oncogenes one year later, has now been used to rationally identify a 
survivin inhibitor that may have activity against this cancer. Our library screen of 1360 drugs, 
including the entire NCI Approved Oncology Drug Set II, confirmed that MCC is very 
chemoresistant and identified only one drug (bortezomib) that was highly active in vitro. 
Bortezomib however was not active in vivo against MCC xenografts. DTS, a quantitative cDNA 
deep sequencing method, not only identified MCV as a new human polyomavirus in MCC but 
also helped to uncover cell signaling pathways that are potential targets for MCV-positive MCC 
treatment.   
 Survivin, an inhibitor of apoptosis protein (IAP) family member[524], contributes to 
chemoresistance of melanoma[525] and is overexpressed in many cancers including MCC[494]. 
Figure 35 Lower survivin levels in mice xenograft tumors treated with YM155.  
qRT-PCR for survivin from saline and YM155 (2 mg/kg) treated tumor tissues. Column represents mean and error 
bars represent standard error. Experiment done in triplicate (mean+ SEM) 
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It increases during non-neoplastic JC polyomavirus infection[480, 524, 526], and by SV40 LT 
through an E2F-regulated mechanism [475, 527]. Our MCV T antigen knockdown and 
expression experiments confirm survivin to be activated by MCV LT’s sequestration of RB-family 
transcription repressors. Survivin has pleiotropic activities in both preventing apoptosis and 
activating cell cycle entry[480]. Our findings are consistent with retinoblastoma protein or other 
pocket proteins repressing survivin expression in primary cells[527], which can be relieved 
when MCV LT is expressed. MCV LT did not further increase survivin levels for transformed cells 
having the retinoblastoma protein pathway signaling blocked by mutation or E1A. MCV 
activation of survivin through retinoblastoma protein targeting may typically serve to promote 
virus replication but is aberrantly activated during MCV-tumorigenesis (10).  
 YM155 is highly cytotoxic in vitro to MCV-positive MCC cells, causing these cells to initiate 
a necroptotic cell death routine. Loss of survivin is commonly linked to mitotic catastrophe in 
cancer cells [515]; however, we did not find this to significantly contribute to MCC cell death. 
There was no distinct G1 or G2-M phase accumulation of cells during YM155 treatment and 
irreversible commitment to cell death occurs too quickly for most MCC cells to have an 
opportunity to transit the cell cycle. YM155 does increase LC3-II, implicating autophagy in 
YM155-induced cell death, but may reflect a consequence rather than a cause for cell death 
[528]. Intriguingly, a very similar cell death phenotype occurs when T antigens are knocked 
down in MCV-positive MCC cells[498], whereas we found that knockdown of survivin alone 
causes apoptosis rather than necroptosis. As with YM155 treatment, this effect was 
predominant in an MCV-positive but not MCV-negative MCC cell line. Since knockdown of 
survivin causes apoptosis rather than necroptosis, we cannot exclude the possibility that YM155 
targets other molecules in addition to survivin, or that different level of survivin inhibition by 
YM155 and survivin knockdown result in different programmed cell death responses.  
 There are several important caveats to our current study. While YM155 was highly active 
in vitro, it was only cytostatic—not cytotoxic—in most mouse xenografts. Once YM155 
treatment was stopped, tumors re-emerged in all of the treated mice. Either prolonged YM155 
treatment or combined use with other drugs (e.g., bortezomib, topoisomerase inhibitors) may 
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more effectively control MCC. YM155 was relatively nontoxic in our study, making it potentially 
more suitable for prolonged or combined therapy. Practical limitations prevented us from 
extensively measuring YM155 activity on a variety of MCC cell line xenografts and we cannot 
exclude the possibility of resistance among other MCC. But it is encouraging that YM155 
reduced tumor masses in two additional MCC xenografts, including one from a MCV-negative 
tumor. Finally, MCV sT (also expressed in MCC cells) increases cap-dependent protein 
translation [504], and could contribute to YM155 resistance[529].   
 DTS [75] is a useful method to discover[74] or exclude [75] viruses being present in 
human cancers. In this study, we show that DTS is also useful in measuring cellular gene 
expression by demonstrating that BIRC5 transcription is activated in MCV-positive MCC. If 
carefully performed and rigorously analyzed, DTS data yields useful information even when no 
cancer viruses are discovered [75]. Prior to discovery of MCV, few clues were available about 
the molecular causes for MCC[333]. Now that MCV has been shown to be central to most MCC, 
rational targeting of survivin and other cellular pathways perturbed by MCV may lead to 
discovery of additional treatments that may be more effective and less toxic than current 
therapies. 
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6.0  CONCLUSIONS AND PERSPECTIVES 
6.1 MCV – A NEW HUMAN CARCINOGEN 
There is substantial evidence that supports MCV’s causal role in ~70-80% of MCC. In the 2012 
IARC (International Agency for Research on Cancer) Monograph meeting MCV was classified as 
a group 2A carcinogen (‘probably carcinogenic to humans’)[530]. MCV’s strong and specific 
association with MCC, consistently found by research groups around the world, fulfills a 
number of A. B. Hill’s criteria for establishing causality between a factor and a human disease. 
Clonal integration of MCV within tumors and prior exposure to the virus both establish a 
significant temporal–relationship requirement. Although experimental evidence supporting 
MCV’s contribution to MCC is critical, similar to other viral cancers additional factors and 
cellular changes are also needed for the outgrowth of the tumor. Following is a summary of the 
current experimental evidence supporting the notion that MCV is a direct carcinogen.  
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6.2 MODEL:	  MOLECULAR	  EVOLUTION	  OF	  MCC	   	   	   	   	   	  
A	  model	  for	  the	  molecular	  evolution	  of	  MCC	  thus	  involves	  (Figure	  36):	  MCV	  infection	  acquired	  
in	   early	   childhood,	   followed	  by	   reactivation	  of	   virus	   in	   the	   context	   of	   immunosuppression	  or	  
senescence	   of	   immune	   surveillance	   in	   elderly;	   genomic	   integration	   of	   MCV	   and	   natural	  
selection	  pressure	  against	  replication-­‐competent	  virus;	  expression	  of	  viral	  oncoprotein	  resulting	  
in	  clonal	  expansion	  of	  transformed	  cells	  leading	  to	  MCC.	   	   	   	   	   	  
	   The	  discovery	  of	  MCV	   in	  ~80%	  MCC,	  has	  made	  a	  dramatic	   impact	  on	  the	  study	  of	   this	  
cancer.	   Although	   MCV’s	   importance	   in	   MCC	   is	   widely	   accepted,	   the	   precise	   mechanisms	  
contributing	   to	  MCC	   tumor	   formation	   are	   still	   unknown.	   Future	   studies	   promise	   to	   elucidate	  
signaling	   pathways	   targeted	   by	  MCV	   leading	   to	   new	   approaches	   to	   treating	   and	   preventing	  
MCC.	  
	  
Figure	  36	  Steps	  in	  molecular	  evolution	  of	  Merkel	  cell	  carcinoma.	  
(Adpated	  from	  Chang	  and	  Moore,	  Ann	  Rev	  Pathol,	  2011)	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6.3 SUMMARY 
New knowledge of the viral etiology of a subset of MCC, has been successfully applied in both 
diagnosis and treatment of the disease. To assess MCV infection and its association with MCC 
and other human diseases, a monoclonal antibody (CM2B4) against an exon 2 epitope in MCV 
large T antigen was developed. We showed that this antibody recognizes both endogenous and 
overexpressed, transfected MCV LT and does not cross react with SV40, JCV and BKV T antigens. 
Using CM2B4, we showed that the expression of MCV T antigen localizes to the nuclei of MCC 
tumor cells, but is absent in adjacent non-tumor cells. The study was extended to two tissue 
microarrays. 74.2% (46/62) CK20 positive MCC tissues were found to be positive for CM2B4 
staining.  A quantitative PCR assay was also developed and MCV genome was found to be 
present at 1.6-48 copies per tumor cell.   
Both these assays were used to survey a large set of human malignancies for their 
association with MCV. These malignancies included (325 +173 + 10) hematolymphoid tumors, 
(26) neuroendocrine tumors and (2) cases of concurrent CLL and MCC. Only 2.2% of 325 
hematolymphoid malignancies tested showed evidence for MCV infection. However the viral 
copy numbers in these positive samples was 2-4 log lower than that seen in MCC.  
In conclusion, these findings document that MCCs frequently express MCV T antigen, 
with good correlation between PCR-based and immunohistochemical detection methods. 
Immunostaining with mAb CM2B4 detects MCV LT in the majority of Merkel cell tumors, but 
not in other cancers. CM2B4 is a useful reagent for the diagnosis of MCV positive MCC.  
To find therapeutic targets for this aggressive cancer, cellular genes dysregulated by 
MCV infection were examined. Digital transcriptome subtraction (DTS) profiles of MCV positive 
versus negative tumor tissue libraries were compared. The analysis found that survivin was 
upregulated seven-fold in virus positive as compared to virus negative tumors. Upon 
knockdown of MCV T antigen in MCV positive MCC cell lines, an associated decrease in survivin 
protein and mRNA was observed. Exogenously expressed MCV large T antigen increased 
survivin expression in non-MCC BJ primary cells. This effect was dependent on an intact 
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retinoblastoma family-binding domain in MCV LT. Survivin expression appears to be critical for 
MCV positive MCC cell survival because knockdown of survivin killed these cells. To follow this 
up, MCC cells were treated with a survivin targeting compound, YM155 (currently in Phase II 
trials for various cancers). YM155 initiates irreversible, non-apoptotic programmed cell death in 
MCV positive MCC cells, but not in MCV negative MCC cells.   
An in vitro drug screening of 1360 other pharmacologically active compounds resulted in 
a single compound, bortezomib, having similar potency to YM155. However, although 
bortezomib was potent it was not selective for killing MCV infected MCC cells.  
Both YM155 and bortezomib were then tested in MKL-1 cell xenograft models for 
preclinical evaluation. Bortezomib did not significantly improve mouse survival (33%) over 
saline (24%) during treatment. In contrast, all YM155-treated mice survived (100%, p<0.001) 
the 3-week treatment period. Tumors resumed growth once YM155 treatment was stopped, 
suggesting that YM155 is cytostatic rather than cytotoxic in vivo. YM155 showed no toxicity in 
mice, whereas bortezomib resulted in significant adverse effects.  
6.4 GENERAL DISCUSSION 
 
Detection of MCV large T antigen expression, determined using the CM2B4 antibody, further 
provided the mechanistic underpinning, which supports the notion that MCV causes a subset of 
MCC. Knockdown of MCV LT kills cells, indicating that MCV LT is critical for MCC survival. MCV 
LT induces survivin expression and this effect is dependent on the retinoblastoma family 
binding LFCDE domain of MCV LT. Many viruses including SV40 and papillomaviruses possess 
LXCXE motifs and target RB family members. In melanocytes, Rb and p53 seem to regulate the 
survivin promoter through its predicted E2F binding sites [475, 531]. However, the link between 
RB targeting by viruses and survivin expression has not yet been characterized.  
  
 143 
Survivin inhibition has become an important and encouraging therapeutic approach to 
cancer.  Virtually every human tumor expresses survivin and exploits one of its many functions.  
The presence of survivin in cancer is universally linked to resistance to apoptosis, evasion of cell 
cycle checkpoints, resistance to therapy, and metastasis [461, 476, 480]. Several survivin 
antagonists, including YM155 and Terameprecol have reached clinical trials (Table 18, Chapter 
4). Valid concerns that survivin’s essential role in stem cells [532] and some expression in 
normal tissues [533] would compromise these compounds in vivo, were resolved by the success 
of Phase I and II trials of these molecules [480, 496, 534]. This may reflect selective “survivin 
addiction” by the tumor, or “qualitative differences” in survivin network wiring in transformed 
cells versus normal healthy cells [476, 535]. 
Although survivin knockdown leads to apoptotic cell death, YM155 mediated cell death 
appears non-apoptotic. Autophagy was observed in cells treated with YM155, however I believe 
that in this context autophagy constitutes a futile cytoprotective attempt of dying cells to adapt 
to lethal stress rather than defining a mechanism that is executing a cell death program. In 
support of this notion, studies have shown that knockdown of essential autophagy genes (such 
as ATG5 and ATG7), which inhibit autophagosome formation, failed to prevent and at times 
even accelerated chemotherapy-induced cell death [528, 536]. Cells appear to be dying with 
autophagy but not by autophagy. YM155 treated MCV positive MCC cells probably undergo a 
quick, sudden form of necroptotic cell death. Due to the lack of direct assays that can 
determine necrosis and non-apoptotic cell death the exact mechanism of YM155-mediated 
cellular death is difficult to determine. 
Single agent YM155 treatment was cytostatic but not cytotoxic for MKL-1 cell MCC 
xenografts in immunodeficient NSG mice. During the YM155 IP dosing over three weeks, most 
tumors regressed and none of the mouse xenograft tumors (n=21) reached the euthanasia end-
point (2cmX2cm tumors). However, tumors resumed growth once treatment was stopped. No 
toxicity was noted during treatment (e.g. weight loss, ruffled fur, hair loss, hunched posture 
etc). Although a xenograft mouse system is an imperfect model of human cancer, it offers an in 
vivo approach to measuring therapeutic modalities that is different from cell culture systems. 
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Although the genetics and cellular complexity of these in vivo tumors are not representative of 
the original tumor in its native state, there are advantages of using mouse models for 
preclinical evaluation of therapeutic responses to drugs. They are easy to use, relatively 
inexpensive and reproducible. Treatment can be initiated when the tumor reaches an optimal 
size and progression of a number of these synchronized, easily observable tumors can be 
followed accordingly in an in vivo system. In addition, only a few mice are required for 
analytical drug efficacy studies and xenografts form tumors in shorter times with a high degree 
of predictability as compared to other genetically engineered mouse models. 
For the evaluation of YM155 in MCC in vivo, we used a mouse xenograft model of a MCV 
positive MCC human cell line (MKL-1). This model closely resembled and maintained certain 
features (CK20 positivity, MCV LT and sT expression etc) of MCC tumors. Whereas both 
bortezomib and YM155 were equally potent in cell culture and showed similar EC50 
concentrations, their effect on tumor cells differed in the mouse and resulted in different 
outcomes. The discovery of MCV as a cause of MCC is impetus to the use of viral oncogenes for 
the creation of transgenic mouse models, similar to the SV40 and MPyV models. In the future of 
MCV research, the development and characterization of such MCC models, in conjunction with 
xenograft models such as those used in this study they will be valuable for the preclinical 
evaluation of compounds such as YM155. 
Survivin is a downstream target gene of multiple oncogenic signaling circuits such as 
STAT3, Akt, EGFR, Notch, Wnt, VEGF and Ang-1 [476, 537-541]. Monotherapeutic, small 
molecule inhibitors of these pathways, have produced modest but promising results. 
Preliminary work in our laboratory supports the importance of the Akt pathway and other 
common oncogenic pathways in MCV positive MCC cells. Combined inhibition of such pathways 
and survivin, is likely to enhance efficacy for treatment of MCC and other cancers, without 
compromising safety and toxicity. 
Survivin antagonists such as YM155, act more broadly as “pathway antagonists” despite 
being single target agents since they disable multiple survivin networks by inhibiting the 
nodal/central protein. Several clinical trials with YM155 have been completed, with more 
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underway. In patients with advanced non-small cell lung cancer, YM155 produced a disease 
control rate of 43% in phase II studies [542]. The treatment was well tolerated and produced 
two partial repsonses and disease stabilization in 14 out of 37 patients. Phase II studies of 
YM155 in melanoma however were less promising. They produced only one partial response in 
patients with stage III and stage IV disease [543]. The Eastern Oncology Cooperative Group 
(ECOG) clinical trial (E1611) for YM155 and bortezomib in MCC patinets will begin in the fourth 
quarter of 2012, and I sincerely hope that YM155 lives its promise for MCC. 
Using genomic technologies, the primary viral cause for ~75% of MCC cases was 
discovered, new diagnostic tests developed and a promising rational drug candidate was 
identified. Moving from discovery to the clinic in less than four years is a resounding success in 
MCC oncology. The approaches described above for diagnosis and therapy remain promising 
and bode well for their continued evaluation in the clinic.  
6.4.1 FUTURE DIRECTIONS 
To optimize YM155 in treating MCC, experiments determining the outcome of prolonged 
YM155 treatment and increased YM155 dosing are underway. Combination studies of YM155 
with cytotoxics and/or radiation therapy for MCC may prove more effective. Sequential 
inhibition of survivin in tumor cells pretreated with taxanes (such as docetaxol), which disrupt 
microtubule function, produces an increased anticancer activity with no toxicity in preclinical 
models [513, 544-546]. Similar approaches that evaluate combination chemotherapies with 
YM155 and low dose topoisomerase inhibitors and/or alkylating agents (such as etoposide, 
carboplatin, currently used for MCC in the clinic[547]), and even YM155 and bortezomib, have 
potential for MCC treatment and will be considered. 
My findings will direct future work in the laboratory to resolve the following 
unanswered questions: What is the mechanism behind upregulation of survivin by MCV LT? 
How does MCV LT increase survivin expression through its LFCDE domain? If the Rb/E2F 
pathway is involved in the phenotype shown, then it would be interesting to identify and 
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narrow down the specific RB family members (pRb, p107 and p130) and specific E2F 
transcription factors involved. Chromatin immunoprecipitation experiments to check for E2F 
binding to the survivin promoter, in the presence and absence of MCV LT and LFCDE mutants, 
may be an approach to address some of these questions.  Assessing survivin upregulation by 
MCV LT after the knockdown of Rb and E2F family proteins, or in cells lacking expression of 
these proteins is another experimental approach to this puzzle. Besides determining how 
YM155 treatement kills MCV positive MCC cells, gene expression microarray analysis and 
structural studies may be informative in identifying other targets and effects of YM155. 
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APPENDIX A 
Table 21 Polyomavirus Information 
      GenBank ID   
Virus Abbreviation Host Full genome 
Large T 
antigen 
Major capsid 
protein VP1 
Genome 
size 
Orthopolyomaviruses (type species Simian virus 40 ) 
Baboon 
polyomavirus 1 SA12 Monkey NC_007611 YP_406555 YP_406554 5230 bp 
Bat 
polyomavirus BatPyV Bat NC_011310 YP_002261489 YP_002261488 5081 bp 
B-lymphotropic 
polyomavirus LPyV Monkey NC_004763 NP_848008 NP_848007 5270 bp 
BK polyomavirus BKV Human NC_001538 YP_717940 YP_717939 5153 bp 
Bornean orang-
utan 
polyomavirus 
OraPyV1 Orang-utan NC_013439 YP_003264534 YP_003264533 5168 bp 
Bovine 
polyomavirus BPyV Cattle NC_001442 NP_040788 NP_040787 4697 bp 
California sea 
lion 
polyomavirus 
SLPyV Sea Lion NC_013796 YP_003429323 YP_003429322 5112 bp 
Hamster 
polyomavirus HaPyV Hamster NC_001663 NP_056730 NP_0567331 5366 bp 
Human 
Polyomavirus 9 HPyV9 Human NC_015150 YP_04243706 YP_004243705 5026 bp 
JC Polyomavirus JCV Human NC_001699 NP_043512 NP_043511 5130 bp 
Merkel cell 
polyomavirus MCV Human NC_010277 AC125312* YP_001651048 5387 bp 
Murine 
pneumotropic 
virus 
MPtV Mouse NC_001505 NP_041232 NP_041234 4754 bp 
Murine 
polyomavirus MPyV Mouse NC_001515 NP_041264 NP_041267 5297 bp 
Simian virus 40 SV40 Monkey NC_001669 YP_003708382 YP_003708381 5243 bp 
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Squirrel monkey 
polyomavirus SqPyV Monkey NC_009951 YP_001531349 YP_001531348 5075 bp 
Sumatran orang-
utan 
polyomavirus 
OraPyV2 Orang-utan FN356901 CAX87759 CAX87757 5358 bp 
Trichodysplasia 
spinulosa-
associated 
polyomavirus 
TSPyV Human NC_014361 YP_003800007 YP_003800006 5232 bp 
Chimpanzee 
polyomavirus ChPyV Chimpanzee NC_014743 YP_004046683 YP_004046682 5086 bp 
Wukipolyomavirus (type species KI polyomavirus) 
Human 
polyomavirus 6 HPyV6 Human NC_014406 YP_003848919 YP_003848918 4926 bp 
Human 
polyomavirus 7 HPyV7 Human NC_014407 
 
YP_003848924 YP_003848923 4952 bp 
KI Polyomavirus KIPyV Human NC_009238 YP_001111259 YP_001111258 5040 bp 
WU 
Polyomavirus WUPyV Human NC_009539 YP_001285488 YP_001285487 5229 bp 
Avipolyomavirus (type species Avian polyomavirus) 
Avian 
polyomavirus APyV Birds NC_004764 YP_004061429 YP_004061428 4981 bp 
Canary 
polyomavirus CaPyV Canary GU345044 ADM88652 ADM88650 5421 bp 
Crow 
polyomavirus CPyV Jackdaw NC_007922 YP_529828 YP_529827 5079 bp 
Finch 
polyomavirus FPyV Bullfinch NC_007923 YP_529834 YP_529833 5278 bp 
Goose 
polyomavirus GHPyV Goose NC_004800 NP_849170 NP_849169 5256 bp 
       * MCV full length large T- 206 isolate was used in this study 
    The MCV Truncated T - 339 isolate commonly used is YP_001651046 
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Figure 37 Updated amino acid alignment of MCV large T antigen with other human polyomavirus, 
SV40, LPyV and MPyV large T antigens. 
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A.1  DETAILS OF DISEASE CATEGORIES OF TABLE 15 
Lymphomas and Myeloid disorders -- Acute Lymphoblastic Leukemia (1/136), Acute myeloid leukemia (0/11), 
Angiocentric T cell lymphoma (nasal type) (0/1), Angioimmunoblastic T-cell lymphoma (1/2), Burkitt 
lymphoma/Burkitt cell leukemia (0/2), Chronic Lymphocytic Leukemia (32/168), Chronic myelogenous leukemia 
(0/5), Classical Hodgkin lymphoma (3/41), Cutaneous gamma/delta T cell lymphoma (0/2), Diffuse follicular center 
lymphoma (0/1), Diffuse large B cell lymphoma (2/118), B-cell lymphoma (9/260), Extranodal marginal zone B-cell 
lymphoma (0/2), Extranodal NK/T-cell lymphoma, nasal type (0/2), Feces of Leukemic children (0/75), Follicular 
lymphoma (2/49), Hodgkin lymphoma (4/76), Large granular lymphocyte leukemia (0/1),  Lymphoblastic 
leukemia/lymphoma (0/5), Lymphomas (1/11), Lymphoplasmacytic lymphoma (0/4), Mantle cell lymphoma (0/15), 
Marginal zone lymphoma (1/9), Mucosa-associated lymphoid tissue lymphoma (0/5), Mycosis Fungoides (0/25), 
Myelodysplastic syndrome (0/3), Myeloid disorder (0/1), Myeloid hyperplasia (0/1), Nasal Swabs from Leukemic 
children (2/106), Necrotizing lymphadenitis (0/2), NK/T-cell lymphoma (2/18),  Nodular lymphocyte predominant 
Hodgkin lymphoma (0/3), Hodgkins lymphoma --Nodular sclerosis (1/29), Non-Hodgkin lymphoma (11/166), 
Pagetoid reticulosis/ cutaneous T cell lymphoma (0/1), Peripheral T-cell lymphoma (0/1), Plasmacytoid dendritic 
cell tumor (0/1), Post-transplant lymphoproliferative disorder (0/13), Primary cutaneous peripheral T cell 
lymphoma (1/4), Primary effusion lymphoma (0/6), Pseudolymphomas (2/13), Reactive Hyperplasia Lymphoid 
Samples (0/6), Splenic marginal zone lymphoma (0/1), T cell lymphomas (0/17), T-cell lymphoma, unspecified 
(1/82), Unclassified lymphomas (1/6) 
Neuroendocrine cancers -- Cervical neuroendocrine carcinomas (0/4), Combined squamous and neuroendocrine 
carcinomas (0/7), High grade mucosal neuroendocrine carcinoma (0/8), High grade neuroendocrine carcinoma of 
the cervix (0/1), Large cell neuroendocrine carcinoma (0/2), Neuroendocrine small cell carcinoma (0/4), 
Neuroendocrine tumor of GI tract (0/15), Neuroendocrine tumors (0/40), Pulmonary neuroendocrine carcinomas 
(0/26), Salivary gland high-grade neuroendocrine carcinoma (0/7), Small cell lung neuroendocrine carcinoma (0/5), 
Visceral high grade neuroendocrine tumors (32 from lung, 16 from gastrointestinal tract,20 female reproductive 
system, 3 soft tissue, 2 from head and neck and 1 from bladder) (1/74), Well differentiated intestinal 
neuroendocrine carcinoma (0/3) 
Skin cancers – Actinic Keratosis (12/92), Epidermodysplasia-Verruciformis skin lesions (16/19), Atypical 
Fibroxanthoma (4/23), Basosquamous carcinomas (0/3), Immunosuppressed non melanoma skin cancer (NMSC) 
(2/45), Inflammatory skin diseases (2/25), Keratoacanthoma (16/87), Kaposi’s Sarcoma (6/63), Lentigo Maligna 
Melanoma (0/10), Malignant Melanoma (2/28), Melanoma (0/95), Metastatic melanoma in the liver (0/94), 
Naevoid basal cell carcinoma syndrome (5/26), Porokeratosis (0/1), Psoriasis (1/44), Serborrheic keratosis (19/81), 
Skin cancers (nonspecified) (0/2), Skin with proliferative, inflammatory or mucosal lesions (0/15), Squamous cell 
carcinoma (155/737), Trichoblastoma (12/42), Urine from Psoriasis patient (0/6), Whole blood from Psoriasis 
patient (0/6), Basal cell carcinoma (77/381). 
Central Nervous System diseases -- Astrocytoma (0/11), Cerebrospinal fluid from Hematopoietic stem cell 
transplantation patients with neurological symptoms (0/20), CNS Tumors (0/25), Encephalitis (0/12), Ependymoma 
(0/3), Ewing Sarcoma/ Primitive Neuroectodermal tumors (1/7), Gliomas (0/2), Ewing tumor (0/30), 
Medulloblastoma/PNET (0/5), Meningioma (0/1), Multiple sclerosis (0/115), Neuroblastomas (0/57), neurological 
syndromes (0/2), Unspecified intracranial intraspinal neoplasm (0/1) 
Other viral related disorders -- BKV positive nephritis (0/1), Benign common warts in immunosuppressed patients 
(5/20), Common warts from healthy individuals (4/60), Papilloma wart (0/4), HPV +ve Invasive carcinoma of 
uterine cervix (0/26), Progressive Multifocal Leukoencephalopathy (PML) (0/35) 
Other cancers and diseases -- Adenocarcinoma (large bowel) (0/38), Biliary cirrhosis (2/2), Cancerous Prostrate 
epithelia (0/28), Carcinomas in situ, immunocompetent patients (2/24), FDC Sarcoma (0/1), Fibromatosis (0/4), 
Follicular lesions of lung (0/10), Fulminant hepatitis (0/9), Gastric cancer (1/20), Mixed cellularity tumors (2/10), 
Bladder cancer (6/8), Bowen's disease (23/126), Breast Cancer (0/718), Colon and Colorectal Cancers (11/190), 
Desmoplastic tumor (0/24), Esophageal cancer (3/5), HPV -ve invasive carcinoma of uterine cervix (0/18), 
Inflammatory tissues (0/7), Large bowel cancer (0/1), Lipoma (0/1), Liver cancer (10/20), Lower respiratory tract 
(bronchioalveolar and bronchioaspirate) samples from patients with Respiratory syndromes (15/87), Lung cancer 
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(10/29), Lymph nodes with non-MCC metastatic cancer (0/27), Mesothelioma (0/45) , Metastatic breast carcinoma 
in the liver (0/16), Metastatic carcinoma in the ovary (0/39), Metastatic colon adenocarcinoma (liver) (3/4), Non 
small cell lung cancer (5/51), Other immunosuppressed samples (nonspecified) (1/36), Other neoplastic non-MCC 
tissues (0/13), Ovarian cancer (0/143), Primary Pulmonary Hypertension (PPH) (0/10), Non cutaneous small cell 
undifferentiated carcinoma (1/75), Prostrate adenocarcinoma (4/22), Pulmonary small cell carcinomas (0/12), 
Renal clear cell carcinoma (3/16), Respiratory tract samples (immunocompetent individuals) (6/250), Respiratory 
tract samples (immunosuppressed individuals) (4/55), Rhabdomyosarcoma (0/25), Seminoma (1/9), Small cell 
carcinomas (9/24), Small cell lung cancer (10/76), WILD Syndrome (27 swabs, whole blood and cellular pellet) 
(1/1), Whole blood from colon cancer patients (0/64), Other unspecified neoplasms (1/13) 
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APPENDIX B 
Table 22 High throughput compound library screen results 
 
LOPAC1280 Library Screen Results 
Compound Name Class 
% 
Survival 
Index 
7-Chloro-4-hydroxy-2-phenyl-1, 8-naphthyridine Adenosine 64.1 
3-Isobutyl-1-methylxanthine Adenosine 70.9 
8-(3-Chlorostyryl) caffeine Adenosine 81.3 
8-(p-Sulfophenyl)theophylline Adenosine 84.1 
2-Chloroadenosine Adenosine 84.3 
1,3-Dimethyl-8-phenylxanthine Adenosine 88.5 
FSCPX Adenosine 88.9 
MRS 1754 Adenosine 89.0 
5 -N-Methyl carboxamidoadenosine Adenosine 90.0 
1,3-Diethyl-8-phenylxanthine Adenosine 90.1 
Metrifudil Adenosine 90.2 
2-Phenylaminoadenosine Adenosine 92.5 
S- (4-Nitrobenzyl)-6-thioguanosine Adenosine 93.3 
1,3-Dipropyl-7-methylxanthine Adenosine 93.4 
8-Cyclopentyl-1,3-dipropylxanthine Adenosine 94.6 
MRS 1523 Adenosine 94.9 
N6-Cyclohexyladenosine Adenosine 95.2 
Alloxazine Adenosine 97.0 
1,3-Dipropyl-8-p-sulfophenylxanthine Adenosine 99.0 
Chloro-IB-MECA Adenosine 99.5 
N6-Methyladenosine Adenosine 100.6 
Theophylline Adenosine 100.7 
Xanthine amine congener Adenosine 101.3 
1,7-Dimethylxanthine Adenosine 102.9 
N6-Benzyl-5 -N-ethylcarboxamidoadenosine Adenosine 103.1 
erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride Adenosine 104.0 
Theobromine Adenosine 104.1 
VUF 5574 Adenosine 104.9 
HE-NECA Adenosine 105.6 
3-n-Propylxanthine Adenosine 105.7 
1-Allyl-3,7-dimethyl-8-p-sulfophenylxanthine Adenosine 106.0 
CGS-21680 hydrochloride Adenosine 106.4 
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N6-Cyclopentyladenosine Adenosine 106.4 
5 -(N-Cyclopropyl)carboxamidoadenosine Adenosine 107.8 
8-Cyclopentyl-1,3-dimethylxanthine Adenosine 108.3 
3,7-Dimethyl-I-propargylxanthine Adenosine 109.5 
(S)-ENBA Adenosine 109.7 
S-(4-Nitrobenzyl)-6-thioinosine Adenosine 110.0 
Dipyridamole Adenosine 110.3 
N6-Phenyladenosine Adenosine 111.2 
IB-MECA Adenosine 111.9 
R(-)-N6-(2-Phenylisopropyl)adenosine Adenosine 113.1 
N6-Cyclopentyl-9-methyladenine Adenosine 113.2 
CGS-15943 Adenosine 114.3 
Adenosine Adenosine 114.5 
N6-2-Phenylethyladenosine Adenosine 116.4 
Dilazep hydrochloride Adenosine 117.4 
5 -N-Ethylcarboxamidoadenosine Adenosine 118.0 
Propentofylline Adenosine 119.7 
AB-MECA Adenosine 120.4 
Aminophylline ethylenediamine Adenosine 121.6 
Caffeine Adenosine 127.1 
Etazolate hydrochloride Adenosine 131.5 
N6-2-(4-Aminophenyl)ethyladenosine Adenosine 133.6 
S(-)-Pindolol Adrenergic 94.4 
Isotharine mesylate Adrenoceptor 78.1 
Naphazoline hydrochloride Adrenoceptor 80.4 
p-Iodoclonidine hydrochloride Adrenoceptor 81.5 
Doxazosin mesylate Adrenoceptor 81.6 
S(+)-Isoproterenol (+)-bitartrate Adrenoceptor 82.3 
Chloroethylclonidine dihydrochloride Adrenoceptor 85.6 
Nortriptyline hydrochloride Adrenoceptor 86.2 
UK 14,304 Adrenoceptor 87.6 
Ritodrine hydrochloride Adrenoceptor 90.1 
Terazosin hydrochloride Adrenoceptor 90.7 
WB-4101 hydrochloride Adrenoceptor 92.8 
p-Aminoclonidine hydrochloride Adrenoceptor 92.9 
(-)-Isoproterenol hydrochloride Adrenoceptor 93.6 
(-)-alpha-Methylnorepinephrine Adrenoceptor 94.3 
(±)-Isoproterenol hydrochloride Adrenoceptor 94.6 
Moxisylyte hydrochloride Adrenoceptor 94.8 
Naftopidil dihydrochloride Adrenoceptor 95.0 
MHPG sulfate potassium Adrenoceptor 95.0 
Oxymetazoline hydrochloride Adrenoceptor 95.0 
R(-)-Isoproterenol (+)-bitartrate Adrenoceptor 95.5 
Amitriptyline hydrochloride Adrenoceptor 96.3 
DSP-4 hydrochloride Adrenoceptor 96.8 
Methoxamine hydrochloride Adrenoceptor 97.0 
Pindolol Adrenoceptor 97.1 
Betaxolol hydrochloride Adrenoceptor 97.3 
(-)-Epinephrine bitartrate Adrenoceptor 97.4 
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Terbutaline hemisulfate Adrenoceptor 97.6 
Fenspiride hydrochloride Adrenoceptor 98.5 
Moxonidine hydrochloride Adrenoceptor 99.0 
(S)-(-)-propafenone hydrochloride Adrenoceptor 99.3 
Salbutamol Adrenoceptor 99.4 
A-315456 Adrenoceptor 99.5 
(±)-Sotalol hydrochloride Adrenoceptor 99.7 
Xylazine hydrochloride Adrenoceptor 100.6 
Tetrahydrozoline hydrochloride Adrenoceptor 100.6 
Imiloxan hydrochloride Adrenoceptor 101.0 
Bretylium tosylate Adrenoceptor 101.1 
Doxepin hydrochloride Adrenoceptor 101.3 
Dobutamine hydrochloride Adrenoceptor 101.8 
Phenoxybenzamine hydrochloride Adrenoceptor 101.8 
S(-)-Timolol maleate Adrenoceptor 102.3 
R(+)-Atenolol Adrenoceptor 102.6 
(±)-Normetanephrine hydrochloride Adrenoceptor 102.6 
(±)-CGP-12177A hydrochloride Adrenoceptor 102.7 
Yohimbine hydrochloride Adrenoceptor 103.3 
Benoxathian hydrochloride Adrenoceptor 103.5 
Nylidrin hydrochloride Adrenoceptor 103.8 
Nisoxetine hydrochloride Adrenoceptor 104.0 
(±)-Metoprolol (+)-tartrate Adrenoceptor 104.4 
Metaproterenol hemisulfate Adrenoceptor 104.4 
(-)-Ephedrine hemisulfate Adrenoceptor 105.1 
(±)-Atenolol Adrenoceptor 105.3 
Fiduxosin hydrochloride Adrenoceptor 105.4 
Rauwolscine hydrochloride Adrenoceptor 105.5 
Prazosin hydrochloride Adrenoceptor 105.6 
ICI 118,551 hydrochloride Adrenoceptor 106.8 
(±)-Norepinephrine (+)bitartrate Adrenoceptor 107.0 
L(-)-Norepinephrine bitartrate Adrenoceptor 107.4 
Formoterol Adrenoceptor 107.5 
L-765,314 Adrenoceptor 108.5 
6-Hydroxy-DL-DOPA Adrenoceptor 108.6 
MK-912 Adrenoceptor 108.7 
Maprotiline hydrochloride Adrenoceptor 108.8 
MHPG piperazine Adrenoceptor 109.1 
Salmeterol xinafoate Adrenoceptor 109.4 
(±)-Propranolol hydrochloride Adrenoceptor 110.1 
Guanabenz acetate Adrenoceptor 110.1 
B-HT 933 dihydrochloride Adrenoceptor 110.4 
(±)-Epinephrine hydrochloride Adrenoceptor 110.5 
Fenoterol hydrobromide Adrenoceptor 110.8 
R(-)-Denopamine Adrenoceptor 112.8 
BRL 37344 sodium Adrenoceptor 113.2 
Bromoacetyl alprenolol menthane Adrenoceptor 113.9 
Amiodarone hydrochloride Adrenoceptor 114.2 
SKF 86466 Adrenoceptor 114.2 
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(±)-Octopamine hydrochloride Adrenoceptor 114.3 
RX 821002 hydrochloride Adrenoceptor 114.4 
6-Fluoronorepinephrine hydrochloride Adrenoceptor 114.4 
Tulobuterol hydrochloride Adrenoceptor 114.4 
Labetalol hydrochloride Adrenoceptor 114.6 
(±)-Vanillylmandelic acid Adrenoceptor 114.7 
Phentolamine mesylate Adrenoceptor 115.1 
 Xamoterol hemifumarate Adrenoceptor 115.2 
Cirazoline hydrochloride Adrenoceptor 115.3 
Urapidil, 5-Methyl- Adrenoceptor 115.4 
CL 316,243 Adrenoceptor 115.7 
(±)-Synephrine Adrenoceptor 115.8 
Desipramine hydrochloride Adrenoceptor 116.9 
(S)-Propranolol hydrochloride Adrenoceptor 117.2 
Protriptyline hydrochloride Adrenoceptor 117.2 
Alprenolol hydrochloride Adrenoceptor 117.4 
S(-)-Atenolol Adrenoceptor 117.5 
Phenylephrine hydrochloride Adrenoceptor 117.9 
Urapidil hydrochloride Adrenoceptor 118.3 
Xylometazoline hydrochloride Adrenoceptor 119.3 
SR 59230A oxalate Adrenoceptor 119.8 
Guanfacine hydrochloride Adrenoceptor 120.0 
CGP 20712A methanesulfonate Adrenoceptor 121.9 
Amoxapine Adrenoceptor 122.3 
Clonidine hydrochloride Adrenoceptor 123.1 
Tomoxetine Adrenoceptor 124.4 
Albuterol hemisulfate Adrenoceptor 129.8 
(±)-Pindobind Adrenoceptors 26.4 
DL-alpha-Difluoromethylornithine hydrochloride Angiogenesis 83.2 
Niclosamide Antibiotic 29.2 
Demeclocycline hydrochloride Antibiotic 87.7 
Cinoxacin Antibiotic 90.1 
Phosphomycin disodium Antibiotic 92.8 
Praziquantel Antibiotic 93.2 
Thiolactomycin Antibiotic 95.7 
Cefsulodin sodium salt hydrate Antibiotic 97.0 
Vancomycin hydrochloride from Streptomyces orientalis Antibiotic 97.3 
Doxycycline hydrochloride Antibiotic 97.6 
Cephapirin sodium Antibiotic 97.9 
Ofloxacin Antibiotic 99.5 
Nalidixic acid sodium Antibiotic 100.5 
Cefmetazole sodium Antibiotic 100.6 
Pyrazinecarboxamide Antibiotic 102.1 
Aminopterin Antibiotic 102.7 
Oxolinic acid Antibiotic 103.7 
Cephradine Antibiotic 104.0 
Cephalexin hydrate Antibiotic 105.0 
Cefaclor Antibiotic 109.1 
Lomefloxacin hydrochloride Antibiotic 111.3 
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Paromomycin sulfate Antibiotic 111.4 
Cefazolin sodium Antibiotic 112.6 
Mevastatin Antibiotic 112.6 
Cefotaxime sodium Antibiotic 113.9 
Cephalothin sodium Antibiotic 115.8 
Ceftriaxone sodium Antibiotic 116.1 
Trimethoprim Antibiotic 118.2 
Cephalosporin C zinc salt Antibiotic 122.3 
Foliosidine Anticonvulsant 86.8 
Phenytoin sodium Anticonvulsant 88.5 
Valproic acid sodium Anticonvulsant 89.5 
5,5-Diphenylhydantoin Anticonvulsant 93.9 
Ethosuximide Anticonvulsant 94.6 
Lamotrigine Anticonvulsant 97.7 
N-(4-Amino-2-chlorophenyl)phthalimide Anticonvulsant 102.7 
Primidone Anticonvulsant 105.4 
Dubinidine Anticonvulsant 106.7 
Zonisamide sodium Anticonvulsant 109.6 
Gabapentin Anticonvulsant 116.9 
Carbamazepine Anticonvulsant 122.7 
(S)-(+)-Camptothecin Apoptosis 17.2 
Etoposide Apoptosis 21.7 
beta-Lapachone Apoptosis 51.5 
Retinoic acid Apoptosis 53.2 
Emetine dihydrochloride hydrate Apoptosis 73.5 
XK469 Apoptosis 87.6 
Benzamide Apoptosis 103.6 
1,5-Isoquinolinediol Apoptosis 105.5 
Aurintricarboxylic acid Apoptosis 108.5 
4-Amino-1,8-naphthalimide Apoptosis 110.2 
m-Iodobenzylguanidine hemisulfate Apoptosis 112.7 
3-aminobenzamide Apoptosis 120.7 
Flumazenil Benzodiazepine 79.0 
Methyl beta-carboline-3-carboxylate Benzodiazepine 97.3 
N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide Benzodiazepine 98.2 
Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-
carboxylate Benzodiazepine 109.0 
Zopiclone Benzodiazepine 109.5 
L-655,708 Benzodiazepine 111.2 
CB34 Benzodiazepine 124.8 
3-Methyl-6-(3-[trifluoromethyl]phenyl)-1,2,4-triazolo[4,3-
b]pyridazine Benzodiazepine  105.0 
Iodoacetamide Biochemistry 1.4 
Tetraethylthiuram disulfide Biochemistry 3.7 
Z-L-Phe chloromethyl ketone Biochemistry 37.8 
Acetamide Biochemistry 71.8 
L-Leucinethiol, oxidized dihydrochloride Biochemistry 75.5 
4-Chloromercuribenzoic acid Biochemistry 78.8 
1-Deoxynojirimycin hydrochloride Biochemistry 85.0 
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4-Methylpyrazole hydrochloride Biochemistry 85.4 
Benserazide hydrochloride Biochemistry 88.9 
Actinonin Biochemistry 89.0 
Bestatin hydrochloride Biochemistry 91.5 
PD 404,182 Biochemistry 92.1 
L-azetidine-2-carboxylic acid Biochemistry 92.6 
1,10-Phenanthroline monohydrate Biochemistry 93.3 
3-Hydroxybenzylhydrazine dihydrochloride Biochemistry 94.7 
10-(alpha-Diethylaminopropionyl)-phenothiazine 
hydrochloride Biochemistry 97.8 
2,2 -Bipyridyl Biochemistry 97.9 
E-64 Biochemistry 98.0 
N-Methyl-1-deoxynojirimycin Biochemistry 98.3 
4-Hydroxybenzhydrazide Biochemistry 98.6 
Chlorothiazide Biochemistry 99.5 
N-p-Tosyl-L-phenylalanine chloromethyl ketone Biochemistry 100.8 
Acetazolamide Biochemistry 101.3 
N-Ethylmaleimide Biochemistry 105.6 
Tetraisopropyl pyrophosphoramide Biochemistry 107.6 
Furafylline Biochemistry 107.8 
L-alpha-Methyl DOPA Biochemistry 109.6 
Hydrochlorothiazide Biochemistry 109.8 
4-Aminobenzamidine dihydrochloride Biochemistry 110.1 
L-allylglycine Biochemistry 110.6 
2-Chloro-2-deoxy-D-glucose Biochemistry 110.8 
Diethylenetriaminepentaacetic acid Biochemistry 111.6 
Sodium Oxamate Biochemistry 112.4 
(±)-p-Aminoglutethimide Biochemistry 112.4 
3,4-Dichloroisocoumarin Biochemistry 112.6 
Betaine hydrochloride Biochemistry 113.4 
P1,P4-Di(adenosine-5 )tetraphosphate triammonium Biochemistry 117.0 
O-(Carboxymethyl)hydroxylamine hemihydrochloride Biochemistry 117.0 
S-(-)-Carbidopa Biochemistry 118.0 
Ethylene glycol-bis(2-aminoethylether)-N,N,N ,N -
tetraacetic acid Biochemistry 118.4 
beta-Chloro-L-alanine hydrochloride Biochemistry 119.5 
2,4-Dinitrophenyl 2-fluoro-2-deoxy-beta-D-
glucopyranoside Biochemistry 119.8 
Epibestatin hydrochloride Biochemistry 120.5 
4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride Biochemistry 121.9 
Phosphoramidon disodium Biochemistry 127.4 
Benzamidine hydrochloride Biochemistry 129.1 
SKF 96365 Ca2+ Channel 56.1 
NNC 55-0396 Ca2+ Channel 70.5 
Diltiazem hydrochloride Ca2+ Channel 94.6 
Mibefradil dihydrochloride Ca2+ Channel 96.1 
Nitrendipine Ca2+ Channel 98.1 
Nifedipine Ca2+ Channel 98.2 
Nicardipine hydrochloride Ca2+ Channel 98.3 
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(±)-Verapamil hydrochloride Ca2+ Channel 98.8 
YS-035 hydrochloride Ca2+ Channel 100.7 
(±)-Methoxyverapamil hydrochloride Ca2+ Channel 102.0 
FPL 64176 Ca2+ Channel 103.2 
Cinnarizine Ca2+ Channel 104.9 
MRS 1845 Ca2+ Channel 105.8 
Phloretin Ca2+ Channel 108.2 
Nimodipine Ca2+ Channel 113.6 
(±)-Bay K 8644 Ca2+ Channel 116.1 
Bepridil hydrochloride Ca2+ Channel 116.3 
Felodipine Ca2+ Channel 128.3 
SKF 94836 Calcium Signaling 95.1 
( R)-(+)-WIN 55,212-2 mesylate Cannabinoid 90.8 
Palmitoylethanolamide Cannabinoid 92.9 
CP55940 Cannabinoid 105.8 
N-arachidonylglycine Cannabinoid 108.5 
JWH-015 Cannabinoid 110.4 
Indomethacin morpholinylamide Cannabinoid  102.7 
Bay 11-7085 Cell Cycle 3.8 
Ellipticine Cell Cycle 5.9 
Caffeic acid phenethyl ester Cell Cycle 40.4 
Pyrocatechol Cell Cycle 83.4 
Apigenin Cell Cycle 87.8 
Se-(methyl)selenocysteine hydrochloride Cell Cycle 89.2 
Daidzein Cell Cycle 90.8 
MDL 28170 Cell Cycle 93.3 
Retinoic acid p-hydroxyanilide Cell Cycle 99.3 
TG003 Cell Cycle 101.7 
5-Fluorouracil Cell Cycle 102.8 
Minocycline hydrochloride Cell Cycle 103.5 
Ganciclovir Cell Cycle 105.6 
Ribavirin Cell Cycle 109.1 
Fusidic acid sodium Cell Cycle 114.8 
Rotenone Cell Stress 36.3 
U-83836 dihydrochloride Cell Stress 49.5 
N,N,N ,N -Tetramethylazodicarboxamide Cell Stress 82.5 
3-Nitropropionic acid Cell Stress 84.3 
2,3-Dimethoxy-1,4-naphthoquinone Cell Stress 86.8 
(±)-Taxifolin Cell Stress 91.2 
(+)-Catechin Hydrate Cell Stress 95.5 
Morin Cell Stress 96.0 
Isoxanthopterin Cell Stress 99.0 
Astaxanthin Cell Stress 101.5 
(±)-alpha-Lipoic Acid Cell Stress 101.8 
U-74389G maleate Cell Stress 102.0 
Lonidamine Cell Stress 102.1 
Carcinine dihydrochloride Cell Stress 106.9 
Hypotaurine Cell Stress 107.5 
5,5-Dimethyl-1-pyrroline-N-oxide Cell Stress 109.1 
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Allopurinol Cell Stress 115.9 
Amifostine Cell Stress 124.7 
Caffeic Acid Cell Stress 130.0 
Proglumide Cholecystokinin 94.6 
CR 2945 Cholecystokinin 100.0 
Lorglumide sodium Cholecystokinin 113.3 
2-(alpha-Naphthoyl)ethyltrimethylammonium iodide Cholinergic 20.5 
MG 624 Cholinergic 38.7 
(-)-Eseroline fumarate Cholinergic 72.9 
N,N,N-trimethyl-1-(4-trans-stilbenoxy)-2-propylammonium 
iodide Cholinergic 78.6 
Pentolinium di[L(+)-tartrate] Cholinergic 79.5 
Atropine methyl bromide Cholinergic 82.9 
Telenzepine dihydrochloride Cholinergic 85.2 
L-Hyoscyamine Cholinergic 86.7 
(±)-Vesamicol hydrochloride Cholinergic 87.2 
Oxybutynin Chloride Cholinergic 87.5 
Decamethonium dibromide Cholinergic 90.5 
BW 284c51 Cholinergic 91.0 
Gallamine triethiodide Cholinergic 91.1 
Linopirdine Cholinergic 91.1 
Carbachol Cholinergic 91.7 
Neostigmine bromide Cholinergic 92.0 
Hemicholinium-3 Cholinergic 92.1 
(-)-Nicotine hydrogen tartrate salt Cholinergic 92.8 
Acetyl-beta-methylcholine chloride Cholinergic 93.7 
WB 64 Cholinergic 94.3 
Ivermectin Cholinergic 94.4 
(-)-Physostigmine Cholinergic 95.3 
(-)-Scopolamine,n-Butyl-, bromide Cholinergic 98.2 
Karakoline Cholinergic 98.3 
Pancuronium bromide Cholinergic 98.9 
Bethanechol chloride Cholinergic 98.9 
Mecamylamine hydrochloride Cholinergic 100.1 
Methylcarbamylcholine chloride Cholinergic 100.4 
Pilocarpine nitrate Cholinergic 100.4 
4-Diphenylacetoxy-N-(2-chloroethyl)piperidine 
hydrochloride Cholinergic 100.7 
Propantheline bromide Cholinergic 100.8 
(-)-Scopolamine methyl bromide Cholinergic 100.9 
Benztropine mesylate Cholinergic 101.4 
Tropicamide Cholinergic 101.8 
(+)-cis-Dioxolane iodide Cholinergic 102.0 
Dicyclomine hydrochloride Cholinergic 102.7 
Edrophonium chloride Cholinergic 103.1 
Pempidine tartrate Cholinergic 103.7 
4-DAMP methiodide Cholinergic 103.8 
Tetraethylammonium chloride Cholinergic 104.2 
Trihexyphenidyl hydrochloride Cholinergic 104.5 
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Pirenzepine dihydrochloride Cholinergic 105.6 
Methoctramine tetrahydrochloride Cholinergic 106.3 
Oxotremorine methiodide Cholinergic 106.3 
Oxotremorine sesquifumarate salt Cholinergic 106.8 
McN-A-343 Cholinergic 107.0 
Hydroxytacrine maleate Cholinergic 107.1 
Ipratropium bromide Cholinergic 107.3 
1,1-Dimethyl-4-phenyl-piperazinium iodide Cholinergic 107.9 
DBO-83 Cholinergic 108.5 
9-Amino-1,2,3,4-tetrahydroacridine hydrochloride Cholinergic 108.8 
(+)-Pilocarpine hydrochloride Cholinergic 109.4 
Orphenadrine hydrochloride Cholinergic 109.7 
Choline bromide Cholinergic 110.7 
Arecaidine propargyl ester hydrobromide Cholinergic 110.9 
alpha-Lobeline hydrochloride Cholinergic 111.0 
Propofol Cholinergic 111.2 
Arecoline hydrobromide Cholinergic 112.3 
Acetylthiocholine chloride Cholinergic 112.5 
Bromoacetylcholine bromide Cholinergic 113.1 
Hexamethonium dichloride Cholinergic 114.2 
(+)-Nicotine (+)-di-p-toluoyl tartrate Cholinergic 114.3 
Hexahydro-sila-difenidol hydrochloride, p-fluoro analog Cholinergic 115.1 
Dihydro-beta-erythroidine hydrobromide Cholinergic 116.1 
Aminobenztropine Cholinergic 116.2 
(-)-Scopolamine methyl nitrate Cholinergic 116.9 
Hexamethonium bromide Cholinergic 117.7 
(-)-Scopolamine hydrobromide Cholinergic 118.2 
OXA-22 iodide Cholinergic 119.4 
DL-Homatropine hydrobromide Cholinergic 120.5 
Pyridostigmine bromide Cholinergic 120.5 
(±)-Muscarine chloride Cholinergic 121.6 
(-)-Cotinine Cholinergic 126.4 
Betaine aldehyde chloride Cholinergic 127.4 
Succinylcholine chloride Cholinergic 135.5 
Atropine sulfate Cholinergic 136.5 
Atropine methyl nitrate Cholinergic 143.8 
5-Nitro-2-(3-phenylpropylamino)benzoic acid Cl- Channel 115.0 
N-Phenylanthranilic acid Cl- Channel 124.8 
R(+)-IAA-94 Cl- Channel 139.8 
Papaverine hydrochloride Cyclic Nucleotides 80.7 
Isoliquiritigenin Cyclic Nucleotides 81.1 
Milrinone Cyclic Nucleotides 87.4 
Protoporphyrin IX disodium Cyclic Nucleotides 88.5 
YC-1 Cyclic Nucleotides 91.9 
Forskolin Cyclic Nucleotides 93.7 
8-Bromo-cAMP sodium Cyclic Nucleotides 95.3 
Quercetin dihydrate Cyclic Nucleotides 96.0 
Trequinsin hydrochloride Cyclic Nucleotides 97.1 
SQ 22536 Cyclic Nucleotides 98.8 
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Na-p-Tosyl-L-lysine chloromethyl ketone hydrochloride Cyclic Nucleotides 99.3 
NS 2028 Cyclic Nucleotides 101.5 
ODQ Cyclic Nucleotides 101.7 
Ro 20-1724 Cyclic Nucleotides 104.0 
T-1032 Cyclic Nucleotides 104.1 
Pentoxifylline Cyclic Nucleotides 106.0 
Enoximone Cyclic Nucleotides 106.4 
Quazinone Cyclic Nucleotides 107.5 
T-0156 Cyclic Nucleotides 107.8 
Imazodan Cyclic Nucleotides 109.9 
Zardaverine Cyclic Nucleotides 110.8 
Cilostazol Cyclic Nucleotides 112.2 
Rolipram Cyclic Nucleotides 112.8 
Vinpocetine Cyclic Nucleotides 113.0 
8-(4-Chlorophenylthio)-cAMP sodium Cyclic Nucleotides 116.0 
Zaprinast Cyclic Nucleotides 117.0 
8-Methoxymethyl-3-isobutyl-1-methylxanthine Cyclic Nucleotides 119.7 
8-Bromo-cGMP sodium Cyclic Nucleotides 120.3 
Cilostamide Cyclic Nucleotides 128.1 
9-cyclopentyladenine Cyclic Nucleotides 130.0 
Ibudilast Cyclic Nucleotides 151.9 
CV-3988 Cytokines & Growth Factors 113.4 
Brefeldin A from Penicillium brefeldianum Cytoskeleton and ECM 22.3 
Vincristine sulfate Cytoskeleton and ECM 41.1 
Podophyllotoxin Cytoskeleton and ECM 42.5 
Colchicine Cytoskeleton and ECM 46.8 
Vinblastine sulfate salt Cytoskeleton and ECM 48.2 
Taxol Cytoskeleton and ECM 63.5 
(±)-Thalidomide Cytoskeleton and ECM 81.7 
Nocodazole Cytoskeleton and ECM 82.3 
2,3-Butanedione Cytoskeleton and ECM 104.9 
Clodronic acid Cytoskeleton and ECM 122.3 
Chlorambucil DNA 89.9 
Nimustine hydrochloride DNA 92.9 
Cisplatin DNA 97.1 
Phosphonoacetic acid DNA 101.5 
Carmustine DNA 108.1 
CB 1954 DNA 116.8 
Chloroquine diphosphate DNA 117.3 
Cyclophosphamide monohydrate DNA 122.0 
Carboplatin DNA 139.4 
Melphalan DNA Metabolism 41.3 
Mitoxantrone DNA Metabolism 43.0 
Idarubicin DNA Metabolism 49.8 
Cytosine-1-beta-D-arabinofuranoside hydrochloride DNA Metabolism 65.9 
5-azacytidine DNA Metabolism 72.0 
(-)Amethopterin DNA Metabolism 84.8 
Ancitabine hydrochloride DNA Metabolism 86.2 
Methotrexate DNA Metabolism 87.2 
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Hydroxyurea DNA Metabolism 91.5 
5-fluoro-5 -deoxyuridine DNA Metabolism 94.3 
Altretamine DNA Metabolism 94.9 
Mizoribine DNA Metabolism 110.0 
5-Bromo-2 -deoxyuridine DNA Metabolism 111.9 
Azelaic acid DNA Metabolism 119.7 
Amsacrine hydrochloride DNA Repair 7.0 
p-Benzoquinone DNA Repair 100.4 
O6-benzylguanine DNA Repair 108.0 
Apomorphine hydrochloride hemihydrate Dopamine 42.3 
3-Phenylpropargylamine hydrochloride Dopamine 44.5 
R(-)-Propylnorapomorphine hydrochloride Dopamine 52.2 
SKF 89626 Dopamine 61.3 
L-750,667 trihydrochloride Dopamine 73.2 
LE 300 Dopamine 73.8 
R(-)-N-Allylnorapomorphine hydrobromide Dopamine 74.9 
Dopamine hydrochloride Dopamine 75.2 
Indatraline hydrochloride Dopamine 77.8 
N-(p-Isothiocyanatophenethyl)spiperone hydrochloride Dopamine 78.1 
Loxapine succinate Dopamine 79.0 
Dihydrexidine hydrochloride Dopamine 79.3 
Thiothixene hydrochloride Dopamine 80.3 
Tiapride hydrochloride Dopamine 80.5 
Methylergonovine maleate Dopamine 82.0 
R(-)-2,10,11-Trihydroxyaporphine hybrobromide Dopamine 82.2 
Pimozide Dopamine 84.6 
Promazine hydrochloride Dopamine 86.0 
L-741,626 Dopamine 87.6 
4-Hydroxy-3-methoxyphenylacetic acid Dopamine 87.6 
Dihydroergocristine methanesulfonate Dopamine 87.6 
3-Methoxy-4-hydroxyphenethylamine hydrochloride Dopamine 87.8 
SKF 83565 hydrobromide Dopamine 88.0 
(±)-Chloro-APB hydrobromide Dopamine 88.2 
Metoclopramide hydrochloride Dopamine 89.9 
GBR-12935 dihydrochloride Dopamine 90.6 
JL-18 Dopamine 91.3 
A-77636 hydrochloride Dopamine 91.9 
R(+)-Terguride Dopamine 92.5 
R(-)-2,10,11-Trihydroxy-N-propylnoraporphine 
hydrobromide Dopamine 92.6 
1-Phenyl-3-(2-thiazolyl)-2-thiourea Dopamine 94.4 
4 -Chloro-3-alpha-(diphenylmethoxy)tropane 
hydrochloride Dopamine 94.8 
Fluphenazine dihydrochloride Dopamine 95.1 
Haloperidol Dopamine 95.2 
1-(4-Hydroxybenzyl)imidazole-2-thiol Dopamine 95.4 
BP 897 Dopamine 96.0 
(±)-Sulpiride Dopamine 96.2 
SKF 75670 hydrobromide Dopamine 96.3 
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(±)-Quinpirole dihydrochloride Dopamine 96.4 
Perphenazine Dopamine 96.7 
R(-)-Apocodeine hydrochloride Dopamine 97.0 
L-745,870 hydrochloride Dopamine 97.8 
cis-(±)-8-OH-PBZI hydrobromide Dopamine 97.9 
Fusaric acid Dopamine 98.7 
(+)-Butaclamol hydrochloride Dopamine 99.0 
Domperidone Dopamine 99.1 
R(+)-6-Bromo-APB hydrobromide Dopamine 99.3 
N-Methyldopamine hydrochloride Dopamine 99.3 
R-(+)-7-Hydroxy-DPAT hydrobromide Dopamine 99.4 
Propionylpromazine hydrochloride Dopamine 99.5 
Chlorpromazine hydrochloride Dopamine 99.7 
4-Hydroxyphenethylamine hydrochloride Dopamine 100.1 
Fenoldopam bromide Dopamine 101.5 
Prochlorperazine dimaleate Dopamine 101.5 
4-Methoxy-3-hydroxyphenethylamine hydrochloride Dopamine 101.7 
BTCP hydrochloride Dopamine 101.9 
Triflupromazine hydrochloride Dopamine 102.5 
S-(-)-Eticlopride hydrochloride Dopamine 102.7 
Thioridazine hydrochloride Dopamine 103.2 
R(+)-SCH-23390 hydrochloride Dopamine 103.5 
(-)-Sulpiride Dopamine 103.8 
cis-(Z)-Flupenthixol dihydrochloride Dopamine 104.4 
Amantadine hydrochloride Dopamine 104.6 
GYKI 52895 Dopamine 104.8 
L-3,4-Dihydroxyphenylalanine Dopamine 105.1 
Ropinirole hydrochloride Dopamine 105.1 
Spiperone hydrochloride Dopamine 105.3 
(±)-SKF 38393, N-allyl-, hydrobromide Dopamine 105.3 
S(-)-IBZM Dopamine 105.6 
SKF 83959 hydrobromide Dopamine 105.8 
Fluspirilene Dopamine 106.0 
S(-)-DS 121 hydrochloride Dopamine 106.4 
PD 168,077 maleate Dopamine 107.0 
U-99194A maleate Dopamine 107.1 
R(+)-3PPP hydrochloride Dopamine 107.3 
(+)-Bromocriptine methanesulfonate Dopamine 107.7 
S(+)-Raclopride L-tartrate Dopamine 108.0 
Cortexolone maleate Dopamine 108.4 
L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride Dopamine 108.9 
N-Acetyldopamine monohydrate Dopamine 109.6 
S(-)-3PPP hydrochloride Dopamine 110.1 
Piribedil maleate Dopamine 110.3 
R(+)-Lisuride hydrogen maleate Dopamine 110.3 
Chlorprothixene hydrochloride Dopamine 110.4 
S-(-)-Lisuride Dopamine 110.9 
N-(2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl)-3-
methoxybenzamide Dopamine 111.1 
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(±)-7-Hydroxy-DPAT hydrobromide Dopamine 111.4 
(±)-PD 128,907 hydrochloride Dopamine 111.4 
Trifluoperazine dihydrochloride Dopamine 111.7 
R(-)-SCH-12679 maleate Dopamine 112.4 
(±)-6-Chloro-PB hydrobromide Dopamine 112.9 
Risperidone Dopamine 112.9 
Mesulergine hydrochloride Dopamine 113.1 
Bupropion hydrochloride Dopamine 113.5 
Quinelorane dihydrochloride Dopamine 113.6 
Droperidol Dopamine 113.7 
(±)-Octoclothepin maleate Dopamine 114.0 
(±)-PPHT hydrochloride Dopamine 114.3 
6,7-ADTN hydrobromide Dopamine 115.6 
Amfonelic acid Dopamine 116.6 
Ergocristine Dopamine 116.7 
U-101958 maleate Dopamine 116.8 
(±)-SKF-38393 hydrochloride Dopamine 117.9 
GBR-12909 dihydrochloride Dopamine 118.9 
Nomifensine maleate Dopamine 120.1 
Pergolide methanesulfonate Dopamine 121.2 
(±)-Butaclamol hydrochloride Dopamine 121.3 
S(+)-PD 128,907 hydrochloride Dopamine 121.4 
(-)-Quinpirole hydrochloride Dopamine 121.4 
Dipropyldopamine hydrobromide Dopamine 121.8 
Trifluperidol hydrochloride Dopamine 124.7 
3,4-Dihydroxyphenylacetic acid Dopamine 127.0 
Clozapine Dopamine 128.2 
Agroclavine Dopamine 130.6 
Farnesylthiosalicylic acid G protein 77.9 
(-)-Perillic acid G protein 100.8 
SCH-202676 hydrobromide G protein 107.9 
NF449 octasodium salt G protein 126.7 
TPMPA GABA 74.2 
GABA GABA 86.3 
Picrotoxin GABA 89.8 
Isoguvacine hydrochloride GABA 90.4 
(±)-Baclofen GABA 92.1 
CGP-13501 GABA 93.0 
3-Amino-1-propanesulfonic acid sodium GABA 93.7 
Gabaculine hydrochloride GABA 93.9 
NCS-356 GABA 94.2 
3-alpha,21-Dihydroxy-5-alpha-pregnan-20-one GABA 94.5 
NCS-382 GABA 94.9 
(+)-Hydrastine GABA 95.8 
3-Aminopropylphosphonic acid GABA 96.9 
THIP hydrochloride GABA 97.5 
Dehydroisoandrosterone 3-sulfate sodium GABA 98.5 
Muscimol hydrobromide GABA 99.2 
NO-711 hydrochloride GABA 99.3 
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(-)-Bicuculline methbromide, 1(S), 9(R) GABA 99.9 
SB 205384 GABA 101.1 
Guvacine hydrochloride GABA 101.9 
5alpha-Pregnan-3alpha-ol-20-one GABA 103.0 
(±)-gamma-Vinyl GABA GABA 103.5 
(E)-4-amino-2-butenoic acid GABA 105.9 
Pregnenolone sulfate sodium GABA 106.3 
N-Methyl-beta-carboline-3-carboxamide GABA 107.0 
Piperidine-4-sulphonic acid GABA 110.7 
SKF 89976A hydrochloride GABA 111.3 
Isonipecotic acid GABA 112.8 
CGP-7930 GABA 114.0 
5alpha-Pregnan-3alpha-ol-11,20-dione GABA 116.7 
5-Aminovaleric acid hydrochloride GABA 117.9 
2-Hydroxysaclofen GABA 119.9 
Phaclofen GABA 120.7 
Tracazolate GABA 122.4 
gamma-Acetylinic GABA GABA 122.6 
Imidazole-4-acetic acid hydrochloride GABA 123.3 
(±)-Nipecotic acid GABA 124.6 
SR-95531 GABA 127.0 
cis-4-Aminocrotonic acid GABA 132.4 
PK 11195 GABA 132.7 
SKF 97541 hydrochloride GABA 135.6 
Sobuzoxane Gene Regulation 96.2 
Spermidine trihydrochloride Glutamate 24.5 
SIB 1757 Glutamate 72.2 
Kainic acid Glutamate 73.0 
Eliprodil Glutamate 80.0 
Aniracetam Glutamate 83.9 
DNQX Glutamate 85.4 
Cyclothiazide Glutamate 87.8 
Ifenprodil tartrate Glutamate 88.1 
(±)-2-Amino-3-phosphonopropionic acid Glutamate 91.4 
Pentamidine isethionate Glutamate 92.3 
(±)-HA-966 Glutamate 94.2 
Dihydrokainic acid Glutamate 94.5 
D-Cycloserine Glutamate 95.4 
(±)-CPP Glutamate 96.2 
trans-(±)-ACPD Glutamate 97.0 
2,6-Difluoro-4-[2-
(phenylsulfonylamino)ethylthio]phenoxyacetamide Glutamate 97.1 
L-Glutamic acid, N-phthaloyl- Glutamate 97.4 
(2S,1 S,2 S)-2-(carboxycyclopropyl)glycine Glutamate 98.0 
CR 2249 Glutamate 98.3 
GYKI 52466 hydrochloride Glutamate 98.3 
(-)-MK-801 hydrogen maleate Glutamate 98.3 
CX 546 Glutamate 98.6 
(±)-Ibotenic acid Glutamate 100.3 
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Piracetam Glutamate 100.4 
6,7-Dichloroquinoxaline-2,3-dione Glutamate 100.8 
L-701,324 Glutamate 100.8 
SIB 1893 Glutamate 101.8 
NS 521 oxalate Glutamate 101.8 
NBQX disodium Glutamate 102.8 
(+)-Quisqualic acid Glutamate 102.8 
Flupirtine maleate Glutamate 103.0 
(S)-3,5-Dihydroxyphenylglycine Glutamate 103.6 
N-Methyl-D-aspartic acid Glutamate 103.8 
(±)-AMPA hydrobromide Glutamate 103.9 
trans-Azetidine-2,4-dicarboxylic acid Glutamate 104.1 
Quinolinic acid Glutamate 104.1 
Dextromethorphan hydrobromide monohydrate Glutamate 104.3 
(±)-2-Amino-4-phosphonobutyric acid Glutamate 104.3 
S(-)-Willardiine Glutamate 104.4 
3-Methoxy-morphanin hydrochloride Glutamate 105.2 
MDL 105,519 Glutamate 105.9 
Kynurenic acid Glutamate 106.0 
CNQX disodium Glutamate 106.4 
ATPO Glutamate 106.9 
S-5-Iodowillardiine Glutamate 107.3 
IEM-1460 Glutamate 107.3 
gamma-D-Glutamylaminomethylsulfonic acid Glutamate 107.5 
N-(3,3-Diphenylpropyl)glycinamide Glutamate 108.1 
6-Methyl-2-(phenylethynyl)pyridine hydrochloride Glutamate 108.1 
O-Phospho-L-serine Glutamate 108.3 
DL-threo-beta-hydroxyaspartic acid Glutamate 108.7 
Spermine tetrahydrochloride Glutamate 108.7 
L-Methionine sulfoximine Glutamate 110.6 
5-Fluoroindole-2-carboxylic acid Glutamate 110.6 
(+)-MK-801 hydrogen maleate Glutamate 110.6 
Phthalamoyl-L-glutamic acid trisodium Glutamate 111.1 
L-Glutamine Glutamate 111.4 
Memantine hydrochloride Glutamate 111.6 
(±)-2-Amino-5-phosphonopentanoic acid Glutamate 112.0 
7-Chlorokynurenic acid Glutamate 112.1 
(S)-MAP4 hydrochloride Glutamate 112.7 
Cystamine dihydrochloride Glutamate 113.0 
N-Acetyl-L-Cysteine Glutamate 113.2 
Ro 8-4304 Glutamate 114.3 
L-2-aminoadipic acid Glutamate 114.6 
MDL 26,630 trihydrochloride Glutamate 115.9 
D(-)-2-Amino-7-phosphonoheptanoic acid Glutamate 116.0 
L-Cysteinesulfinic Acid Glutamate 116.3 
L-Aspartic acid Glutamate 118.0 
(±)-cis-Piperidine-2,3-dicarboxylic acid Glutamate 118.2 
(±)-2-Amino-7-phosphonoheptanoic acid Glutamate 118.5 
(±)-alpha-Methyl-4-carboxyphenylglycine Glutamate 118.6 
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Felbamate Glutamate 119.8 
CNS-1102 Glutamate 120.1 
AIDA Glutamate 121.0 
ATPA Glutamate 121.3 
Dextrorphan D-tartrate Glutamate 122.3 
5,7-Dichlorokynurenic acid Glutamate 122.9 
Putrescine dihydrochloride Glutamate 126.0 
1-Aminocyclopropanecarboxylic acid hydrochloride Glutamate 127.7 
L-Glutamic acid hydrochloride Glutamate 128.6 
CPCCOEt Glutamate 131.2 
Riluzole Glutamate 131.5 
1,10-Diaminodecane Glutamate 132.3 
D-Serine Glutamate 134.8 
Chelidamic acid Glutamate 136.8 
Arcaine sulfate Glutamate 141.8 
Ro 25-6981 hydrochloride Glutamate 151.6 
cis-Azetidine-2,4-dicarboxylic acid Glutamate 152.6 
Taurine Glycine 87.7 
Phenylbenzene-omega-phosphono-alpha-amino acid Glycine 147.5 
Clemastine fumarate Histamine 77.4 
Terfenadine Histamine 86.1 
Fexofenadine hydrochloride Histamine 87.9 
Pheniramine maleate Histamine 88.6 
Doxylamine succinate Histamine 90.0 
Promethazine hydrochloride Histamine 90.8 
(+)-Brompheniramine maleate Histamine 92.7 
Diphenhydramine hydrochloride Histamine 98.3 
L-Histidine hydrochloride Histamine 98.4 
Cimetidine Histamine 98.6 
Famotidine Histamine 99.0 
Ketotifen fumarate Histamine 99.8 
Clemizole hydrochloride Histamine 100.6 
Methapyrilene hydrochloride Histamine 100.8 
1-Methylhistamine dihydrochloride Histamine 101.4 
4-Imidazolemethanol hydrochloride Histamine 101.8 
(±)-Chlorpheniramine maleate Histamine 102.6 
Histamine dihydrochloride Histamine 103.1 
SKF 95282 dimaleate Histamine 103.2 
Pyrilamine maleate Histamine 104.0 
Loratadine Histamine 105.3 
4-Imidazoleacrylic acid Histamine 107.0 
3-(1H-Imidazol-4-yl)propyl di(p-fluorophenyl)methyl ether 
hydrochloride Histamine 107.0 
(+)-Chlorpheniramine maleate Histamine 107.1 
Thioperamide maleate Histamine 107.4 
Imetit dihydrobromide Histamine 108.3 
Triprolidine hydrochloride Histamine 111.9 
(±)-Brompheniramine maleate Histamine 114.0 
SKF 91488 dihydrochloride Histamine 116.5 
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Histamine, R(-)-alpha-methyl-, dihydrochloride Histamine 127.8 
Ranitidine hydrochloride Histamine 149.3 
2-methoxyestradiol Hormone 52.0 
Cortexolone Hormone 63.4 
Raloxifene hydrochloride Hormone 79.3 
Danazol Hormone 84.5 
Nilutamide Hormone 94.2 
Beclomethasone Hormone 95.1 
Hydrocortisone Hormone 95.1 
Flutamide Hormone 98.9 
4-Androstene-3,17-dione Hormone 99.4 
(R,R)-cis-Diethyl tetrahydro-2,8-chrysenediol Hormone 99.6 
Progesterone Hormone 99.8 
Corticosterone Hormone 102.0 
4-Androsten-4-ol-3,17-dione Hormone 102.8 
5alpha-Androstane-3alpha,17beta-diol Hormone 103.2 
Androsterone Hormone 103.9 
Estrone Hormone 104.7 
17alpha-hydroxyprogesterone Hormone 105.4 
Triamcinolone Hormone 106.2 
Cortisone 21-acetate Hormone 107.1 
trans-Dehydroandrosterone Hormone 107.6 
Cyproterone acetate Hormone 108.0 
Budesonide Hormone 108.7 
Mifepristone Hormone 108.9 
Tolazamide Hormone 109.8 
Acetohexamide Hormone 110.3 
Chlorpropamide Hormone 110.6 
beta-Estradiol Hormone 111.2 
Hydrocortisone 21-hemisuccinate sodium Hormone 112.5 
1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane Hormone 113.2 
Cortisone Hormone 113.4 
1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole Hormone 115.5 
Spironolactone Hormone 118.4 
Betamethasone Hormone 121.7 
Tolbutamide Hormone 122.9 
Idazoxan hydrochloride Imidazoline 67.9 
Antozoline hydrochloride Imidazoline 86.7 
BU99006 Imidazoline 95.9 
Metrazoline oxalate Imidazoline 100.5 
Benazoline oxalate Imidazoline 104.7 
Rilmenidine hemifumarate Imidazoline 109.1 
Agmatine sulfate Imidazoline 117.8 
Harmane Imidazoline 117.8 
AGN 192403 hydrochloride Imidazoline 133.9 
BU224 hydrochloride Imidazoline 138.3 
Efaroxan hydrochloride Imidazoline  107.3 
Leflunomide Immune System 77.3 
3 -Azido-3 -deoxythymidine Immune System 79.4 
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Pirfenidone Immune System 90.1 
6-Aminohexanoic acid Immune System 102.4 
Oxatomide Immune System 104.8 
Amiprilose hydrochloride Immune System 105.6 
3-deazaadenosine Immune System 106.3 
2 ,3 -didehydro-3 -deoxythymidine Immune System 106.9 
(E)-5-(2-Bromovinyl)-2 -deoxyuridine Immune System 111.0 
Acyclovir Immune System 131.3 
2 ,3 -dideoxycytidine Immune System 133.5 
Calmidazolium chloride Intracellular Calcium 3.5 
Calcimycin Intracellular Calcium 35.9 
Thapsigargin Intracellular Calcium 45.8 
N-(4-Aminobutyl)-5-chloro-2-naphthalenesulfonamide 
hydrochloride Intracellular Calcium 95.0 
W-7 hydrochloride Intracellular Calcium 96.4 
Thio-NADP sodium Intracellular Calcium 98.8 
Dantrolene sodium Intracellular Calcium 113.0 
TMB-8 hydrochloride Intracellular Calcium 135.4 
SCH-28080 Ion Channels 116.6 
Sanguinarine chloride Ion Pump 3.2 
Dihydroouabain Ion Pump 38.0 
Ouabain Ion Pump 46.1 
5-(N-Ethyl-N-isopropyl)amiloride Ion Pump 69.2 
5-(N,N-Dimethyl)amiloride hydrochloride Ion Pump 80.0 
Ruthenium red Ion Pump 90.0 
Benzamil hydrochloride Ion Pump 97.4 
Metolazone Ion Pump 98.4 
3 ,4 -Dichlorobenzamil Ion Pump 98.6 
Lansoprazole Ion Pump 98.7 
Furosemide Ion Pump 98.8 
R(+)-Butylindazone Ion Pump 108.5 
Bumetanide Ion Pump 111.3 
5-(N,N-hexamethylene)amiloride Ion Pump 114.5 
5-(N-Methyl-N-isobutyl)amiloride Ion Pump 128.5 
Flunarizine dihydrochloride Ion Pump 132.3 
Disopyramide phosphate K+ Channel 20.9 
Dequalinium dichloride K+ Channel 39.1 
Rutaecarpine K+ Channel 81.4 
IMID-4F hydrochloride K+ Channel 81.9 
Propafenone hydrochloride K+ Channel 86.2 
2,3-Butanedione monoxime K+ Channel 87.4 
Quinine sulfate K+ Channel 99.0 
NS-1619 K+ Channel 99.2 
PNU-37887A K+ Channel 101.8 
Clotrimazole K+ Channel 104.2 
4-Aminopyridine K+ Channel 105.3 
Glipizide K+ Channel 105.5 
Pinacidil K+ Channel 106.4 
5-hydroxydecanoic acid sodium K+ Channel 109.9 
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Minoxidil K+ Channel 110.9 
Glibenclamide K+ Channel 112.4 
DCEBIO K+ Channel 113.0 
Psora-4 K+ Channel 118.0 
Diazoxide K+ Channel 126.3 
Hydroquinone Leukotriene 73.6 
Nordihydroguaiaretic acid from Larrea divaricata (creosote 
bush) Leukotriene 81.0 
Ebselen Leukotriene 84.7 
U-75302 Leukotriene 93.6 
SR 2640 Leukotriene 98.0 
AA-861 Leukotriene 99.8 
MK-886 Leukotriene 114.3 
Tranilast Leukotriene 115.1 
REV 5901 Leukotriene 119.9 
BWB70C Leukotriene 132.3 
U-73122 Lipid 73.1 
Sandoz 58-035 Lipid 87.2 
Clofibrate Lipid 99.6 
Bromoenol lactone Lipid 104.0 
MJ33 Lipid 106.3 
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid Lipid 111.6 
D-609 potassium Lipid 112.7 
Citicoline sodium Lipid 114.1 
Ranolazine dihydrochloride Lipid 115.3 
ET-18-OCH3 Lipid 138.9 
L-165,041 Lipid Signaling 109.1 
(Z)-Gugglesterone Lipid Signaling 123.8 
Melatonin Melatonin 85.8 
2-Iodomelatonin Melatonin 90.1 
6-Chloromelatonin Melatonin 97.2 
IIK7 Melatonin 98.8 
N-Acetyltryptamine Melatonin 107.6 
N-Acetyl-5-hydroxytryptamine Melatonin 107.9 
K 185 Melatonin 110.3 
6-Hydroxymelatonin Melatonin 124.7 
1-(4-Chlorobenzyl)-5-methoxy-2-methylindole-3-acetic acid Multi-Drug Resistance 78.1 
Sulfaphenazole Multi-Drug Resistance 85.3 
1-(4-Fluorobenzyl)-5-methoxy-2-methylindole-3-acetic acid Multi-Drug Resistance 95.0 
3-Aminopropionitrile fumarate Multi-Drug Resistance 95.9 
SKF-525A hydrochloride Multi-Drug Resistance 96.1 
Sodium Taurocholate Multi-Drug Resistance 103.2 
L-Buthionine-sulfoximine Multi-Drug Resistance 109.9 
Ketoconazole Multi-Drug Resistance 110.3 
1-benzoyl-5-methoxy-2-methylindole-3-acetic acid Multi-Drug Resistance 113.4 
S-(p-Azidophenacyl)glutathione Multi-Drug Resistance 113.7 
DL-Buthionine-[S,R]-sulfoximine Multi-Drug Resistance 116.2 
1-Aminobenzotriazole Multi-Drug Resistance 126.9 
Lidocaine hydrochloride Na+ Channel 85.9 
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N-Acetylprocainamide hydrochloride Na+ Channel 86.0 
Lidocaine N-ethyl bromide quaternary salt Na+ Channel 93.5 
Mexiletene hydrochloride Na+ Channel 94.8 
Lidocaine N-methyl hydrochloride Na+ Channel 95.8 
Flecainide acetate Na+ Channel 95.9 
N-Bromoacetamide Na+ Channel 96.9 
Quinidine sulfate Na+ Channel 97.3 
Triamterene Na+ Channel 97.9 
Procainamide hydrochloride Na+ Channel 101.2 
Tetracaine hydrochloride Na+ Channel 101.6 
Procaine hydrochloride Na+ Channel 106.0 
Prilocaine hydrochloride Na+ Channel 110.3 
R(-)-Me5 Na+ Channel 112.7 
Phenamil methanesulfonate Na+ Channel 113.8 
Disopyramide Na+ Channel 114.3 
Amiloride hydrochloride Na+ Channel 128.3 
Quinacrine dihydrochloride Neurotransmission 5.0 
N-Oleoyldopamine Neurotransmission 30.4 
1-Amino-1-cyclohexanecarboxylic acid hydrochloride Neurotransmission 82.2 
Phenelzine sulfate Neurotransmission 86.3 
Clorgyline hydrochloride Neurotransmission 87.5 
L-162,313 Neurotransmission 88.4 
Carisoprodol Neurotransmission 90.1 
NBI 27914 Neurotransmission 93.1 
3-Iodo-L-tyrosine Neurotransmission 93.8 
R-(-)-Desmethyldeprenyl hydrochloride Neurotransmission 96.9 
DL-alpha-Methyl-p-tyrosine Neurotransmission 97.6 
Iproniazid phosphate Neurotransmission 98.5 
Tranylcypromine hydrochloride Neurotransmission 101.1 
DL-Thiorphan Neurotransmission 102.5 
6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4b] indole Neurotransmission 103.1 
DL-p-Chlorophenylalanine methyl ester hydrochloride Neurotransmission 103.6 
Nialamide Neurotransmission 104.0 
(-)-cis-(1S,2R)-U-50488 tartrate Neurotransmission 104.3 
Icilin Neurotransmission 104.9 
Ro 16-6491 hydrochloride Neurotransmission 104.9 
(±)-3-(3,4-dihydroxyphenyl)-2-methyl-DL-alanine Neurotransmission 105.9 
Chlormezanone Neurotransmission 107.1 
3,5-Dinitrocatechol Neurotransmission 107.2 
Pentylenetetrazole Neurotransmission 107.3 
R-(-)-Deprenyl hydrochloride Neurotransmission 107.7 
(±)-2,3-Dichloro-alpha-methylbenzylamine hydrochloride Neurotransmission 109.1 
N-Succinyl-L-proline Neurotransmission 109.2 
SB 218795 Neurotransmission 110.3 
alpha-Methyl-DL-tyrosine methyl ester hydrochloride Neurotransmission 110.6 
Ro 41-1049 hydrochloride Neurotransmission 110.7 
L-368,899 Neurotransmission 110.9 
(6R)-5,6,7,8-Tetrahydro-L-biopterin hydrochloride Neurotransmission 111.3 
Hydroxylamine hydrochloride Neurotransmission 111.6 
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Hydralazine hydrochloride Neurotransmission 111.9 
Captopril Neurotransmission 113.3 
Semicarbazide hydrochloride Neurotransmission 113.7 
Lithium Chloride Neurotransmission 115.1 
p-Fluoro-L-phenylalanine Neurotransmission 115.5 
Pargyline hydrochloride Neurotransmission 117.4 
Ro 41-0960 Neurotransmission 118.5 
L-alpha-Methyl-p-tyrosine Neurotransmission 121.1 
Iofetamine hydrochloride Neurotransmission 121.6 
BRL 52537 hydrochloride Neurotransmission 125.6 
Debrisoquin sulfate Neurotransmission 126.0 
2-Cyclooctyl-2-hydroxyethylamine hydrochloride Neurotransmission 126.7 
(±)-p-Chlorophenylalanine Neurotransmission 133.8 
Diphenyleneiodonium chloride Nitric Oxide 23.4 
Ammonium pyrrolidinedithiocarbamate Nitric Oxide 46.7 
4-Phenyl-3-furoxancarbonitrile Nitric Oxide 59.5 
Thiocitrulline Nitric Oxide 80.3 
NG-Nitro-L-arginine Nitric Oxide 83.6 
S-Nitrosoglutathione Nitric Oxide 87.4 
L-N5-(1-Iminoethyl)ornithine hydrochloride Nitric Oxide 92.0 
L-Canavanine sulfate Nitric Oxide 94.7 
1400W dihydrochloride Nitric Oxide 95.3 
Chlorzoxazone Nitric Oxide 97.5 
L-Arginine Nitric Oxide 99.6 
alpha-Guanidinoglutaric acid Nitric Oxide 101.2 
NG-Nitro-L-arginine methyl ester hydrochloride Nitric Oxide 102.3 
1,4-PBIT dihydrobromide Nitric Oxide 102.6 
1-[2-(Trifluoromethyl)phenyl]imidazole Nitric Oxide 102.8 
Aminoguanidine hydrochloride Nitric Oxide 104.0 
7-Nitroindazole Nitric Oxide 104.2 
(±)-AMT hydrochloride Nitric Oxide 104.4 
N^G,N^G-Dimethylarginine hydrochloride Nitric Oxide 104.6 
1,3-PBIT dihydrobromide Nitric Oxide 105.0 
L-N6-(1-Iminoethyl)lysine hydrochloride Nitric Oxide 105.8 
Sepiapterin Nitric Oxide 106.2 
TFPI hydrochloride Nitric Oxide 106.4 
3-Bromo-7-nitroindazole Nitric Oxide 106.7 
NG-Monomethyl-L-arginine acetate Nitric Oxide 107.8 
Sodium nitroprusside dihydrate Nitric Oxide 109.5 
S-Nitroso-N-acetylpenicillamine Nitric Oxide 109.7 
S-Methyl-L-thiocitrulline acetate Nitric Oxide 109.9 
NG-Hydroxy-L-arginine acetate Nitric Oxide 110.9 
NADPH tetrasodium Nitric Oxide 112.2 
Aminoguanidine hemisulfate Nitric Oxide 112.8 
Molsidomine Nitric Oxide 114.4 
S-Ethylisothiourea hydrobromide Nitric Oxide 114.5 
3-Morpholinosydnonimine hydrochloride Nitric Oxide 117.7 
Guanidinoethyl disulfide dihydrobromide Nitric Oxide 119.2 
2-(2-Aminoethyl)isothiourea dihydrobromide Nitric Oxide 125.5 
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S-Methylisothiourea hemisulfate Nitric Oxide 129.5 
DM 235 Nootropic 102.2 
Oxiracetam Nootropic 108.5 
Centrophenoxine hydrochloride Nootropic 133.0 
L-687,384 hydrochloride Opioid 85.6 
Loperamide hydrochloride Opioid 88.5 
Naloxone hydrochloride Opioid 89.5 
Guanidinyl-naltrindole di-trifluoroacetate Opioid 92.7 
(-)-trans-(1S,2S)-U-50488 hydrochloride Opioid 94.2 
Nalbuphine hydrochloride Opioid 94.4 
Levallorphan tartrate Opioid 94.7 
Naloxonazine dihydrochloride Opioid 95.0 
(+)-Cyclazocine Opioid 96.6 
(±)-N-Allylnormetazocine hydrochloride Opioid 96.8 
(+)-N-Allylnormetazocine hydrochloride Opioid 96.9 
Naloxone benzoylhydrazone Opioid 97.6 
U-69593 Opioid 97.7 
Naltriben methanesulfonate Opioid 98.3 
AC 915 oxalate Opioid 98.5 
nor-Binaltorphimine dihydrochloride Opioid 98.9 
(+)-trans-(1R,2R)-U-50488 hydrochloride Opioid 99.3 
PRE-084 Opioid 102.4 
ICI 204,448 hydrochloride Opioid 103.8 
(±) trans-U-50488 methanesulfonate Opioid 105.8 
Naltrexone hydrochloride Opioid 106.1 
SNC80 Opioid 107.9 
Naltrindole hydrochloride Opioid 112.3 
Carbetapentane citrate Opioid 113.5 
Metaphit methanesulfonate Opioid 113.6 
U-62066 Opioid 113.7 
Noscapine hydrchloride Opioid 117.3 
(-)-3-Methoxynaltrexone hydrochloride Opioid 117.9 
GR-89696 fumarate Opioid 118.1 
2-Chloroadenosine triphosphate tetrasodium P2 Receptor 88.5 
PPADS P2 Receptor 97.3 
MRS 2159 P2 Receptor 97.4 
Azathioprine P2 Receptor 99.8 
PPNDS tetrasodium P2 Receptor 100.0 
MRS 2179 P2 Receptor 102.8 
Uridine 5 -diphosphate sodium P2 Receptor 104.7 
Reactive Blue 2 P2 Receptor 106.4 
alpha,beta-Methylene adenosine 5 -triphosphate dilithium P2 Receptor 107.7 
NF 023 P2 Receptor 107.8 
2-Methylthioadenosine triphosphate tetrasodium P2 Receptor 108.1 
2-Methylthioadenosine diphosphate trisodium P2 Receptor 115.2 
ARL 67156 trisodium salt P2 Receptor 116.0 
Suramin hexasodium P2 Receptor 119.1 
BRL 50481  Phosphodiesterase 100.2 
Dequalinium analog, C-14 linker Phosphorylation 3.2 
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NSC 95397 Phosphorylation 3.4 
Chelerythrine chloride Phosphorylation 3.5 
ZM 39923 hydrochloride Phosphorylation 13.0 
CGP-74514A hydrochloride Phosphorylation 23.8 
Tyrphostin A9 Phosphorylation 27.9 
Rottlerin Phosphorylation 32.0 
Tyrphostin AG 879 Phosphorylation 34.8 
Cantharidin Phosphorylation 40.3 
Cantharidic Acid Phosphorylation 42.3 
Myricetin Phosphorylation 50.5 
Tyrphostin AG 808 Phosphorylation 62.4 
Tyrphostin AG 555 Phosphorylation 62.6 
IC 261 Phosphorylation 66.0 
rac-2-Ethoxy-3-octadecanamido-1-propylphosphocholine Phosphorylation 66.2 
SU 6656 Phosphorylation 66.7 
Tyrphostin AG 835 Phosphorylation 73.0 
Purvalanol A Phosphorylation 74.4 
Kenpaullone Phosphorylation 75.7 
Emodin Phosphorylation 84.2 
U0126 Phosphorylation 84.6 
Tyrphostin 47 Phosphorylation 85.6 
2,6-Diamino-4-pyrimidinone Phosphorylation 86.0 
Piceatannol Phosphorylation 86.6 
Palmitoyl-DL-Carnitine chloride Phosphorylation 86.7 
rac-2-Ethoxy-3-hexadecanamido-1-propylphosphocholine Phosphorylation 86.9 
Tyrphostin 25 Phosphorylation 87.0 
Tyrphostin AG 528 Phosphorylation 87.2 
SB 202190 Phosphorylation 87.7 
1-(5-Isoquinolinylsulfonyl)-3-methylpiperazine 
dihydrochloride Phosphorylation 88.3 
Daphnetin Phosphorylation 89.0 
Tyrphostin AG 34 Phosphorylation 90.0 
Sphingosine Phosphorylation 90.2 
Tyrphostin AG 494 Phosphorylation 90.4 
ML-7 Phosphorylation 90.5 
Diacylglycerol kinase inhibitor I Phosphorylation 90.8 
1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine 
dihydrochloride Phosphorylation 91.0 
Tyrphostin 23 Phosphorylation 91.6 
Tyrphostin AG 490 Phosphorylation 92.8 
H-89 Phosphorylation 93.0 
Cyclosporin A Phosphorylation 93.4 
H-7 dihydrochloride Phosphorylation 93.5 
Genistein Phosphorylation 94.4 
Indirubin-3 -oxime Phosphorylation 94.5 
HA-1004 hydrochloride Phosphorylation 94.8 
H-8 dihydrochloride Phosphorylation 95.1 
SB 415286 Phosphorylation 95.3 
Phorbol 12-myristate 13-acetate Phosphorylation 95.5 
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Tyrphostin AG 698 Phosphorylation 95.8 
Y-27632 dihydrochloride Phosphorylation 96.2 
Hispidin Phosphorylation 96.2 
LY-294,002 hydrochloride Phosphorylation 96.9 
1,4-Dideoxy-1,4-imino-D-arabinitol Phosphorylation 97.2 
LFM-A13 Phosphorylation 97.2 
Me-3,4-dephostatin Phosphorylation 98.4 
Tetramisole hydrochloride Phosphorylation 98.8 
ML-9 Phosphorylation 98.9 
SP600125 Phosphorylation 99.7 
H-9 dihydrochloride Phosphorylation 101.1 
DL-Stearoylcarnitine chloride Phosphorylation 101.5 
SU 4312 Phosphorylation 102.0 
PD 98,059 Phosphorylation 102.1 
Tamoxifen citrate Phosphorylation 102.7 
Dephostatin Phosphorylation 102.9 
Tyrphostin AG 538 Phosphorylation 104.3 
Endothall Phosphorylation 106.6 
Tyrphostin 51 Phosphorylation 107.3 
Tyrphostin AG 537 Phosphorylation 107.6 
DL-erythro-Dihydrosphingosine Phosphorylation 107.9 
Tyrphostin AG 1478 Phosphorylation 107.9 
Olomoucine Phosphorylation 107.9 
Oleic Acid Phosphorylation 108.5 
I-OMe-Tyrphostin AG 538 Phosphorylation 108.7 
GW2974 Phosphorylation 109.1 
Furegrelate sodium Phosphorylation 109.2 
GW5074 Phosphorylation 109.3 
HA-100 Phosphorylation 109.8 
Tyrphostin 1 Phosphorylation 109.8 
S(-)-p-Bromotetramisole oxalate Phosphorylation 109.9 
Adenosine 3 ,5 -cyclic monophosphate Phosphorylation 110.0 
SU 5416 Phosphorylation 112.6 
Ceramide Phosphorylation 113.8 
(-)-Tetramisole hydrochloride Phosphorylation 114.1 
Tyrphostin AG 126 Phosphorylation 115.3 
Wortmannin from Penicillium funiculosum Phosphorylation 115.4 
Norcantharidin Phosphorylation 117.9 
Tyrphostin AG 112 Phosphorylation 119.6 
SB 216763 Phosphorylation 119.7 
Tyrphostin AG 527 Phosphorylation 120.2 
Roscovitine Phosphorylation 123.9 
Diacylglycerol Kinase Inhibitor II Phosphorylation 125.1 
7-Cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,3-
d]pyrimidin-4-ylamine Phosphorylation 126.5 
Meclofenamic acid sodium Prostaglandin 82.8 
loxoprofen Prostaglandin 83.7 
(-)-Naproxen sodium Prostaglandin 85.6 
Ketoprofen Prostaglandin 95.6 
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Niflumic acid Prostaglandin 96.5 
S(+)-Ibuprofen Prostaglandin 101.0 
Resveratrol Prostaglandin 101.2 
(±)-Ibuprofen Prostaglandin 103.6 
Indomethacin Prostaglandin 104.1 
Sulindac sulfone Prostaglandin 104.6 
Etodolac Prostaglandin 104.8 
Diclofenac sodium Prostaglandin 105.1 
Piroxicam Prostaglandin 106.1 
Ketorolac tris salt Prostaglandin 106.2 
Nimesulide Prostaglandin 114.3 
Meloxicam sodium Prostaglandin 114.4 
SC 19220 Prostaglandin 114.6 
1-Methylimidazole Prostaglandin 114.7 
Sulindac Prostaglandin 117.9 
Acetylsalicylic acid Prostaglandin 122.6 
SC-560 Prostaglandin 124.9 
Oxaprozin Prostaglandin 125.4 
AL-8810 Prostaglandin 134.7 
Phenylbutazone Prostaglandin 137.9 
BW 245C Prostanoids 115.2 
LY-367,265 Serotonin 25.2 
Parthenolide Serotonin 41.8 
Zimelidine dihydrochloride Serotonin 46.3 
WAY-100635 maleate Serotonin 61.8 
Fluoxetine hydrochloride Serotonin 75.5 
LY-278,584 maleate Serotonin 77.5 
SB 224289 hydrochloride Serotonin 84.6 
GR 127935 hydrochloride Serotonin 85.0 
(±)-8-Hydroxy-DPAT hydrobromide Serotonin 85.8 
N-omega-Methyl-5-hydroxytryptamine oxalate salt Serotonin 86.9 
SB 228357 Serotonin 89.6 
alpha-Methyl-5-hydroxytryptamine maleate Serotonin 89.7 
Mianserin hydrochloride Serotonin 90.2 
p-MPPI hydrochloride Serotonin 90.7 
Citalopram hydrobromide Serotonin 91.5 
S(-)-UH-301 hydrochloride Serotonin 91.8 
Ritanserin Serotonin 92.3 
SB-215505 Serotonin 92.7 
VER-3323 hemifumarate salt Serotonin 92.8 
p-MPPF dihydrochloride Serotonin 93.2 
( R)-(-)-DOI hydrochloride Serotonin 93.6 
Dihydroergotamine methanesulfonate Serotonin 93.8 
5-Hydroxyindolacetic acid Serotonin 93.8 
LY-310,762 hydrochloride Serotonin 94.0 
Clomipramine hydrochloride Serotonin 94.9 
5-Methoxy DMT oxalate Serotonin 95.5 
S-(+)-Fluoxetine hydrochloride Serotonin 96.8 
Methysergide maleate Serotonin 97.2 
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LY-53,857 maleate Serotonin 97.4 
BRL 15572 Serotonin 98.5 
O-Methylserotonin hydrochloride Serotonin 98.6 
SB 204741 Serotonin 98.9 
5-Hydroxy-L-tryptophan Serotonin 99.4 
R-(+)-8-Hydroxy-DPAT hydrobromide Serotonin 99.7 
N,N-Dipropyl-5-carboxamidotryptamine maleate Serotonin 100.2 
Serotonin hydrochloride Serotonin 100.3 
Trazodone hydrochloride Serotonin 101.0 
Imipramine hydrochloride Serotonin 101.5 
Quipazine dimaleate Serotonin 102.2 
Metergoline Serotonin 103.8 
Methiothepin mesylate Serotonin 104.2 
3-Tropanyl-3,5-dichlorobenzoate Serotonin 104.3 
S(-)-Pindolol Serotonin 104.6 
BW 723C86 Serotonin 104.9 
NAN-190 hydrobromide Serotonin 105.0 
1-Phenylbiguanide Serotonin 106.4 
Amperozide hydrochloride Serotonin 106.5 
(±)-DOI hydrochloride Serotonin 107.2 
GR 4661 Serotonin 107.6 
Buspirone hydrochloride Serotonin 108.0 
SR 57227A Serotonin 108.3 
1-(m-Chlorophenyl)-biguanide hydrochloride Serotonin 108.4 
GR 125487 sulfamate salt Serotonin 109.2 
R(+)-UH-301 hydrochloride Serotonin 109.8 
1-(3-Chlorophenyl)piperazine dihydrochloride Serotonin 109.9 
Quipazine, N-methyl-, dimaleate Serotonin 110.2 
Cyproheptadine hydrochloride Serotonin 110.4 
1-(1-Naphthyl)piperazine hydrochloride Serotonin 110.5 
SB 206553 hydrochloride Serotonin 111.3 
SB 203186 Serotonin 111.6 
Reserpine Serotonin 111.6 
3-Tropanylindole-3-carboxylate methiodide Serotonin 111.9 
Quipazine, 6-nitro-, maleate Serotonin 112.9 
Spiroxatrine Serotonin 113.3 
Cyclobenzaprine hydrochloride Serotonin 113.3 
CGS-12066A maleate Serotonin 113.7 
Tryptamine hydrochloride Serotonin 114.6 
SB 204070 hydrochloride Serotonin 114.8 
Pirenperone Serotonin 115.2 
Trimipramine maleate Serotonin 115.3 
PAPP Serotonin 116.2 
3-Tropanyl-indole-3-carboxylate hydrochloride Serotonin 116.3 
BRL 54443 maleate Serotonin 118.6 
SB 269970 hydrochloride Serotonin 119.4 
Fluvoxamine maleate Serotonin 120.0 
Ro 04-6790 dihydrochloride Serotonin 121.0 
R-(-)-Fluoxetine hydrochloride Serotonin 121.7 
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L-Tryptophan Serotonin 123.8 
2-Methyl-5-hydroxytryptamine maleate Serotonin 124.9 
5-Carboxamidotryptamine maleate Serotonin 128.7 
Alaproclate hydrochloride Serotonin 130.2 
SB 200646 hydrochloride Serotonin 130.5 
1-(2-Methoxyphenyl)piperazine hydrochloride Serotonin 131.8 
GR 113808 Serotonin 132.7 
Ketanserin tartrate Serotonin 134.5 
BMY 7378 dihydrochloride Serotonin 135.2 
SDZ-205,557 hydrochloride Serotonin 139.2 
Cysteamine hydrochloride Somatostatin 95.6 
Seglitide Somatostatin 103.2 
(±)-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-
propanol hydrochloride Sphingolipid 77.3 
N-Oleoylethanolamine Sphingolipid 99.6 
L-Cycloserine Sphingolipid 101.7 
DL-Cycloserine Sphingolipid 115.9 
L-703,606 oxalate Tachykinin 81.3 
WIN 62,577 Tachykinin 88.2 
L-733,060 hydrochloride Tachykinin 100.7 
SB 222200 Tachykinin 105.9 
L-732,138 Tachykinin 123.4 
L-655,240 Thromboxane 101.8 
Picotamide Thromboxane 149.2 
13-cis-retinoic acid Transcription 62.4 
6-Nitroso-1,2-benzopyrone Transcription 66.6 
GW9662 Transcription 77.0 
TTNPB Transcription 92.2 
Ciprofibrate Transcription 96.2 
6(5H)-Phenanthridinone Transcription 103.0 
TCPOBOP Transcription 104.1 
Fenofibrate Transcription 109.2 
D-ribofuranosylbenzimidazole Transcription 113.8 
Tetradecylthioacetic acid Transcription 116.5 
GW1929 Transcription 118.7 
GW7647 Transcription 143.2 
Dihydrocapsaicin Vanilloid 71.5 
Capsazepine Vanilloid 97.7 
N-Vanillylnonanamide Vanilloid 102.5 
SB-366791 Vanilloid 103.9 
Vanillic acid diethylamide Vanilloid 106.0 
NCI Approved Oncology Drug Set II Screening Results 
Pentostatin Adenosine 140.0 
Etoposide Apoptosis 19.7 
Arsenic trioxide Apoptosis 122.8 
Zolendronic acid Cell Biology 101.3 
Mitotane Cell Biology/Adrenal gland function 130.4 
Capecitabine Cell Cycle 105.2 
  
 179 
Fluorouracil Cell Cycle  107.3 
Amifostine Cell Stress 102.8 
Allopurinol Cell Stress 115.9 
Dexrazoxone Cell Stress 131.8 
Vinblastine sulfate Cytoskeleton and ECM 36.8 
Vincristine sulfate Cytoskeleton and ECM 38.6 
Ixabepilone Cytoskeleton and ECM 43.3 
Paclitaxel Cytoskeleton and ECM 47.1 
Vinorelbine tartrate Cytoskeleton and ECM 54.7 
Docetaxel Cytoskeleton and ECM 62.6 
Estramustine disodium phosphate Cytoskeleton and ECM 111.7 
Thalidomide Cytoskeleton and ECM 112.4 
Daunorubicin HCl DNA 1.6 
Valrubicin DNA 2.3 
Topotecan HCl DNA 3.8 
Plicamycin DNA 12.3 
Dactinomycin DNA 41.3 
Cladribine DNA 49.6 
Gemcitabine HCl DNA 64.4 
Nitrogen mustard DNA 70.8 
Mitomycin C DNA 78.3 
Fludarabine DNA 92.1 
Decitabine DNA 98.4 
Nelarabine DNA 99.0 
Oxaliplatin DNA 101.8 
Cytarabine hydrochloride DNA 104.0 
Irinotecan HCl DNA 104.7 
Azacitidine DNA 105.0 
Thiotepa DNA 107.3 
Pipobroman DNA 108.0 
Lomustine, CCNU DNA 109.7 
Mercaptopurine DNA 110.1 
Thioguanine DNA 110.7 
Floxuridine DNA 111.1 
Busulfan DNA 111.4 
Streptozocin DNA 113.1 
Procarbazine hydrochloride DNA 114.0 
Methoxsalen DNA 115.1 
Temozolomide DNA 117.1 
Carboplatin DNA 117.5 
Cyclophosphamide DNA 120.2 
Pemetrexed DNA 120.7 
Uracil mustard DNA 123.6 
Acrichine DNA 123.7 
Carmustine DNA 125.6 
Dacarbazine DNA 126.3 
Triethylenemelamine DNA 126.9 
Chlorambucil DNA 127.0 
Cisplatin DNA 127.8 
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Ifosfamide DNA 129.2 
Doxorubicin HCl DNA  2.2 
Teniposide DNA  Repair 7.4 
Mitoxantrone DNA Metabolism 1.3 
Melphalan DNA Metabolism 94.3 
Hydroxyurea DNA Metabolism 105.7 
Methotrexate DNA Metabolism 106.3 
Altretamine DNA Metabolism 110.0 
Clofarabine DNA Repair 33.1 
Bleomycin DNA Repair 104.3 
Vorinostat Gene Regulation and Epigenetics 38.4 
Exemestane Hormone 96.1 
Fulvestrant Hormone 99.0 
Letrozole Hormone 100.5 
Raloxifene HCl Hormone 103.5 
Megestrol acetate Hormone 104.2 
Anastrozole Hormone 105.0 
Imiquimod Immune System 98.7 
Lenalidomide Immune system 100.1 
Aminolevulinic acid Light sensitivity 114.7 
Everolimus mTOR 80.1 
Rapamycin mTOR 115.8 
Lapatinib Phosphorylation 96.7 
Nilotinib Phosphorylation 98.0 
Tamoxifen citrate Phosphorylation 102.5 
Dasatinib Phosphorylation 104.3 
Sunitinib Phosphorylation 105.7 
Erlotinib HCl Phosphorylation 106.3 
Gefitinib Phosphorylation 109.7 
Imatinib Phosphorylation 110.4 
Sorafenib Phosphorylation 119.1 
Celecoxib Prostaglandin 113.8 
Bortezomib Proteasome 8.4 
Tretinoin Transcription 95.7 
 Reference : The NCI/DTP Open Chemical Repository, http://dtp.cancer.gov 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 181 
ATPase Inhibitors 
Bithionol Antihelmintic 120.7 
Hexachlorophene Antiseptic 81.3 
MAL2-11B ATPase 92 
MAL3-101 ATPase 87 
DMT3084 ATPase 99 
MAL2-51 ATPase 93 
References :                                                                                                                                                                                                                                 
- Wright CM, Seguin SP, Fewell SW, Zhang H, Ishwad C, Vats A, Lingwood CA, Wipf P, Fanning E, Pipas JM, 
Brodsky JL.Inhibition of Simian Virus 40 replication by targeting the molecular chaperone function and ATPase 
activity of T antigen.Virus Res. 2009 Apr;141(1):71-80.                                                                                                                                
- S. P. Seguin et al., High-Throughput Screening Identifies a Bisphenol Inhibitor of SV40 Large T Antigen ATPase 
Activity. Journal of biomolecular screening,  (Sep 23, 2011). 
p53-MDM2 Inhibitors 
Nutlin-3  p53 12.6 
YH264A p53 92.7 
YH265A p53 99.1 
KK_NW_16A p53 99.6 
References :                                                                                                                                                                                          
- Czarna, A., et al. Robust generation of lead compounds for protein-protein interactions by computational and 
MCR chemistry: p53/Hdm2 antagonists. Angewandte Chemie 49, 5352-5356 (2010).                                                         
- Popowicz, G.M., et al. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new 
approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell cycle 9, 1104-1111 (2010). 
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  Changepoint	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  of	  the	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  of	  YM155	  on	  Bortezomib	  on	  Tumor	  
Xenograft	  Volume	  	  
(Report	  by	  Dr	  Normolle	  on	  August	  28,	  2011,	  published	  in	  Arora	  et	  al,	  STM,	  2012)	  
Bayesian Hierarchical Changepoint Analysis of the Effect of
YM-155 and Bortezomib on T or Xenograft Volume
August 28, 2011
1 Model Setup
The hierarchical Bayes piecewise linear model [1] previously presented, with a change of param-
eterization to enhance sharing of information, was employed, where the groups are indexed as
follows:
i Cell Line Treatment # Animals
1 MKL-1 Bortezomib 21
2 MKL-1 Saline 31
3 MKL-1 YM155 23
4 MS-1 Saline 5
5 MS-1 YM155 6
6 UISO Saline 5
7 UISO YM155 5
Table 1 Experimental group label definitions and sample sizes.
This is a hierarchical Bayesian model, where animal ij has four model parameters: the nadir log-
volume (aij), growth delay time (erij ), pre-nadir shrinkage rate (eb1ij ) and post-nadir growth rate
(eb2ij ). The values of rij, b1ij and b2ij are exponentiated to ensure they are positive. The animal-
level parameters are distributed around a corresponding treatment group-level parameter, as de-
scribed in Block 2, below. The treatment group-level parameters are centered around a mean meta-
parameter (Block 4, below), which allows for sharing of information between treatment groups.
This is of particular value in this model, where, in some treatment groups (e.g., Saline), there is no
tumor shrinkage, so the growth delay is pushed towards zero, and there is then no information to
estimate the rate of tumor shrinkage (because there is no shrinkage), but the sharing of information
enhances numerical stability by defaulting the vanishingly short tumor shrinkage period to have a
tumor shrinkage rate with a sensible, if irrelevant value.
The model accommodates volumes below the limit of quantitation, which are generally recorded
as zero. We take volumes coded as zero to be values below the limit of quantization (LQ), where
the limit of quantitation is defined to be the smallest non-zero value; for the present data set,
that volume equals 4mm3 (log2(4) = 2). BLQ volumes are utilized in the estimation process,
considered left-censored at LQ.
The complete model parameterization is presented in the following blocks, where N (µ, ⌧) is a
normal distribution with mean µ and precision ⌧, and G( , ⌘) is a gamma distribution with scale  
and shape ⌘ (mean  /⌘ and variance  /⌘2):
1
	  	  
	   183	  
	  
1. Piecewise linear model for log-volume
µij(t) = aijt + e
b1ijmax(erij   t, 0) + eb2ijmax(t  erij , 0)
!ij(t) = e
✓µij(t)
log2(vij)(t) ⇠ N (µij(t),!ij(t))
2. Animal-Level regression parameters
aij ⇠ N (↵i, ⌧a)
b1ij ⇠ N ( 1i, ⌧b1)
b2ij ⇠ N ( 2i, ⌧b2)
rij ⇠ N (⇢i, ⌧a)
3. Experimental group regression parameters
↵i ⇠ N (↵, ⌧↵)
 1i ⇠ N ( 1, ⌧ 1)
 2i ⇠ N ( 2, ⌧ 2)
⇢i ⇠ N (⇢, ⌧⇢)
4. Mean meta-parameters
↵ ⇠ N (0, 0.01)
 1 ⇠ N (0, 0.01)
 2 ⇠ N (0, 0.01)
⇢ ⇠ N (0, 0.01)
✓ ⇠ N (0, 0.01)
5. Dispersion meta-parameters
⌧a ⇠ G(0.1, 0.1) ⌧↵ ⇠ G(0.1, 0.1)
⌧b1 ⇠ G(0.1, 0.1) ⌧ 1 ⇠ G(0.1, 0.1)
⌧b2 ⇠ G(0.1, 0.1) ⌧ 2 ⇠ G(0.1, 0.1)
⌧r ⇠ G(0.1, 0.1) ⌧⇢ ⇠ G(0.1, 0.1)
The most interpretable parameters are in Block 3, Experimental group regression parameters. Dif-
ferences in these parameters will represent differences between, for instance, growth delay rates
between treatments.
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2 Parameter Estimates
Parameters as described in the Model Setup section were estimated using JAGS (Just Another
Gibbs Sampler) with 20,000 MCMC iterations. Traces of the estimated parameters were checked
visually for convergence. The relationship of all the estimated parameters to the data can be
checked visually in the section Animal-Level Model; the numerical estimates of the treatment-
level parameters are presented here with 95% credible intervals.
↵i e 1i e 2i e⇢i
MKL-1 Bortezomib 5.5(5,6) 0.00069(6.1e-12,1.4) 0.32(0.28,0.35) 1.3e-05(7.7e-21,0.053)
MKL-1 Saline 5.3(4.9,5.7) 0.00037(5.5e-10,0.1) 0.4(0.37,0.44) 1.1e-05(1.3e-10,0.041)
MKL-1 YM155 4.1(3.6,4.6) 0.0014(3.5e-08,0.025) 0.37(0.33,0.41) 5.5(2.6,9.5)
MS-1 Saline 4.4(3.4,5.3) 0.00053(2.2e-10,0.61) 0.21(0.17,0.26) 2.2e-05(3.3e-19,0.19)
MS-1 YM155 4.4(3.5,5.2) 0.00049(2.2e-11,0.35) 0.19(0.16,0.23) 5.6e-06(5.6e-20,0.17)
UISO Saline 2.4(1.5,3.5) 0.00055(3.3e-10,0.26) 0.19(0.16,0.23) 1.7e-05(5.2e-16,1.5)
UISO YM155 2.6(1.5,3.6) 0.00025(1.6e-11,0.017) 0.23(0.19,0.28) 11(3.1,36)
Table 2 Estimated values and 95% credible intervals for nadir volume (↵i), shrinkage rate (e 1i),
growth rate (e 2i) and time to nadir (e⇢i).
The most notable feature of the estimates is the increased delay in growth in animals with MKL-1
and UISO tumors treated with YM155 (5.5 and 11 days, respectively). Animals with MS-1 tumors
so treated experienced no such apparent delay in growth. Tumors with delay in growth did not
shrink prior to the resumption of growth (e 1i ⇡ 0). The post-nadir growth rates of all the animals
with MKL-1 tumors were similar, and faster than MS-1 and UISO tumors. The estimated nadir
(↵i) appears smaller for the UISO tumors, but the nadir value may be confounded with the baseline
tumor volumes, which are significantly smaller in the UISO tumors than the others, as displayed
in Figure 1.
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Figure 1 Day 0 volumes (base 2 log-transformed). The experimental
groups are defined in Table 1; groups 6 and 7 are UISO Saline and YM155,
respectively.
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3 Plots by Treatment and Cell Line
The panels of curves in Figures 2 and 3 represent the summary of the population model for the
seven experimental groups. The red lines indicate the central estimates, while the shaded areas
95% credible regions (Bayesian confidence regions) for the growth curves. The credible regions
are wider for the experimental groups with fewer animals. It is seen that there is evidence of
growth delay for the YM155-treated animals with MKL-1 and UISO tumors, but not for the other
experimental groups. It is also seen that the YM155 does not uniformly suppress tumor growth; it
appears to have no effect on some tumors, while delaying growth a great deal more than average
in others. Figure 2 displays the population estimates against the observed tumor volume profiles,
demonstrating the correspondence between the population estimates and the raw data, while Figure
3 displays the population- and animal-level models together, to demonstrate the correspondence
between the animal-level and population-level models.
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Figure 2 Population tumor volume growth curves for the seven experi-
mental groups. The bold red lines are the central estimates, while the shaded
regions are 95% credible intervals. Individual animal growth curves are rep-
resented by grey lines. The limit of quantitation is 2 on this scale; 0 volumes
are represented as 2.
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Figure 3 Population tumor volume growth curves for the seven experi-
mental groups. The bold red lines are the central estimates, while the shaded
regions are 95% credible intervals. Modeled individual animal growth
curves are represented by blue lines.
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4 Animal-Level Model Fit
The Figures 4.1-4.12 confirm the fit of the model to the data. Circles are the observed data, blue
lines are the animal-level models (based on aij, b1ij, b2ij and rij, for the ith animal in the j th group),
and the red lines are the experimental group-level model (based on ↵j,  1j,  2j and ⇢j, for the ith
animal in the j th group)). The animals are sorted according to the experimental group in Table 1.
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Figure 4.1 Animal-level plots. Circles are data, blue lines animal-level model, red lines experi-
mental group-level model.
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Figure 4.2 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.3 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.4 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.5 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.6 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.7 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.8 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.9 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.10 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.11 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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Figure 4.12 Animal-level plots. Open circles are data, filled circles are BLQ, blue lines animal-
level model, red lines experimental group-level model. Values are (top to bottom) ai, eb1i , eb2i , eri .
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